PCIDB

KNApSAcK Metabolite C00018055

Metabolite

KNApSAcK Entry

id C00018055
Name Rapamycin
CAS RN 53123-88-9
Standard InChI InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1
Standard InChI (Main Layer) InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3

Cluster

Phytochemical cluster
KCF-S cluster No. 2347

Link

ChEMBL

By standard InChI CHEMBL413
By standard InChI Main Layer CHEMBL413 CHEMBL295272 CHEMBL1328768 CHEMBL1329171 CHEMBL1446796 CHEMBL1473145 CHEMBL1706754 CHEMBL1988195

KEGG

By LinkDB C07909

CTD

By CAS RN D020123

Species

Summary

Plant class

class name count

Family

family name count
Streptomycetaceae 1

List (1)

* NCBI
KNApSAcK organism *ID *family *plant class *kingdom
Streptomyces hygroscopicus AY B-994 1883 Streptomycetaceae Bacteria

Human Protein / Gene in interaction

349 ChEMBL Protein in interactions

accession description class description compound assay ID (# of activities) # of diseases
(OMIM / KEGG)
P10635 Cytochrome P450 2D6 Cytochrome P450 2D6 CHEMBL413 CHEMBL1909136 (2)
1 / 0
P42345 Serine/threonine-protein kinase mTOR Enzyme CHEMBL413 CHEMBL677281 (1) CHEMBL881403 (1)
CHEMBL871328 (1) CHEMBL920880 (1)
CHEMBL945533 (1) CHEMBL945534 (1)
CHEMBL940624 (1) CHEMBL940625 (1)
CHEMBL940626 (1) CHEMBL940627 (1)
CHEMBL940628 (1) CHEMBL940629 (1)
CHEMBL997061 (1) CHEMBL1037643 (1)
CHEMBL1037644 (1) CHEMBL1037645 (1)
CHEMBL1037646 (1) CHEMBL1949072 (1)
CHEMBL1949073 (1) CHEMBL2219345 (1)
CHEMBL2219346 (1) CHEMBL2219347 (1)
CHEMBL2219348 (1)
0 / 0
Q02750 Dual specificity mitogen-activated protein kinase kinase 1 Ste7 CHEMBL413 CHEMBL1062820 (1) CHEMBL2219261 (1)
CHEMBL2219262 (1)
1 / 1
P36897 TGF-beta receptor type-1 TKL dual-specificity kinase STKR type 1 subfamily CHEMBL413 CHEMBL2219207 (1) CHEMBL2219208 (1)
3 / 2
Q13555 Calcium/calmodulin-dependent protein kinase type II subunit gamma Camk2 CHEMBL413 CHEMBL2219012 (1) CHEMBL2219013 (1)
0 / 0
P29322 Ephrin type-A receptor 8 Eph CHEMBL413 CHEMBL2219048 (1) CHEMBL2219049 (1)
0 / 0
P42685 Tyrosine-protein kinase FRK Src CHEMBL413 CHEMBL2219131 (1) CHEMBL2219132 (1)
0 / 0
Q13043 Serine/threonine-protein kinase 4 STE serine/threonine protein kinase MST subfamily CHEMBL413 CHEMBL2219285 (1) CHEMBL2219286 (1)
1 / 0
Q9P1W9 Serine/threonine-protein kinase pim-2 Pim CHEMBL413 CHEMBL1061086 (1) CHEMBL2219137 (1)
CHEMBL2219138 (1)
0 / 0
Q8TDX7 Serine/threonine-protein kinase Nek7 Nek CHEMBL413 CHEMBL1060151 (1) CHEMBL2219353 (1)
CHEMBL2219354 (1)
0 / 0
Q5VT25 Serine/threonine-protein kinase MRCK alpha AGC serine/threonine protein kinase GEK subfamily CHEMBL413 CHEMBL2219275 (1) CHEMBL2219276 (1)
0 / 0
Q14289 Protein-tyrosine kinase 2-beta Fak CHEMBL413 CHEMBL2219147 (1) CHEMBL2219148 (1)
0 / 0
P08922 Proto-oncogene tyrosine-protein kinase ROS TK tyrosine-protein kinase SEV CHEMBL413 CHEMBL2219159 (1) CHEMBL2219160 (1)
0 / 1
Q15831 Serine/threonine-protein kinase STK11 Lkb CHEMBL413 CHEMBL2219241 (1) CHEMBL2219242 (1)
2 / 2
Q9Y6L6 Solute carrier organic anion transporter family member 1B1 Electrochemical transporter CHEMBL413 CHEMBL2077073 (1)
1 / 0
Q9BYP7 Serine/threonine-protein kinase WNK3 WNK serine/threonine protein kinase subfamily CHEMBL413 CHEMBL2219329 (1) CHEMBL2219330 (1)
0 / 0
P21728 D(1A) dopamine receptor Dopamine receptor CHEMBL413 CHEMBL1909139 (2)
0 / 0
P35354 Prostaglandin G/H synthase 2 Oxidoreductase CHEMBL413 CHEMBL1909131 (2)
0 / 3
Q12809 Potassium voltage-gated channel subfamily H member 2 KCNH, Kv10-12.x (Ether-a-go-go) CHEMBL413 CHEMBL1909190 (2)
2 / 2
P08069 Insulin-like growth factor 1 receptor TK tyrosine-protein kinase INSR subfamily CHEMBL413 CHEMBL2219110 (1) CHEMBL2219111 (1)
CHEMBL2219209 (1) CHEMBL2219210 (1)
1 / 3
P08246 Neutrophil elastase S1A CHEMBL413 CHEMBL1909195 (2)
2 / 1
P33765 Adenosine receptor A3 Adenosine receptor CHEMBL413 CHEMBL1909215 (2)
0 / 0
Q15759 Mitogen-activated protein kinase 11 p38 CHEMBL413 CHEMBL1052111 (1) CHEMBL1249570 (1)
CHEMBL2219173 (1) CHEMBL2219174 (1)
0 / 0
Q16539 Mitogen-activated protein kinase 14 p38 CHEMBL413 CHEMBL1063767 (1) CHEMBL1249569 (1)
CHEMBL1909201 (2) CHEMBL2219171 (1)
CHEMBL2219172 (1)
0 / 0
P21802 Fibroblast growth factor receptor 2 TK tyrosine-protein kinase TLK subfamily CHEMBL413 CHEMBL2219064 (1) CHEMBL2219065 (1)
9 / 3
P49146 Neuropeptide Y receptor type 2 Neuropeptide Y receptor CHEMBL413 CHEMBL1909176 (2)
0 / 0
O15530 3-phosphoinositide-dependent protein kinase 1 Pdk1 CHEMBL413 CHEMBL1063811 (1) CHEMBL2219388 (1)
CHEMBL2219389 (1)
0 / 0
Q9UIK4 Death-associated protein kinase 2 Dapk CHEMBL413 CHEMBL2219022 (1) CHEMBL2219023 (1)
0 / 0
P41240 Tyrosine-protein kinase CSK Csk CHEMBL413 CHEMBL1061954 (1) CHEMBL2219006 (1)
CHEMBL2219007 (1)
0 / 0
P45984 Mitogen-activated protein kinase 9 Jnk CHEMBL413 CHEMBL1060122 (1) CHEMBL2219233 (1)
CHEMBL2219234 (1)
0 / 0
P29466 Caspase-1 C14 CHEMBL413 CHEMBL1909193 (2)
0 / 0
P17252 Protein kinase C alpha type Alpha CHEMBL413 CHEMBL1062776 (1) CHEMBL1249578 (1)
CHEMBL1909198 (2) CHEMBL2219398 (1)
CHEMBL2219399 (1)
0 / 0
P27361 Mitogen-activated protein kinase 3 Erk CHEMBL413 CHEMBL1061959 (1) CHEMBL1909199 (2)
CHEMBL2219251 (1) CHEMBL2219252 (1)
0 / 0
Q15349 Ribosomal protein S6 kinase alpha-2 Rskb CHEMBL413 CHEMBL2219167 (1) CHEMBL2219168 (1)
0 / 0
P04629 High affinity nerve growth factor receptor Trk CHEMBL413 CHEMBL2219315 (1) CHEMBL2219316 (1)
2 / 4
Q05655 Protein kinase C delta type Delta CHEMBL413 CHEMBL2219406 (1) CHEMBL2219407 (1)
0 / 0
P14780 Matrix metalloproteinase-9 M10A CHEMBL413 CHEMBL1909197 (2)
2 / 2
Q04759 Protein kinase C theta type Delta CHEMBL413 CHEMBL2219115 (1) CHEMBL2219116 (1)
0 / 1
Q15303 Receptor tyrosine-protein kinase erbB-4 TK tyrosine-protein kinase EGFR subfamily CHEMBL413 CHEMBL2219058 (1) CHEMBL2219059 (1)
0 / 0
O14757 Serine/threonine-protein kinase Chk1 Chk1 CHEMBL413 CHEMBL1051374 (1) CHEMBL1249589 (1)
CHEMBL2218986 (1) CHEMBL2218987 (1)
0 / 0
O14965 Aurora kinase A Aur CHEMBL413 CHEMBL2218948 (1) CHEMBL2218949 (1)
0 / 0
Q7KZI7 Serine/threonine-protein kinase MARK2 CAMK serine/threonine protein kinase MARK subfamily CHEMBL413 CHEMBL2219367 (1) CHEMBL2219368 (1)
0 / 0
Q13882 Protein-tyrosine kinase 6 Src CHEMBL413 CHEMBL2218956 (1) CHEMBL2218957 (1)
0 / 0
Q8IWQ3 Serine/threonine-protein kinase BRSK2 CAMK serine/threonine protein kinase BRSK subfamily CHEMBL413 CHEMBL1051367 (1) CHEMBL2218966 (1)
CHEMBL2218967 (1)
0 / 0
P27448 MAP/microtubule affinity-regulating kinase 3 CAMK serine/threonine protein kinase MARK subfamily CHEMBL413 CHEMBL1063734 (1)
0 / 0
Q9UHD2 Serine/threonine-protein kinase TBK1 Ikk CHEMBL413 CHEMBL2219205 (1) CHEMBL2219206 (1)
1 / 0
P21709 Ephrin type-A receptor 1 Eph CHEMBL413 CHEMBL2219036 (1) CHEMBL2219037 (1)
0 / 0
Q9P0L2 Serine/threonine-protein kinase MARK1 CAMK serine/threonine protein kinase MARK subfamily CHEMBL413 CHEMBL2219259 (1) CHEMBL2219260 (1)
0 / 0
Q96PF2 Testis-specific serine/threonine-protein kinase 2 CAMK serine/threonine protein kinase TSSK subfamily CHEMBL413 CHEMBL2219309 (1) CHEMBL2219310 (1)
0 / 0
P51956 Serine/threonine-protein kinase Nek3 Nek1 CHEMBL413 CHEMBL2219303 (1) CHEMBL2219304 (1)
0 / 0
P37840 Alpha-synuclein Unclassified protein CHEMBL413 CHEMBL1706754 CHEMBL2354282 (2)
4 / 2
P00519 Tyrosine-protein kinase ABL1 Abl CHEMBL413 CHEMBL2218944 (1) CHEMBL2218945 (1)
1 / 4
P00918 Carbonic anhydrase 2 Lyase CHEMBL413 CHEMBL1909123 (2)
1 / 2
P07550 Beta-2 adrenergic receptor Adrenergic receptor CHEMBL413 CHEMBL1909092 (2)
0 / 1
P21397 Amine oxidase [flavin-containing] A Oxidoreductase CHEMBL413 CHEMBL1909169 (2)
1 / 1
P25021 Histamine H2 receptor Histamine receptor CHEMBL413 CHEMBL1909157 (2)
0 / 0
P35367 Histamine H1 receptor Histamine receptor CHEMBL413 CHEMBL1909156 (2)
0 / 0
Q01959 Sodium-dependent dopamine transporter Dopamine CHEMBL413 CHEMBL1909143 (2)
1 / 0
P08912 Muscarinic acetylcholine receptor M5 Acetylcholine receptor CHEMBL413 CHEMBL1909174 (2)
0 / 0
P18825 Alpha-2C adrenergic receptor Adrenergic receptor CHEMBL413 CHEMBL1909090 (2)
0 / 0
P13945 Beta-3 adrenergic receptor Adrenergic receptor CHEMBL413 CHEMBL1909093 (2)
0 / 0
Q05513 Protein kinase C zeta type Iota CHEMBL413 CHEMBL1052114 (1) CHEMBL2219112 (1)
CHEMBL2218942 (1)
0 / 0
P11309 Serine/threonine-protein kinase pim-1 Pim CHEMBL413 CHEMBL1063736 (1) CHEMBL2219135 (1)
CHEMBL2219136 (1)
0 / 0
Q02156 Protein kinase C epsilon type Eta CHEMBL413 CHEMBL2219408 (1) CHEMBL2219409 (1)
0 / 0
P41743 Protein kinase C iota type Iota CHEMBL413 CHEMBL2219117 (1) CHEMBL2219118 (1)
0 / 0
Q9UK32 Ribosomal protein S6 kinase alpha-6 Rskb CHEMBL413 CHEMBL2219169 (1) CHEMBL2219170 (1)
0 / 0
Q04912 Macrophage-stimulating protein receptor TK tyrosine-protein kinase MET subfamily CHEMBL413 CHEMBL2219157 (1) CHEMBL2219158 (1)
0 / 0
P08183 Multidrug resistance protein 1 drug CHEMBL413 CHEMBL2076695 (1) CHEMBL2075512 (1)
CHEMBL2076148 (1) CHEMBL2075699 (1)
CHEMBL2076253 (1)
1 / 0
P25024 C-X-C chemokine receptor type 1 CXC chemokine receptor CHEMBL413 CHEMBL1909127 (2)
0 / 0
Q13557 Calcium/calmodulin-dependent protein kinase type II subunit delta Camk2 CHEMBL413 CHEMBL2219014 (1) CHEMBL2219015 (1)
0 / 0
P06241 Tyrosine-protein kinase Fyn Src CHEMBL413 CHEMBL1909204 (2) CHEMBL2219084 (1)
CHEMBL2219085 (1)
0 / 0
P80192 Mitogen-activated protein kinase kinase kinase 9 TKL dual-specificity kinase MLK CHEMBL413 CHEMBL2219273 (1) CHEMBL2219274 (1)
0 / 0
P43403 Tyrosine-protein kinase ZAP-70 Syk CHEMBL413 CHEMBL2219333 (1) CHEMBL2219334 (1)
1 / 2
Q08209 Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform Ser_Thr CHEMBL413 CHEMBL1909202 (2)
0 / 0
P16234 Platelet-derived growth factor receptor alpha Pdgfr CHEMBL413 CHEMBL2219384 (1) CHEMBL2219385 (1)
2 / 1
P19784 Casein kinase II subunit alpha' Ck2 CHEMBL413 CHEMBL1061205 (1) CHEMBL2218998 (1)
CHEMBL2218999 (1) CHEMBL2219000 (1)
CHEMBL2219001 (1)
0 / 0
P11712 Cytochrome P450 2C9 Cytochrome P450 2C9 CHEMBL413 CHEMBL1909135 (2)
0 / 1
P23443 Ribosomal protein S6 kinase beta-1 p70 CHEMBL413 CHEMBL1052119 (1) CHEMBL1249582 (1)
CHEMBL2219349 (1) CHEMBL2219350 (1)
0 / 0
Q9UQB9 Aurora kinase C Aur CHEMBL413 CHEMBL1062797 (1) CHEMBL2218952 (1)
CHEMBL2218953 (1)
1 / 1
P49761 Dual specificity protein kinase CLK3 Clk CHEMBL413 CHEMBL2219004 (1) CHEMBL2219005 (1)
0 / 0
P51813 Cytoplasmic tyrosine-protein kinase BMX Tec CHEMBL413 CHEMBL2218962 (1) CHEMBL2218963 (1)
0 / 0
Q9HBH9 MAP kinase-interacting serine/threonine-protein kinase 2 CAMK serine/threonine protein kinase MNK subfamily CHEMBL413 CHEMBL1060126 (1) CHEMBL2219295 (1)
CHEMBL2219296 (1)
0 / 0
Q9NQU5 Serine/threonine-protein kinase PAK 6 STE serine/threonine protein kinase PAKB subfamily CHEMBL413 CHEMBL1063719 (1) CHEMBL2219365 (1)
CHEMBL2219366 (1)
0 / 0
Q16644 MAP kinase-activated protein kinase 3 CAMK serine/threonine protein kinase MAPKAPK CHEMBL413 CHEMBL1061148 (1) CHEMBL2219257 (1)
CHEMBL2219258 (1)
0 / 0
Q06187 Tyrosine-protein kinase BTK Tec CHEMBL413 CHEMBL2218958 (1) CHEMBL2218959 (1)
2 / 2
Q9H422 Homeodomain-interacting protein kinase 3 CMGC dual-specificity kinase HIPK CHEMBL413 CHEMBL1061964 (1) CHEMBL2219102 (1)
CHEMBL2219103 (1)
0 / 0
Q14680 Maternal embryonic leucine zipper kinase Melk CHEMBL413 CHEMBL1052104 (1) CHEMBL2219263 (1)
CHEMBL2219264 (1)
0 / 0
Q9UBE8 Serine/threonine-protein kinase NLK CMGC serine/threonine protein kinase NMO subfamily CHEMBL413 CHEMBL2219355 (1) CHEMBL2219356 (1)
0 / 0
Q12866 Tyrosine-protein kinase Mer TK tyrosine-protein kinase AXL CHEMBL413 CHEMBL2219291 (1) CHEMBL2219292 (1)
1 / 1
Q00535 Cyclin-dependent kinase 5 Cdk5 CHEMBL413 CHEMBL2218976 (1) CHEMBL2218977 (1)
CHEMBL2218978 (1) CHEMBL2218979 (1)
0 / 0
Q15078 Cyclin-dependent kinase 5 activator 1 REG serine/threonine protein kinase family CHEMBL413 CHEMBL2218976 (1) CHEMBL2218977 (1)
CHEMBL2218978 (1) CHEMBL2218979 (1)
0 / 0
Q9Y5S2 Serine/threonine-protein kinase MRCK beta AGC serine/threonine protein kinase GEK subfamily CHEMBL413 CHEMBL2219277 (1) CHEMBL2219278 (1)
0 / 0
Q8N4C8 Misshapen-like kinase 1 STE serine/threonine protein kinase MSN subfamily CHEMBL413 CHEMBL2219265 (1) CHEMBL2219266 (1)
0 / 0
Q9NYY3 Serine/threonine-protein kinase PLK2 Plk2 CHEMBL413 CHEMBL2219193 (1) CHEMBL2219194 (1)
0 / 0
P43250 G protein-coupled receptor kinase 6 AGC serine/threonine protein kinase GRK subfamily CHEMBL413 CHEMBL2219090 (1) CHEMBL2219091 (1)
0 / 0
Q96BR1 Serine/threonine-protein kinase Sgk3 AGC serine/threonine protein kinase SGK subfamily CHEMBL413 CHEMBL2219183 (1) CHEMBL2219184 (1)
0 / 0
P00533 Epidermal growth factor receptor TK tyrosine-protein kinase EGFR subfamily CHEMBL413 CHEMBL1909203 (2) CHEMBL2219034 (1)
CHEMBL2219035 (1)
1 / 11
P11473 Vitamin D3 receptor NR1I1 CHEMBL1329171 CHEMBL1446796 CHEMBL1794311 (2)
2 / 3
P14416 D(2) dopamine receptor Dopamine receptor CHEMBL413 CHEMBL1909140 (2)
2 / 0
P23219 Prostaglandin G/H synthase 1 Oxidoreductase CHEMBL413 CHEMBL1909130 (2)
0 / 0
P37288 Vasopressin V1a receptor Vasopressin and oxytocin receptor CHEMBL413 CHEMBL1909120 (2)
0 / 0
P41145 Kappa-type opioid receptor Opioid receptor CHEMBL413 CHEMBL1909181 (2)
0 / 0
Q9Y271 Cysteinyl leukotriene receptor 1 Leukotriene receptor CHEMBL413 CHEMBL1909164 (2)
0 / 0
P29274 Adenosine receptor A2a Adenosine receptor CHEMBL413 CHEMBL1909214 (2)
0 / 0
O43293 Death-associated protein kinase 3 Dapk CHEMBL413 CHEMBL2219335 (1) CHEMBL2219336 (1)
0 / 0
Q15746 Myosin light chain kinase, smooth muscle Mlck CHEMBL413 CHEMBL1062028 (1) CHEMBL2219271 (1)
CHEMBL2219272 (1)
1 / 1
Q13188 Serine/threonine-protein kinase 3 STE serine/threonine protein kinase MST subfamily CHEMBL413 CHEMBL1060209 (1) CHEMBL2219287 (1)
CHEMBL2219288 (1)
0 / 0
P25929 Neuropeptide Y receptor type 1 Neuropeptide Y receptor CHEMBL413 CHEMBL1909175 (2)
0 / 0
P31751 RAC-beta serine/threonine-protein kinase Akt CHEMBL413 CHEMBL1061917 (1) CHEMBL2219394 (1)
CHEMBL2219395 (1)
2 / 2
Q9Y243 RAC-gamma serine/threonine-protein kinase Akt CHEMBL413 CHEMBL2219396 (1) CHEMBL2219397 (1)
1 / 0
O75582 Ribosomal protein S6 kinase alpha-5 CAMK serine/threonine protein kinase MSKB subfamily CHEMBL413 CHEMBL1062767 (1) CHEMBL1249575 (1)
CHEMBL2219279 (1) CHEMBL2219280 (1)
0 / 0
P50052 Type-2 angiotensin II receptor Angiotensin receptor CHEMBL413 CHEMBL1909096 (2)
1 / 1
O14920 Inhibitor of nuclear factor kappa-B kinase subunit beta Other serine/threonine protein kinase CHEMBL413 CHEMBL1062809 (1) CHEMBL2219213 (1)
CHEMBL2219214 (1)
0 / 0
Q13464 Rho-associated protein kinase 1 Rock CHEMBL413 CHEMBL2219151 (1) CHEMBL2219152 (1)
0 / 0
Q16513 Serine/threonine-protein kinase N2 Pkn CHEMBL413 CHEMBL1060217 (1) CHEMBL2219129 (1)
CHEMBL2219130 (1)
0 / 0
Q15139 Serine/threonine-protein kinase D1 Pkd CHEMBL413 CHEMBL1062021 (1) CHEMBL2219119 (1)
CHEMBL2219120 (1)
0 / 0
P17948 Vascular endothelial growth factor receptor 1 Vegfr CHEMBL413 CHEMBL1909118 (2) CHEMBL2219076 (1)
CHEMBL2219077 (1)
0 / 0
P41968 Melanocortin receptor 3 Melanocortin receptor CHEMBL413 CHEMBL1909166 (2)
1 / 0
P00352 Retinal dehydrogenase 1 Enzyme CHEMBL1329171 CHEMBL1614458 (2)
0 / 0
P78368 Casein kinase I isoform gamma-2 Ck1 CHEMBL413 CHEMBL2218992 (1) CHEMBL2218993 (1)
0 / 0
P36888 Receptor-type tyrosine-protein kinase FLT3 Pdgfr CHEMBL413 CHEMBL2219078 (1) CHEMBL2219079 (1)
1 / 1
P07947 Tyrosine-protein kinase Yes Src CHEMBL413 CHEMBL2219331 (1) CHEMBL2219332 (1)
0 / 0
P51617 Interleukin-1 receptor-associated kinase 1 Irak CHEMBL413 CHEMBL2219219 (1) CHEMBL2219220 (1)
0 / 0
Q9NWZ3 Interleukin-1 receptor-associated kinase 4 Irak CHEMBL413 CHEMBL2219221 (1) CHEMBL2219222 (1)
2 / 1
O43353 Receptor-interacting serine/threonine-protein kinase 2 Ripk CHEMBL413 CHEMBL2219149 (1) CHEMBL2219150 (1)
0 / 0
P11509 Cytochrome P450 2A6 Cytochrome P450 2A6 CHEMBL413 CHEMBL1909133 (2)
0 / 0
P29320 Ephrin type-A receptor 3 Eph CHEMBL413 CHEMBL2219040 (1) CHEMBL2219041 (1)
1 / 0
P54764 Ephrin type-A receptor 4 Eph CHEMBL413 CHEMBL2219042 (1) CHEMBL2219043 (1)
0 / 0
Q8N5S9 Calcium/calmodulin-dependent protein kinase kinase 1 META serine/threonine protein kinase subfamily CHEMBL413 CHEMBL1061198 (1)
0 / 0
Q9P286 Serine/threonine-protein kinase PAK 7 STE serine/threonine protein kinase PAKB subfamily CHEMBL413 CHEMBL1061163 (1) CHEMBL2219363 (1)
CHEMBL2219364 (1)
0 / 0
Q16665 Hypoxia-inducible factor 1-alpha Transcription Factor CHEMBL1328768 CHEMBL1614456 (1) CHEMBL1613803 (1)
0 / 0
Q16620 BDNF/NT-3 growth factors receptor Trk CHEMBL413 CHEMBL2219317 (1) CHEMBL2219318 (1)
1 / 1
P42680 Tyrosine-protein kinase Tec Tec CHEMBL413 CHEMBL2219311 (1) CHEMBL2219312 (1)
0 / 0
P42681 Tyrosine-protein kinase TXK Tec CHEMBL413 CHEMBL2219319 (1) CHEMBL2219320 (1)
0 / 0
Q96SB4 SRSF protein kinase 1 Srpk CHEMBL413 CHEMBL1060225 (1) CHEMBL2219187 (1)
CHEMBL2219188 (1)
0 / 0
Q92630 Dual specificity tyrosine-phosphorylation-regulated kinase 2 CMGC dual-specificity kinase DYRK2 CHEMBL413 CHEMBL1062802 (1) CHEMBL2219032 (1)
CHEMBL2219033 (1)
0 / 0
O43781 Dual specificity tyrosine-phosphorylation-regulated kinase 3 CMGC dual-specificity kinase DYRK2 CHEMBL413 CHEMBL1061956 (1)
0 / 0
P07332 Tyrosine-protein kinase Fes/Fps Fer CHEMBL413 CHEMBL2219072 (1) CHEMBL2219073 (1)
0 / 0
O96013 Serine/threonine-protein kinase PAK 4 STE serine/threonine protein kinase PAKB subfamily CHEMBL413 CHEMBL1061162 (1) CHEMBL2219361 (1)
CHEMBL2219362 (1)
0 / 0
P09769 Tyrosine-protein kinase Fgr Src CHEMBL413 CHEMBL2219074 (1) CHEMBL2219075 (1)
0 / 0
P54760 Ephrin type-B receptor 4 Eph CHEMBL413 CHEMBL2219056 (1) CHEMBL2219057 (1)
0 / 0
P39748 Flap endonuclease 1 Enzyme CHEMBL1706754 CHEMBL1794486 (1)
0 / 0
Q09013 Myotonin-protein kinase AGC serine/threonine protein kinase GEK subfamily CHEMBL413 CHEMBL2219028 (1) CHEMBL2219029 (1)
1 / 1
Q16832 Discoidin domain-containing receptor 2 Ddr CHEMBL413 CHEMBL2219026 (1) CHEMBL2219027 (1)
1 / 1
Q8IYT8 Serine/threonine-protein kinase ULK2 ULK serine/threonine protein kinase CHEMBL413 CHEMBL2219321 (1) CHEMBL2219322 (1)
0 / 0
Q9BYT3 Serine/threonine-protein kinase 33 Unique CAMK serine/threonine protein kinase CHEMBL413 CHEMBL2219191 (1) CHEMBL2219192 (1)
0 / 0
P57059 Serine/threonine-protein kinase SIK1 CAMK serine/threonine protein kinase QIK subfamily CHEMBL413 CHEMBL2219185 (1) CHEMBL2219186 (1)
0 / 0
P78362 SRSF protein kinase 2 Srpk CHEMBL413 CHEMBL2219189 (1) CHEMBL2219190 (1)
0 / 0
Q9HBY8 Serine/threonine-protein kinase Sgk2 AGC serine/threonine protein kinase SGK subfamily CHEMBL413 CHEMBL2219181 (1) CHEMBL2219182 (1)
0 / 0
P84022 Mothers against decapentaplegic homolog 3 Unclassified protein CHEMBL413 CHEMBL1706754 CHEMBL1794584 (2)
2 / 0
O75496 Geminin Unclassified protein CHEMBL413 CHEMBL1446796 CHEMBL2114843 (2) CHEMBL2114780 (2)
0 / 0
Q86Y07 Serine/threonine-protein kinase VRK2 Enzyme CHEMBL413 CHEMBL2219325 (1) CHEMBL2219326 (1)
0 / 0
Q9Y3S1 Serine/threonine-protein kinase WNK2 WNK serine/threonine protein kinase subfamily CHEMBL413 CHEMBL2219327 (1) CHEMBL2219328 (1)
0 / 0
P04035 3-hydroxy-3-methylglutaryl-coenzyme A reductase Oxidoreductase CHEMBL413 CHEMBL1909158 (2)
0 / 0
P08913 Alpha-2A adrenergic receptor Adrenergic receptor CHEMBL413 CHEMBL1909088 (2)
0 / 0
P21917 D(4) dopamine receptor Dopamine receptor CHEMBL413 CHEMBL1909142 (2)
0 / 0
P30988 Calcitonin receptor Calcitonin receptor CHEMBL413 CHEMBL1909101 (2)
0 / 0
P35462 D(3) dopamine receptor Dopamine receptor CHEMBL413 CHEMBL1909141 (2)
1 / 0
P41143 Delta-type opioid receptor Opioid receptor CHEMBL413 CHEMBL1909180 (2)
0 / 0
Q92731 Estrogen receptor beta NR3A2 CHEMBL413 CHEMBL1909146 (2)
0 / 1
P41595 5-hydroxytryptamine receptor 2B Serotonin receptor CHEMBL413 CHEMBL1909104 (2)
0 / 0
P25101 Endothelin-1 receptor Endothelin receptor CHEMBL413 CHEMBL1909144 (2)
0 / 0
P30411 B2 bradykinin receptor Bradykinin receptor CHEMBL413 CHEMBL1909100 (2)
0 / 0
P32245 Melanocortin receptor 4 Melanocortin receptor CHEMBL413 CHEMBL1909167 (2)
1 / 0
P49841 Glycogen synthase kinase-3 beta Gsk CHEMBL413 CHEMBL1060118 (1) CHEMBL1249583 (1)
CHEMBL2219096 (1) CHEMBL2219097 (1)
0 / 0
P32238 Cholecystokinin receptor type A Cholecystokinin receptor CHEMBL413 CHEMBL1909129 (2)
0 / 0
P08311 Cathepsin G S1A CHEMBL413 CHEMBL1909194 (2)
0 / 0
Q15418 Ribosomal protein S6 kinase alpha-1 Rskb CHEMBL413 CHEMBL1052116 (1) CHEMBL2219163 (1)
CHEMBL2219164 (1)
0 / 0
O15264 Mitogen-activated protein kinase 13 p38 CHEMBL413 CHEMBL1060132 (1) CHEMBL1249572 (1)
CHEMBL2219177 (1) CHEMBL2219178 (1)
0 / 0
P42684 Abelson tyrosine-protein kinase 2 Abl CHEMBL413 CHEMBL2218946 (1) CHEMBL2218947 (1)
0 / 0
Q05397 Focal adhesion kinase 1 Fak CHEMBL413 CHEMBL2219060 (1) CHEMBL2219061 (1)
0 / 0
Q99720 Sigma non-opioid intracellular receptor 1 Membrane receptor CHEMBL413 CHEMBL1909110 (2)
1 / 0
P53779 Mitogen-activated protein kinase 10 Jnk CHEMBL413 CHEMBL1060123 (1) CHEMBL2219235 (1)
CHEMBL2219236 (1)
0 / 1
P29323 Ephrin type-B receptor 2 Eph CHEMBL413 CHEMBL2219052 (1) CHEMBL2219053 (1)
2 / 0
O75914 Serine/threonine-protein kinase PAK 3 STE serine/threonine protein kinase PAKA subfamily CHEMBL413 CHEMBL2219359 (1) CHEMBL2219360 (1)
1 / 1
P15735 Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Phk CHEMBL413 CHEMBL2219133 (1) CHEMBL2219134 (1)
1 / 1
Q02763 Angiopoietin-1 receptor Tie CHEMBL413 CHEMBL2219313 (1) CHEMBL2219314 (1)
1 / 1
P03956 Interstitial collagenase M10A CHEMBL413 CHEMBL1909196 (2)
0 / 1
P29317 Ephrin type-A receptor 2 Eph CHEMBL413 CHEMBL2219038 (1) CHEMBL2219039 (1)
1 / 1
P51955 Serine/threonine-protein kinase Nek2 Nek CHEMBL413 CHEMBL1062822 (1) CHEMBL2219301 (1)
CHEMBL2219302 (1)
0 / 0
Q15375 Ephrin type-A receptor 7 Eph CHEMBL413 CHEMBL2219046 (1) CHEMBL2219047 (1)
0 / 0
Q96RR4 Calcium/calmodulin-dependent protein kinase kinase 2 META serine/threonine protein kinase subfamily CHEMBL413 CHEMBL1052080 (1)
0 / 0
Q99683 Mitogen-activated protein kinase kinase kinase 5 Ste11 CHEMBL413 CHEMBL2219383 (1) CHEMBL2218943 (1)
0 / 0
P32241 Vasoactive intestinal polypeptide receptor 1 Vasoactive intestinal peptide receptor CHEMBL413 CHEMBL1909119 (2)
0 / 0
Q9H4B4 Serine/threonine-protein kinase PLK3 PLK serine/threonine protein kinase subfamily CHEMBL413 CHEMBL2219143 (1) CHEMBL2219144 (1)
0 / 0
P54753 Ephrin type-B receptor 3 Eph CHEMBL413 CHEMBL2219054 (1) CHEMBL2219055 (1)
0 / 0
Q9UM73 ALK tyrosine kinase receptor TKL serine/threonine protein kinase STKR type 1 subfamily CHEMBL413 CHEMBL2219373 (1) CHEMBL2219374 (1)
1 / 1
Q9BUB5 MAP kinase-interacting serine/threonine-protein kinase 1 CAMK serine/threonine protein kinase MNK subfamily CHEMBL413 CHEMBL1063759 (1)
0 / 0
O15146 Muscle, skeletal receptor tyrosine-protein kinase Musk CHEMBL413 CHEMBL2219297 (1) CHEMBL2219298 (1)
1 / 1
O60285 NUAK family SNF1-like kinase 1 CAMK serine/threonine protein kinase NUAK subfamily CHEMBL413 CHEMBL2219381 (1) CHEMBL2219382 (1)
0 / 0
O94782 Ubiquitin carboxyl-terminal hydrolase 1 Enzyme CHEMBL413 CHEMBL1446796 CHEMBL1794467 (2)
0 / 0
Q96RG2 PAS domain-containing serine/threonine-protein kinase Pask CHEMBL413 CHEMBL2219369 (1) CHEMBL2219370 (1)
0 / 0
P34947 G protein-coupled receptor kinase 5 AGC serine/threonine protein kinase GRK subfamily CHEMBL413 CHEMBL2219088 (1) CHEMBL2219089 (1)
0 / 0
P04150 Glucocorticoid receptor NR3C1 CHEMBL413 CHEMBL1909150 (2)
0 / 1
P06213 Insulin receptor TK tyrosine-protein kinase INSR subfamily CHEMBL413 CHEMBL2219215 (1) CHEMBL2219216 (1)
CHEMBL2219217 (1) CHEMBL2219218 (1)
5 / 4
P08172 Muscarinic acetylcholine receptor M2 Acetylcholine receptor CHEMBL413 CHEMBL1909171 (2)
2 / 0
P11229 Muscarinic acetylcholine receptor M1 Acetylcholine receptor CHEMBL413 CHEMBL1909170 (2)
0 / 0
P21554 Cannabinoid receptor 1 Cannabinoid receptor CHEMBL413 CHEMBL1909122 (2)
0 / 0
P31645 Sodium-dependent serotonin transporter Serotonin CHEMBL413 CHEMBL1909109 (2)
2 / 0
P04626 Receptor tyrosine-protein kinase erbB-2 TK tyrosine-protein kinase EGFR subfamily CHEMBL413 CHEMBL1909205 (2)
5 / 10
P09619 Platelet-derived growth factor receptor beta Pdgfr CHEMBL413 CHEMBL2219386 (1) CHEMBL2219387 (1)
5 / 1
P20309 Muscarinic acetylcholine receptor M3 Acetylcholine receptor CHEMBL413 CHEMBL1909172 (2)
1 / 0
P21452 Substance-K receptor Neurokinin receptor CHEMBL413 CHEMBL1909114 (2)
0 / 0
P52564 Dual specificity mitogen-activated protein kinase kinase 6 Ste7 CHEMBL413 CHEMBL2219267 (1) CHEMBL2219268 (1)
0 / 0
P48730 Casein kinase I isoform delta Ck1 CHEMBL413 CHEMBL1062001 (1) CHEMBL2218996 (1)
CHEMBL2218997 (1)
1 / 0
P12931 Proto-oncogene tyrosine-protein kinase Src Src CHEMBL413 CHEMBL2219341 (1) CHEMBL2219342 (1)
0 / 0
P51679 C-C chemokine receptor type 4 CC chemokine receptor CHEMBL413 CHEMBL1909125 (2)
0 / 0
P51681 C-C chemokine receptor type 5 CC chemokine receptor CHEMBL413 CHEMBL1909126 (2)
3 / 0
P50406 5-hydroxytryptamine receptor 6 Serotonin receptor CHEMBL413 CHEMBL1909108 (2)
0 / 0
O15111 Inhibitor of nuclear factor kappa-B kinase subunit alpha Other serine/threonine protein kinase CHEMBL413 CHEMBL2219211 (1) CHEMBL2219212 (1)
1 / 1
Q96GD4 Aurora kinase B Aur CHEMBL413 CHEMBL1051365 (1) CHEMBL2218950 (1)
CHEMBL2218951 (1)
0 / 0
O75676 Ribosomal protein S6 kinase alpha-4 CAMK serine/threonine protein kinase MSKB subfamily CHEMBL413 CHEMBL2219281 (1) CHEMBL2219282 (1)
0 / 0
P05129 Protein kinase C gamma type Alpha CHEMBL413 CHEMBL2219404 (1) CHEMBL2219405 (1)
1 / 1
O60674 Tyrosine-protein kinase JAK2 Jakb CHEMBL413 CHEMBL2219227 (1) CHEMBL2219228 (1)
5 / 2
P35968 Vascular endothelial growth factor receptor 2 Vegfr CHEMBL413 CHEMBL2219237 (1) CHEMBL2219238 (1)
1 / 0
P49137 MAP kinase-activated protein kinase 2 CAMK serine/threonine protein kinase MAPKAPK CHEMBL413 CHEMBL1051342 (1) CHEMBL1249574 (1)
CHEMBL2219255 (1) CHEMBL2219256 (1)
0 / 0
P08581 Hepatocyte growth factor receptor TK tyrosine-protein kinase MET subfamily CHEMBL413 CHEMBL2219293 (1) CHEMBL2219294 (1)
2 / 3
P41597 C-C chemokine receptor type 2 CC chemokine receptor CHEMBL413 CHEMBL1909124 (2)
1 / 0
P28482 Mitogen-activated protein kinase 1 Erk CHEMBL413 CHEMBL1052091 (1) CHEMBL1249567 (1)
CHEMBL1909200 (2) CHEMBL2219253 (1)
CHEMBL2219254 (1)
0 / 0
P35916 Vascular endothelial growth factor receptor 3 Vegfr CHEMBL413 CHEMBL2219080 (1) CHEMBL2219081 (1)
2 / 1
P22455 Fibroblast growth factor receptor 4 Fgfr CHEMBL413 CHEMBL2219068 (1) CHEMBL2219069 (1)
0 / 0
P22607 Fibroblast growth factor receptor 3 Fgfr CHEMBL413 CHEMBL2219066 (1) CHEMBL2219067 (1)
14 / 6
P08575 Receptor-type tyrosine-protein phosphatase C Enzyme CHEMBL413 CHEMBL1909207 (2)
2 / 1
P45983 Mitogen-activated protein kinase 8 Jnk CHEMBL413 CHEMBL1061969 (1) CHEMBL1249568 (1)
CHEMBL2219231 (1) CHEMBL2219232 (1)
0 / 0
P05177 Cytochrome P450 1A2 Cytochrome P450 1A2 CHEMBL413 CHEMBL1909132 (2)
0 / 0
O94804 Serine/threonine-protein kinase 10 STE serine/threonine protein kinase SLK subfamily CHEMBL413 CHEMBL2219243 (1) CHEMBL2219244 (1)
1 / 0
P53667 LIM domain kinase 1 Limk CHEMBL413 CHEMBL2219239 (1) CHEMBL2219240 (1)
0 / 0
Q13177 Serine/threonine-protein kinase PAK 2 STE serine/threonine protein kinase PAKA subfamily CHEMBL413 CHEMBL2219357 (1) CHEMBL2219358 (1)
0 / 0
Q06418 Tyrosine-protein kinase receptor TYRO3 TK tyrosine-protein kinase AXL CHEMBL413 CHEMBL2219161 (1) CHEMBL2219162 (1)
0 / 0
Q6PHR2 Serine/threonine-protein kinase ULK3 ULK serine/threonine protein kinase CHEMBL413 CHEMBL2219323 (1) CHEMBL2219324 (1)
0 / 0
Q7L7X3 Serine/threonine-protein kinase TAO1 STE serine/threonine protein kinase TAO subfamily CHEMBL413 CHEMBL2219199 (1) CHEMBL2219200 (1)
0 / 0
P14616 Insulin receptor-related protein TK tyrosine-protein kinase INSR CHEMBL413 CHEMBL2219223 (1) CHEMBL2219224 (1)
0 / 0
O43318 Mitogen-activated protein kinase kinase kinase 7 Tak1 CHEMBL413 CHEMBL2219197 (1) CHEMBL2219198 (1)
0 / 0
Q9BXA7 Testis-specific serine/threonine-protein kinase 1 Tssk CHEMBL413 CHEMBL2219307 (1) CHEMBL2219308 (1)
0 / 0
Q9H2K8 Serine/threonine-protein kinase TAO3 STE serine/threonine protein kinase TAO subfamily CHEMBL413 CHEMBL2219203 (1) CHEMBL2219204 (1)
0 / 0
Q96QE3 ATPase family AAA domain-containing protein 5 Unclassified protein CHEMBL1328768 CHEMBL1738588 (1)
0 / 0
Q8NG66 Serine/threonine-protein kinase Nek11 Nek11 CHEMBL413 CHEMBL2219299 (1) CHEMBL2219300 (1)
0 / 0
Q8WTQ7 G protein-coupled receptor kinase 7 AGC serine/threonine protein kinase GRK subfamily CHEMBL413 CHEMBL2219092 (1) CHEMBL2219093 (1)
0 / 0
Q8TF76 Serine/threonine-protein kinase haspin Haspin CHEMBL413 CHEMBL2219104 (1) CHEMBL2219105 (1)
0 / 0
O76074 cGMP-specific 3',5'-cyclic phosphodiesterase PDE_5A CHEMBL413 CHEMBL1909186 (2)
0 / 0
P03372 Estrogen receptor NR3A1 CHEMBL413 CHEMBL1909145 (2)
1 / 1
P08588 Beta-1 adrenergic receptor Adrenergic receptor CHEMBL413 CHEMBL1909091 (2)
1 / 0
P62942 Peptidyl-prolyl cis-trans isomerase FKBP1A Isomerase CHEMBL413 CHEMBL295272 CHEMBL678141 (1) CHEMBL678143 (1)
CHEMBL678147 (1) CHEMBL678159 (1)
CHEMBL677106 (1) CHEMBL881779 (1)
CHEMBL2219347 (1) CHEMBL2219348 (1)
CHEMBL2320778 (1)
0 / 0
P22303 Acetylcholinesterase Hydrolase CHEMBL413 CHEMBL1909212 (2)
1 / 0
P28223 5-hydroxytryptamine receptor 2A Serotonin receptor CHEMBL413 CHEMBL1909211 (2)
0 / 0
P28335 5-hydroxytryptamine receptor 2C Serotonin receptor CHEMBL413 CHEMBL1909105 (2)
0 / 0
P35372 Mu-type opioid receptor Opioid receptor CHEMBL413 CHEMBL1909182 (2)
0 / 0
P08173 Muscarinic acetylcholine receptor M4 Acetylcholine receptor CHEMBL413 CHEMBL1909173 (2)
0 / 0
P25103 Substance-P receptor Neurokinin receptor CHEMBL413 CHEMBL1909113 (2)
0 / 0
P25105 Platelet-activating factor receptor PAF receptor CHEMBL413 CHEMBL1909187 (2)
0 / 0
P11362 Fibroblast growth factor receptor 1 Fgfr CHEMBL413 CHEMBL2219062 (1) CHEMBL2219063 (1)
4 / 5
P53350 Serine/threonine-protein kinase PLK1 PLK serine/threonine protein kinase subfamily CHEMBL413 CHEMBL1052115 (1) CHEMBL2219141 (1)
CHEMBL2219142 (1)
0 / 0
Q08881 Tyrosine-protein kinase ITK/TSK Tec CHEMBL413 CHEMBL2219225 (1) CHEMBL2219226 (1)
1 / 1
P33032 Melanocortin receptor 5 Melanocortin receptor CHEMBL413 CHEMBL1909168 (2)
0 / 0
P49840 Glycogen synthase kinase-3 alpha Gsk CHEMBL413 CHEMBL2219094 (1) CHEMBL2219095 (1)
0 / 0
Q13976 cGMP-dependent protein kinase 1 Pkg CHEMBL413 CHEMBL2219123 (1) CHEMBL2219124 (1)
CHEMBL2219125 (1) CHEMBL2219126 (1)
0 / 0
Q8IW41 MAP kinase-activated protein kinase 5 CAMK serine/threonine protein kinase MAPKAPK CHEMBL413 CHEMBL1061101 (1) CHEMBL1249576 (1)
CHEMBL2219127 (1) CHEMBL2219128 (1)
0 / 0
O75116 Rho-associated protein kinase 2 Rock CHEMBL413 CHEMBL1063671 (1) CHEMBL2219153 (1)
CHEMBL2219154 (1)
0 / 0
P05771 Protein kinase C beta type Alpha CHEMBL413 CHEMBL2219400 (1) CHEMBL2219401 (1)
CHEMBL2219402 (1) CHEMBL2219403 (1)
0 / 0
P08631 Tyrosine-protein kinase HCK Src CHEMBL413 CHEMBL2219106 (1) CHEMBL2219107 (1)
CHEMBL2219108 (1) CHEMBL2219109 (1)
0 / 0
P07948 Tyrosine-protein kinase Lyn Src CHEMBL413 CHEMBL2219249 (1) CHEMBL2219250 (1)
0 / 0
P31749 RAC-alpha serine/threonine-protein kinase Akt CHEMBL413 CHEMBL1061172 (1) CHEMBL1249580 (1)
CHEMBL2219392 (1) CHEMBL2219393 (1)
4 / 1
Q15118 [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 1, mitochondrial Pdhk CHEMBL413 CHEMBL1249579 (1)
0 / 0
O00141 Serine/threonine-protein kinase Sgk1 AGC serine/threonine protein kinase SGK subfamily CHEMBL413 CHEMBL1063673 (1) CHEMBL1249581 (1)
CHEMBL2219179 (1) CHEMBL2219180 (1)
0 / 0
P51812 Ribosomal protein S6 kinase alpha-3 Rskb CHEMBL413 CHEMBL1063683 (1) CHEMBL2219165 (1)
CHEMBL2219166 (1)
2 / 2
P07333 Macrophage colony-stimulating factor 1 receptor Pdgfr CHEMBL413 CHEMBL2219082 (1) CHEMBL2219083 (1)
1 / 1
P33261 Cytochrome P450 2C19 Cytochrome P450 2C19 CHEMBL413 CHEMBL1909134 (2)
1 / 1
P08684 Cytochrome P450 3A4 Cytochrome P450 3A4 CHEMBL413 CHEMBL836230 (1) CHEMBL1743273 (1)
CHEMBL1909138 (2)
0 / 1
P05181 Cytochrome P450 2E1 Cytochrome P450 2E1 CHEMBL413 CHEMBL1909137 (2)
0 / 0
P16591 Tyrosine-protein kinase Fer Fer CHEMBL413 CHEMBL2219070 (1) CHEMBL2219071 (1)
0 / 0
Q8IU85 Calcium/calmodulin-dependent protein kinase type 1D Camk1 CHEMBL413 CHEMBL2219018 (1) CHEMBL2219019 (1)
0 / 0
Q9HC98 Serine/threonine-protein kinase Nek6 Nek CHEMBL413 CHEMBL1060128 (1) CHEMBL2219351 (1)
CHEMBL2219352 (1)
0 / 0
Q9UEE5 Serine/threonine-protein kinase 17A Dapk CHEMBL413 CHEMBL2219030 (1) CHEMBL2219031 (1)
0 / 0
P07949 Proto-oncogene tyrosine-protein kinase receptor Ret Ret CHEMBL413 CHEMBL2219155 (1) CHEMBL2219156 (1)
9 / 5
Q9H2X6 Homeodomain-interacting protein kinase 2 CMGC dual-specificity kinase HIPK CHEMBL413 CHEMBL1062015 (1) CHEMBL2219100 (1)
CHEMBL2219101 (1)
0 / 0
P36896 Activin receptor type-1B TKL serine/threonine protein kinase STKR type 1 subfamily CHEMBL413 CHEMBL2219375 (1) CHEMBL2219376 (1)
0 / 0
Q86UE8 Serine/threonine-protein kinase tousled-like 2 TLK serine/threonine protein kinase CHEMBL413 CHEMBL2219305 (1) CHEMBL2219306 (1)
0 / 0
Q86Z02 Homeodomain-interacting protein kinase 1 CMGC serine/threonine protein kinase HIPK subfamily CHEMBL413 CHEMBL2219098 (1) CHEMBL2219099 (1)
0 / 0
P10636 Microtubule-associated protein tau Unclassified protein CHEMBL1328768 CHEMBL1329171 CHEMBL1473145 CHEMBL1614250 (1) CHEMBL1614421 (4)
4 / 3
Q16236 Nuclear factor erythroid 2-related factor 2 Unclassified protein CHEMBL1706754 CHEMBL1738184 (1)
0 / 0
P23975 Sodium-dependent noradrenaline transporter Norepinephrine CHEMBL413 CHEMBL1909094 (2)
1 / 1
P25100 Alpha-1D adrenergic receptor Adrenergic receptor CHEMBL413 CHEMBL1909087 (2)
0 / 0
P30542 Adenosine receptor A1 Adenosine receptor CHEMBL413 CHEMBL1909213 (2)
0 / 0
P18089 Alpha-2B adrenergic receptor Adrenergic receptor CHEMBL413 CHEMBL1909089 (2)
0 / 0
P10721 Mast/stem cell growth factor receptor Kit Pdgfr CHEMBL413 CHEMBL2219339 (1) CHEMBL2219340 (1)
4 / 4
P24557 Thromboxane-A synthase Cytochrome P450 5A1 CHEMBL413 CHEMBL1909116 (2)
1 / 1
P06239 Tyrosine-protein kinase Lck Src CHEMBL413 CHEMBL1249588 (1) CHEMBL1909206 (2)
CHEMBL2219245 (1) CHEMBL2219246 (1)
CHEMBL2219247 (1) CHEMBL2219248 (1)
0 / 1
Q9HCP0 Casein kinase I isoform gamma-1 Ck1 CHEMBL413 CHEMBL2218990 (1) CHEMBL2218991 (1)
0 / 0
Q13554 Calcium/calmodulin-dependent protein kinase type II subunit beta Camk2 CHEMBL413 CHEMBL2219010 (1) CHEMBL2219011 (1)
0 / 0
O96017 Serine/threonine-protein kinase Chk2 Rad53 CHEMBL413 CHEMBL1062000 (1) CHEMBL2218988 (1)
CHEMBL2218989 (1)
4 / 1
P25025 C-X-C chemokine receptor type 2 CXC chemokine receptor CHEMBL413 CHEMBL1909128 (2)
0 / 0
P52333 Tyrosine-protein kinase JAK3 Jakb CHEMBL413 CHEMBL2219229 (1) CHEMBL2219230 (1)
1 / 1
P04049 RAF proto-oncogene serine/threonine-protein kinase Raf CHEMBL413 CHEMBL2219337 (1) CHEMBL2219338 (1)
2 / 0
P43405 Tyrosine-protein kinase SYK Syk CHEMBL413 CHEMBL2219195 (1) CHEMBL2219196 (1)
0 / 0
Q14012 Calcium/calmodulin-dependent protein kinase type 1 Camk1 CHEMBL413 CHEMBL1051272 (1) CHEMBL2219008 (1)
CHEMBL2219009 (1)
0 / 0
Q16566 Calcium/calmodulin-dependent protein kinase type IV Camk1 CHEMBL413 CHEMBL2219016 (1) CHEMBL2219017 (1)
0 / 0
P53355 Death-associated protein kinase 1 Dapk CHEMBL413 CHEMBL2219020 (1) CHEMBL2219021 (1)
0 / 1
P24723 Protein kinase C eta type Eta CHEMBL413 CHEMBL2219113 (1) CHEMBL2219114 (1)
1 / 0
P51451 Tyrosine-protein kinase Blk Src CHEMBL413 CHEMBL2218960 (1) CHEMBL2218961 (1)
1 / 1
P17612 cAMP-dependent protein kinase catalytic subunit alpha Pka CHEMBL413 CHEMBL1062854 (1) CHEMBL2219390 (1)
CHEMBL2219391 (1)
0 / 0
Q13627 Dual specificity tyrosine-phosphorylation-regulated kinase 1A CMGC dual-specificity kinase DYRK1 CHEMBL413 CHEMBL1062005 (1)
1 / 0
O14733 Dual specificity mitogen-activated protein kinase kinase 7 Ste7 CHEMBL413 CHEMBL2219269 (1) CHEMBL2219270 (1)
0 / 0
P53778 Mitogen-activated protein kinase 12 p38 CHEMBL413 CHEMBL1062773 (1) CHEMBL1249571 (1)
CHEMBL2219175 (1) CHEMBL2219176 (1)
0 / 0
O00418 Eukaryotic elongation factor 2 kinase Atypical serine/threonine protein kinase alpha subfamily CHEMBL413 CHEMBL1060113 (1) CHEMBL2219343 (1)
CHEMBL2219344 (1)
0 / 0
P35557 Glucokinase Enzyme CHEMBL413 CHEMBL2219086 (1) CHEMBL2219087 (1)
3 / 3
P49760 Dual specificity protein kinase CLK2 Clk CHEMBL413 CHEMBL2219002 (1) CHEMBL2219003 (1)
0 / 0
P54756 Ephrin type-A receptor 5 Eph CHEMBL413 CHEMBL2219044 (1) CHEMBL2219045 (1)
0 / 0
P54762 Ephrin type-B receptor 1 Eph CHEMBL413 CHEMBL2219050 (1) CHEMBL2219051 (1)
0 / 0
Q07912 Activated CDC42 kinase 1 TK tyrosine-protein kinase ACK subfamily CHEMBL413 CHEMBL2219371 (1) CHEMBL2219372 (1)
0 / 0
P30530 Tyrosine-protein kinase receptor UFO TK tyrosine-protein kinase AXL subfamily CHEMBL413 CHEMBL2218954 (1) CHEMBL2218955 (1)
0 / 0
Q9BZL6 Serine/threonine-protein kinase D2 Pkd CHEMBL413 CHEMBL2219121 (1) CHEMBL2219122 (1)
0 / 0
Q8TD08 Mitogen-activated protein kinase 15 Mapk CHEMBL413 CHEMBL1062012 (1)
0 / 0
P06730 Eukaryotic translation initiation factor 4E Other nuclear protein CHEMBL413 CHEMBL1639015 (1)
1 / 0
Q86V86 Serine/threonine-protein kinase pim-3 Pim CHEMBL413 CHEMBL1061912 (1) CHEMBL2219139 (1)
CHEMBL2219140 (1)
0 / 0
Q9UPE1 SRSF protein kinase 3 Srpk CHEMBL413 CHEMBL2219283 (1) CHEMBL2219284 (1)
0 / 0
Q9Y6E0 Serine/threonine-protein kinase 24 STE serine/threonine protein kinase YSK subfamily CHEMBL413 CHEMBL2219289 (1) CHEMBL2219290 (1)
0 / 0
Q9Y6M4 Casein kinase I isoform gamma-3 Ck1-g CHEMBL413 CHEMBL2218994 (1) CHEMBL2218995 (1)
0 / 0
Q8N568 Serine/threonine-protein kinase DCLK2 CAMK serine/threonine protein kinase DCAMK1 CHEMBL413 CHEMBL2219024 (1) CHEMBL2219025 (1)
0 / 0
Q8TDC3 Serine/threonine-protein kinase BRSK1 CAMK serine/threonine protein kinase BRSK subfamily CHEMBL413 CHEMBL2218964 (1) CHEMBL2218965 (1)
0 / 0
P51817 cAMP-dependent protein kinase catalytic subunit PRKX Pka CHEMBL413 CHEMBL2219145 (1) CHEMBL2219146 (1)
0 / 0
Q53EL6 Programmed cell death protein 4 Unclassified protein CHEMBL413 CHEMBL1787264 (1)
0 / 0
Q96KQ7 Histone-lysine N-methyltransferase EHMT2 Enzyme CHEMBL1329171 CHEMBL1738442 (1)
0 / 0
Q9UL54 Serine/threonine-protein kinase TAO2 STE serine/threonine protein kinase TAO subfamily CHEMBL413 CHEMBL2219201 (1) CHEMBL2219202 (1)
0 / 0
Q13451 Peptidyl-prolyl cis-trans isomerase FKBP5 Enzyme CHEMBL413 CHEMBL2351899 (1)
0 / 0
P51946 Cyclin-H Other cytosolic protein CHEMBL413 CHEMBL2218982 (1) CHEMBL2218983 (1)
0 / 0
P50613 Cyclin-dependent kinase 7 Cdk7 CHEMBL413 CHEMBL2218982 (1) CHEMBL2218983 (1)
0 / 0
P24864 G1/S-specific cyclin-E1 Other cytosolic protein CHEMBL413 CHEMBL2218972 (1) CHEMBL2218973 (1)
CHEMBL2218974 (1) CHEMBL2218975 (1)
0 / 2
P24941 Cyclin-dependent kinase 2 Cdc2 CHEMBL413 CHEMBL1056886 (1) CHEMBL2218970 (1)
CHEMBL2218971 (1) CHEMBL2218972 (1)
CHEMBL2218973 (1)
0 / 0
O96020 G1/S-specific cyclin-E2 Other cytosolic protein CHEMBL413 CHEMBL2218972 (1) CHEMBL2218973 (1)
CHEMBL2218974 (1) CHEMBL2218975 (1)
0 / 2
O95067 G2/mitotic-specific cyclin-B2 Other cytosolic protein CHEMBL413 CHEMBL2218968 (1) CHEMBL2218969 (1)
0 / 0
P14635 G2/mitotic-specific cyclin-B1 Other cytosolic protein CHEMBL413 CHEMBL2218968 (1) CHEMBL2218969 (1)
0 / 0
P06493 Cyclin-dependent kinase 1 Cdc2 CHEMBL413 CHEMBL2218968 (1) CHEMBL2218969 (1)
0 / 0
Q8WWL7 G2/mitotic-specific cyclin-B3 Other cytosolic protein CHEMBL413 CHEMBL2218968 (1) CHEMBL2218969 (1)
0 / 0
P20248 Cyclin-A2 Other cytosolic protein CHEMBL413 CHEMBL1056886 (1) CHEMBL2218970 (1)
CHEMBL2218971 (1)
0 / 0
P78396 Cyclin-A1 Other cytosolic protein CHEMBL413 CHEMBL1056886 (1) CHEMBL2218970 (1)
CHEMBL2218971 (1)
0 / 0
P68400 Casein kinase II subunit alpha Ck2 CHEMBL413 CHEMBL1061205 (1) CHEMBL2218998 (1)
CHEMBL2218999 (1)
0 / 0
P67870 Casein kinase II subunit beta REG serine/threonine protein kinase family CHEMBL413 CHEMBL1061205 (1) CHEMBL2218998 (1)
CHEMBL2218999 (1)
0 / 0
P54619 5'-AMP-activated protein kinase subunit gamma-1 REG serine/threonine protein kinase family CHEMBL413 CHEMBL2219377 (1) CHEMBL2219378 (1)
CHEMBL2219379 (1) CHEMBL2219380 (1)
0 / 0
Q9Y478 5'-AMP-activated protein kinase subunit beta-1 REG serine/threonine protein kinase family CHEMBL413 CHEMBL2219377 (1) CHEMBL2219378 (1)
CHEMBL2219379 (1) CHEMBL2219380 (1)
0 / 0
P54646 5'-AMP-activated protein kinase catalytic subunit alpha-2 Ampk CHEMBL413 CHEMBL2219379 (1) CHEMBL2219380 (1)
0 / 0
Q13131 5'-AMP-activated protein kinase catalytic subunit alpha-1 Ampk CHEMBL413 CHEMBL2219377 (1) CHEMBL2219378 (1)
CHEMBL2219379 (1) CHEMBL2219380 (1)
0 / 0
O43741 5'-AMP-activated protein kinase subunit beta-2 REG serine/threonine protein kinase family CHEMBL413 CHEMBL2219379 (1) CHEMBL2219380 (1)
0 / 0
Q9UGJ0 5'-AMP-activated protein kinase subunit gamma-2 REG serine/threonine protein kinase family CHEMBL413 CHEMBL2219379 (1) CHEMBL2219380 (1)
3 / 3
O60563 Cyclin-T1 Other cytosolic protein CHEMBL413 CHEMBL2218984 (1) CHEMBL2218985 (1)
0 / 0
P50750 Cyclin-dependent kinase 9 Cdk9 CHEMBL413 CHEMBL2218984 (1) CHEMBL2218985 (1)
0 / 0
Q00526 Cyclin-dependent kinase 3 Cdc2 CHEMBL413 CHEMBL2218974 (1) CHEMBL2218975 (1)
0 / 0
Q00534 Cyclin-dependent kinase 6 CMGC serine/threonine protein kinase family CHEMBL413 CHEMBL2218980 (1) CHEMBL2218981 (1)
1 / 0
P30281 G1/S-specific cyclin-D3 Other cytosolic protein CHEMBL413 CHEMBL2218980 (1) CHEMBL2218981 (1)
0 / 1
Q9UGI9 5'-AMP-activated protein kinase subunit gamma-3 Kinase CHEMBL413 CHEMBL2219379 (1) CHEMBL2219380 (1)
0 / 0

CTD interaction (614)

compound gene gene name gene description interaction interaction type form reference
pmid
D020123 19 ABCA1
ABC-1
ABC1
CERP
HDLDT1
TGD
ATP-binding cassette, sub-family A (ABC1), member 1 [Sirolimus co-treated with Cyclosporine] results in decreased expression of ABCA1 protein affects cotreatment
/ decreases expression
protein 17016853
D020123 19 ABCA1
ABC-1
ABC1
CERP
HDLDT1
TGD
ATP-binding cassette, sub-family A (ABC1), member 1 [Sirolimus co-treated with Tacrolimus] results in increased expression of ABCA1 protein affects cotreatment
/ increases expression
protein 17016853
D020123 19 ABCA1
ABC-1
ABC1
CERP
HDLDT1
TGD
ATP-binding cassette, sub-family A (ABC1), member 1 Sirolimus results in increased expression of ABCA1 mRNA increases expression
mRNA 17016853
D020123 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) ABCB1 protein affects the metabolism of Sirolimus affects metabolic processing
protein 15707415
15760093
D020123 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) ABCB1 protein affects the transport of Sirolimus affects transport
protein 15964407
D020123 340485 ACER2
ALKCDase2
ASAH3L
alkaline ceramidase 2 (EC:3.5.1.23) Sirolimus inhibits the reaction [TP73 protein results in decreased expression of ACER2 mRNA] decreases expression
/ decreases reaction
mRNA 21245298
D020123 59 ACTA2
AAT6
ACTSA
MYMY5
actin, alpha 2, smooth muscle, aorta [Sirolimus co-treated with IGF1 protein] results in increased expression of ACTA2 protein affects cotreatment
/ increases expression
protein 17908691
D020123 9131 AIFM1
AIF
CMTX4
COWCK
COXPD6
PDCD8
apoptosis-inducing factor, mitochondrion-associated, 1 [7-hydroxystaurosporine co-treated with Sirolimus] affects the localization of AIFM1 protein affects cotreatment
/ affects localization
protein 15767555
D020123 9131 AIFM1
AIF
CMTX4
COWCK
COXPD6
PDCD8
apoptosis-inducing factor, mitochondrion-associated, 1 Boc-D-FMK inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] affects the localization of AIFM1 protein] affects cotreatment
/ affects localization
/ decreases reaction
protein 15767555
D020123 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) Cisplatin inhibits the reaction [Sirolimus results in increased phosphorylation of AKT1 protein] decreases reaction
/ increases phosphorylation
protein 21092744
D020123 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3A protein] decreases reaction
/ increases phosphorylation
protein 21092744
D020123 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) [Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3A protein]] which results in increased expression of BCL2L11 protein decreases reaction
/ increases expression
/ increases phosphorylation
protein 21092744
D020123 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) [Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3A protein]] which results in increased expression of CDKN1B protein decreases reaction
/ increases expression
/ increases phosphorylation
protein 21092744
D020123 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of AKT1 protein affects cotreatment
/ decreases phosphorylation
protein 18622747
D020123 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) Sirolimus inhibits the reaction [Tretinoin results in increased phosphorylation of AKT1 protein] decreases reaction
/ increases phosphorylation
protein 19176369
D020123 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) Sirolimus results in decreased phosphorylation of AKT1 protein decreases phosphorylation
protein 19176369
21976531
D020123 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) Sirolimus results in increased phosphorylation of AKT1 protein increases phosphorylation
protein 21092744
D020123 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) [Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3A protein increases phosphorylation
protein 21092744
D020123 208 AKT2
HIHGHH
PKBB
PKBBETA
PRKBB
RAC-BETA
v-akt murine thymoma viral oncogene homolog 2 (EC:2.7.11.1) [Sirolimus results in increased activity of AKT2 protein] which results in increased expression of CALD1 protein increases activity
/ increases expression
protein 17908691
D020123 208 AKT2
HIHGHH
PKBB
PKBBETA
PRKBB
RAC-BETA
v-akt murine thymoma viral oncogene homolog 2 (EC:2.7.11.1) [Sirolimus results in increased activity of AKT2 protein] which results in increased expression of MYH11 protein increases activity
/ increases expression
protein 17908691
D020123 208 AKT2
HIHGHH
PKBB
PKBBETA
PRKBB
RAC-BETA
v-akt murine thymoma viral oncogene homolog 2 (EC:2.7.11.1) Sirolimus results in increased phosphorylation of and results in increased activity of AKT2 protein increases activity
/ increases phosphorylation
protein 17908691
D020123 351 APP
AAA
ABETA
ABPP
AD1
APPI
CTFgamma
CVAP
PN-II
PN2
amyloid beta (A4) precursor protein Sirolimus results in decreased expression of APP protein modified form decreases expression
protein 20542014
D020123 351 APP
AAA
ABETA
ABPP
AD1
APPI
CTFgamma
CVAP
PN-II
PN2
amyloid beta (A4) precursor protein Sirolimus results in increased expression of APP protein modified form increases expression
protein 20542014
D020123 367 AR
AIS
DHTR
HUMARA
HYSP1
KD
NR3C4
SBMA
SMAX1
TFM
androgen receptor bicalutamide inhibits the reaction [Sirolimus results in increased activity of AR protein] decreases reaction
/ increases activity
protein 18776922
D020123 367 AR
AIS
DHTR
HUMARA
HYSP1
KD
NR3C4
SBMA
SMAX1
TFM
androgen receptor RPTOR protein inhibits the reaction [Sirolimus results in increased activity of AR protein] decreases reaction
/ increases activity
protein 18776922
D020123 367 AR
AIS
DHTR
HUMARA
HYSP1
KD
NR3C4
SBMA
SMAX1
TFM
androgen receptor Sirolimus affects the reaction [Testosterone results in increased expression of AR protein] affects reaction
/ increases expression
protein 21036700
D020123 367 AR
AIS
DHTR
HUMARA
HYSP1
KD
NR3C4
SBMA
SMAX1
TFM
androgen receptor Sirolimus promotes the reaction [Dihydrotestosterone affects the expression of AR protein] affects expression
/ increases reaction
protein 21036700
D020123 367 AR
AIS
DHTR
HUMARA
HYSP1
KD
NR3C4
SBMA
SMAX1
TFM
androgen receptor [Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein]] which results in increased activity of AR protein affects binding
/ decreases activity
/ increases activity
protein 18776922
D020123 367 AR
AIS
DHTR
HUMARA
HYSP1
KD
NR3C4
SBMA
SMAX1
TFM
androgen receptor Sirolimus results in increased activity of AR protein increases activity
protein 18776922
D020123 367 AR
AIS
DHTR
HUMARA
HYSP1
KD
NR3C4
SBMA
SMAX1
TFM
androgen receptor Sirolimus results in increased expression of AR protein increases expression
protein 18776922
D020123 9474 ATG5
APG5
APG5-LIKE
APG5L
ASP
hAPG5
autophagy related 5 ATG5 protein affects the reaction [Sirolimus inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein]] affects reaction
/ decreases reaction
/ increases cleavage
protein 19682553
D020123 9212 AURKB
AIK2
AIM-1
AIM1
ARK2
AurB
IPL1
PPP1R48
STK12
STK5
aurkb-sv1
aurkb-sv2
aurora kinase B (EC:2.7.11.1) [fulvestrant co-treated with Sirolimus] results in decreased expression of AURKB mRNA affects cotreatment
/ decreases expression
mRNA 19016759
D020123 581 BAX
BCL2L4
BCL2-associated X protein [Curcumin co-treated with Sirolimus] results in increased expression of BAX affects cotreatment
/ increases expression
19373661
D020123 581 BAX
BCL2L4
BCL2-associated X protein Sirolimus affects the localization of BAX protein affects localization
protein 11602639
D020123 581 BAX
BCL2L4
BCL2-associated X protein Sirolimus results in increased expression of BAX protein increases expression
protein 15782132
D020123 27113 BBC3
JFY-1
JFY1
PUMA
BCL2 binding component 3 [[Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein] which results in increased expression of BBC3 protein affects cotreatment
/ increases expression
protein 20686837
D020123 27113 BBC3
JFY-1
JFY1
PUMA
BCL2 binding component 3 Sirolimus promotes the reaction [TP53 protein results in increased expression of BBC3 protein] increases expression
/ increases reaction
protein 19560264
D020123 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [Curcumin co-treated with Sirolimus] results in decreased expression of BCL2 affects cotreatment
/ decreases expression
19373661
D020123 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Sirolimus inhibits the reaction [Doxorubicin results in increased expression of BCL2 protein] decreases reaction
/ increases expression
protein 15571967
D020123 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Sirolimus promotes the reaction [Ethanol results in increased expression of BCL2 protein] increases expression
/ increases reaction
protein 21410490
D020123 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Sirolimus results in decreased expression of BCL2 mRNA decreases expression
mRNA 19764996
D020123 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Sirolimus results in decreased expression of BCL2 protein decreases expression
protein 19815708
D020123 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of BCL2L1 protein affects cotreatment
/ decreases expression
protein 15767555
D020123 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 Sirolimus inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2L1 protein] decreases reaction
/ increases expression
protein 18789402
D020123 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 Sirolimus results in decreased expression of BCL2L1 protein decreases expression
protein 15782132
D020123 10018 BCL2L11
BAM
BIM
BOD
BCL2-like 11 (apoptosis facilitator) [Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3A protein]] which results in increased expression of BCL2L11 protein decreases reaction
/ increases expression
/ increases phosphorylation
protein 21092744
D020123 10018 BCL2L11
BAM
BIM
BOD
BCL2-like 11 (apoptosis facilitator) Sirolimus promotes the reaction [Cisplatin results in increased expression of BCL2L11 mRNA] increases expression
/ increases reaction
mRNA 21092744
D020123 10018 BCL2L11
BAM
BIM
BOD
BCL2-like 11 (apoptosis facilitator) Sirolimus results in increased expression of BCL2L11 protein increases expression
protein 21092744
D020123 8678 BECN1
ATG6
VPS30
beclin1
beclin 1, autophagy related Sirolimus inhibits the reaction [Ethanol results in increased degradation of BECN1 protein] decreases reaction
/ increases degradation
protein 21410490
D020123 637 BID
FP497
BH3 interacting domain death agonist [7-hydroxystaurosporine co-treated with Sirolimus] results in increased cleavage of BID protein affects cotreatment
/ increases cleavage
protein 15767555
D020123 329 BIRC2
API1
HIAP2
Hiap-2
MIHB
RNF48
c-IAP1
cIAP1
baculoviral IAP repeat containing 2 Sirolimus inhibits the reaction [Doxorubicin results in increased expression of BIRC2 protein] decreases reaction
/ increases expression
protein 15571967
D020123 332 BIRC5
API4
EPR-1
baculoviral IAP repeat containing 5 [fulvestrant co-treated with Sirolimus] results in decreased expression of BIRC5 mRNA affects cotreatment
/ decreases expression
mRNA 19016759
D020123 332 BIRC5
API4
EPR-1
baculoviral IAP repeat containing 5 Sirolimus promotes the reaction [Tamoxifen results in decreased expression of BIRC5 protein] decreases expression
/ increases reaction
protein 19931998
D020123 332 BIRC5
API4
EPR-1
baculoviral IAP repeat containing 5 Sirolimus results in decreased expression of BIRC5 protein decreases expression
protein 19931998
21601561
D020123 121551 BTBD11
ABTB2B
BTB (POZ) domain containing 11 Sirolimus inhibits the reaction [TP73 protein results in increased expression of BTBD11 mRNA] decreases reaction
/ increases expression
mRNA 21245298
D020123 699 BUB1
BUB1A
BUB1L
hBUB1
BUB1 mitotic checkpoint serine/threonine kinase (EC:2.7.11.1) [fulvestrant co-treated with Sirolimus] results in decreased expression of BUB1 mRNA affects cotreatment
/ decreases expression
mRNA 19016759
D020123 701 BUB1B
BUB1beta
BUBR1
Bub1A
MAD3L
MVA1
SSK1
hBUBR1
BUB1 mitotic checkpoint serine/threonine kinase B (EC:2.7.11.1) [fulvestrant co-treated with Sirolimus] results in decreased expression of BUB1B mRNA affects cotreatment
/ decreases expression
mRNA 19016759
D020123 84909 C9orf3
AOPEP
AP-O
APO
C90RF3
ONPEP
chromosome 9 open reading frame 3 Sirolimus inhibits the reaction [TP73 protein results in increased expression of C9ORF3 mRNA] decreases reaction
/ increases expression
mRNA 21245298
D020123 800 CALD1
CDM
H-CAD
HCAD
L-CAD
LCAD
NAG22
caldesmon 1 [Sirolimus co-treated with IGF1 protein] results in increased expression of CALD1 protein affects cotreatment
/ increases expression
protein 17908691
D020123 800 CALD1
CDM
H-CAD
HCAD
L-CAD
LCAD
NAG22
caldesmon 1 [Sirolimus results in increased activity of AKT2 protein] which results in increased expression of CALD1 protein increases activity
/ increases expression
protein 17908691
D020123 800 CALD1
CDM
H-CAD
HCAD
L-CAD
LCAD
NAG22
caldesmon 1 Sirolimus results in increased expression of CALD1 protein increases expression
protein 17908691
D020123 835 CASP2
CASP-2
ICH1
NEDD-2
NEDD2
PPP1R57
caspase 2, apoptosis-related cysteine peptidase (EC:3.4.22.55) [Boc-D-FMK co-treated with Sirolimus] results in increased cleavage of CASP2 protein affects cotreatment
/ increases cleavage
protein 15767555
D020123 835 CASP2
CASP-2
ICH1
NEDD-2
NEDD2
PPP1R57
caspase 2, apoptosis-related cysteine peptidase (EC:3.4.22.55) Boc-D-FMK inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP2 protein] affects cotreatment
/ decreases reaction
/ increases cleavage
protein 15767555
D020123 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [7-hydroxystaurosporine co-treated with Sirolimus] results in increased cleavage of CASP3 protein affects cotreatment
/ increases cleavage
protein 15767555
D020123 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) anthra(1,9-cd)pyrazol-6(2H)-one inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP3 protein] affects cotreatment
/ decreases reaction
/ increases cleavage
protein 15767555
D020123 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Boc-D-FMK inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP3 protein] affects cotreatment
/ decreases reaction
/ increases cleavage
protein 15767555
D020123 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [Curcumin co-treated with Sirolimus] results in increased activity of CASP3 protein affects cotreatment
/ increases activity
protein 19373661
D020123 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Fluorouracil promotes the reaction [Sirolimus results in increased expression of CASP3 mRNA] increases expression
/ increases reaction
mRNA 19764996
D020123 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [S 1 (combination) co-treated with Sirolimus] results in increased expression of CASP3 protein affects cotreatment
/ increases expression
protein 19764996
D020123 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [Sirolimus co-treated with Paclitaxel] results in increased cleavage of CASP3 protein affects cotreatment
/ increases cleavage
protein 15753396
D020123 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Sirolimus inhibits the reaction [Ethanol results in increased cleavage of CASP3 protein] decreases reaction
/ increases cleavage
protein 21410490
D020123 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Sirolimus inhibits the reaction [Rotenone results in increased cleavage of CASP3 protein] decreases reaction
/ increases cleavage
protein 19682553
D020123 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Sirolimus promotes the reaction [Cisplatin results in increased cleavage of CASP3 protein] increases cleavage
/ increases reaction
protein 18058806
D020123 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Sirolimus promotes the reaction [Doxorubicin results in increased activity of CASP3 protein] increases activity
/ increases reaction
protein 15571967
D020123 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Sirolimus promotes the reaction [Fluorouracil results in increased expression of CASP3 mRNA] increases expression
/ increases reaction
mRNA 19764996
D020123 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Sirolimus results in increased activity of CASP3 protein increases activity
protein 15782132
D020123 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Sirolimus results in increased cleavage of CASP3 protein increases cleavage
protein 15878982
D020123 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Sirolimus results in increased expression of CASP3 mRNA increases expression
mRNA 19764996
D020123 840 CASP7
CASP-7
CMH-1
ICE-LAP3
LICE2
MCH3
caspase 7, apoptosis-related cysteine peptidase (EC:3.4.22.60) [Curcumin co-treated with Sirolimus] results in increased activity of CASP7 protein affects cotreatment
/ increases activity
protein 19373661
D020123 840 CASP7
CASP-7
CMH-1
ICE-LAP3
LICE2
MCH3
caspase 7, apoptosis-related cysteine peptidase (EC:3.4.22.60) [Sirolimus co-treated with Paclitaxel] results in increased cleavage of CASP7 protein affects cotreatment
/ increases cleavage
protein 15753396
D020123 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) [7-hydroxystaurosporine co-treated with Sirolimus] results in increased cleavage of CASP8 protein affects cotreatment
/ increases cleavage
protein 15767555
D020123 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) anthra(1,9-cd)pyrazol-6(2H)-one inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP8 protein] affects cotreatment
/ decreases reaction
/ increases cleavage
protein 15767555
D020123 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) Sirolimus promotes the reaction [Cisplatin results in increased cleavage of CASP8 protein] increases cleavage
/ increases reaction
protein 18058806
D020123 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) [tanespimycin co-treated with Sirolimus] results in increased cleavage of CASP8 protein affects cotreatment
/ increases cleavage
protein 17121904
D020123 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) [7-hydroxystaurosporine co-treated with Sirolimus] results in increased cleavage of CASP9 protein affects cotreatment
/ increases cleavage
protein 15767555
D020123 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) [Curcumin co-treated with Sirolimus] results in increased activity of CASP9 protein affects cotreatment
/ increases activity
protein 19373661
D020123 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) [Sirolimus co-treated with Cisplatin] results in increased activity of CASP9 protein affects cotreatment
/ increases activity
protein 20138251
D020123 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) [Sirolimus co-treated with Paclitaxel] results in increased cleavage of CASP9 protein affects cotreatment
/ increases cleavage
protein 15753396
D020123 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) Sirolimus promotes the reaction [Cisplatin results in increased cleavage of CASP9 protein] increases cleavage
/ increases reaction
protein 18058806
D020123 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) [tanespimycin co-treated with Sirolimus] results in increased cleavage of CASP9 protein affects cotreatment
/ increases cleavage
protein 17121904
D020123 859 CAV3
LGMD1C
LQT9
VIP-21
VIP21
caveolin 3 Sirolimus inhibits the reaction [TP73 protein results in increased expression of CAV3 mRNA] decreases reaction
/ increases expression
mRNA 21245298
D020123 890 CCNA2
CCN1
CCNA
cyclin A2 [fulvestrant co-treated with Sirolimus] results in decreased expression of CCNA2 mRNA affects cotreatment
/ decreases expression
mRNA 19016759
D020123 890 CCNA2
CCN1
CCNA
cyclin A2 Sirolimus results in decreased expression of CCNA2 decreases expression
8419408
D020123 890 CCNA2
CCN1
CCNA
cyclin A2 Sirolimus results in decreased expression of CCNA2 protein decreases expression
protein 19505958
D020123 9133 CCNB2
HsT17299
cyclin B2 [fulvestrant co-treated with Sirolimus] results in decreased expression of CCNB2 mRNA affects cotreatment
/ decreases expression
mRNA 19016759
D020123 595 CCND1
BCL1
D11S287E
PRAD1
U21B31
cyclin D1 [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with Sirolimus] results in decreased expression of CCND1 affects cotreatment
/ decreases expression
23006739
D020123 595 CCND1
BCL1
D11S287E
PRAD1
U21B31
cyclin D1 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Sirolimus results in increased expression of CCND1 protein] decreases reaction
/ increases expression
protein 19661225
D020123 595 CCND1
BCL1
D11S287E
PRAD1
U21B31
cyclin D1 [3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein] decreases activity
/ decreases expression
/ decreases reaction
protein 15753396
D020123 595 CCND1
BCL1
D11S287E
PRAD1
U21B31
cyclin D1 [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of CCND1 protein affects cotreatment
/ decreases expression
protein 15767555
D020123 595 CCND1
BCL1
D11S287E
PRAD1
U21B31
cyclin D1 [Lithium Chloride results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein] decreases activity
/ decreases expression
/ decreases reaction
protein 15753396
D020123 595 CCND1
BCL1
D11S287E
PRAD1
U21B31
cyclin D1 [SB 216763 results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein] decreases activity
/ decreases expression
/ decreases reaction
protein 15753396
D020123 595 CCND1
BCL1
D11S287E
PRAD1
U21B31
cyclin D1 [Sirolimus co-treated with letrozole] results in decreased expression of CCND1 protein affects cotreatment
/ decreases expression
protein 20054642
D020123 595 CCND1
BCL1
D11S287E
PRAD1
U21B31
cyclin D1 [Sirolimus co-treated with tanespimycin] results in decreased expression of CCND1 protein affects cotreatment
/ decreases expression
protein 17121904
D020123 595 CCND1
BCL1
D11S287E
PRAD1
U21B31
cyclin D1 Sirolimus results in decreased expression of CCND1 protein decreases expression
protein 15753396
17121904
19505958
D020123 595 CCND1
BCL1
D11S287E
PRAD1
U21B31
cyclin D1 [Sirolimus results in increased activity of GSK3B protein] which results in increased phosphorylation of and results in increased degradation of CCND1 protein increases activity
/ increases degradation
/ increases phosphorylation
protein 15753396
D020123 595 CCND1
BCL1
D11S287E
PRAD1
U21B31
cyclin D1 Sirolimus results in increased degradation of CCND1 protein increases degradation
protein 15753396
D020123 595 CCND1
BCL1
D11S287E
PRAD1
U21B31
cyclin D1 Sirolimus results in increased expression of CCND1 protein increases expression
protein 19661225
D020123 894 CCND2
KIAK0002
cyclin D2 [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased expression of CCND2 protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 15778701
D020123 894 CCND2
KIAK0002
cyclin D2 Sirolimus inhibits the reaction [IL2 protein results in increased expression of CCND2 mRNA] decreases reaction
/ increases expression
mRNA 15778701
D020123 894 CCND2
KIAK0002
cyclin D2 Sirolimus results in decreased expression of CCND2 protein decreases expression
protein 15070696
D020123 896 CCND3
cyclin D3 [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased expression of CCND3 protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 15778701
D020123 896 CCND3
cyclin D3 Sirolimus inhibits the reaction [IL2 protein results in increased expression of CCND3 mRNA] decreases reaction
/ increases expression
mRNA 15778701
D020123 896 CCND3
cyclin D3 Sirolimus results in decreased expression of CCND3 mRNA decreases expression
mRNA 15882288
D020123 896 CCND3
cyclin D3 Sirolimus results in decreased expression of CCND3 protein decreases expression
protein 12393642
15070696
15882288
D020123 896 CCND3
cyclin D3 Sirolimus results in decreased stability of CCND3 mRNA decreases stability
mRNA 15882288
D020123 9134 CCNE2
CYCE2
cyclin E2 [fulvestrant co-treated with Sirolimus] results in decreased expression of CCNE2 mRNA affects cotreatment
/ decreases expression
mRNA 19016759
D020123 901 CCNG2
cyclin G2 [cotylenin A co-treated with Sirolimus] results in increased expression of CCNG2 mRNA affects cotreatment
/ increases expression
mRNA 18754885
D020123 901 CCNG2
cyclin G2 Sirolimus inhibits the reaction [TP73 protein results in increased expression of CCNG2 mRNA] decreases reaction
/ increases expression
mRNA 21245298
D020123 948 CD36
BDPLT10
CHDS7
FAT
GP3B
GP4
GPIV
PASIV
SCARB3
CD36 molecule (thrombospondin receptor) Sirolimus affects the expression of CD36 protein affects expression
protein 17016853
D020123 948 CD36
BDPLT10
CHDS7
FAT
GP3B
GP4
GPIV
PASIV
SCARB3
CD36 molecule (thrombospondin receptor) Sirolimus inhibits the reaction [Oxygen deficiency results in increased expression of CD36 mRNA] decreases reaction
/ increases expression
mRNA 19640849
D020123 968 CD68
GP110
LAMP4
SCARD1
CD68 molecule Sirolimus results in decreased expression of CD68 mRNA decreases expression
mRNA 17016853
D020123 991 CDC20
CDC20A
bA276H19.3
p55CDC
cell division cycle 20 [fulvestrant co-treated with Sirolimus] results in decreased expression of CDC20 mRNA affects cotreatment
/ decreases expression
mRNA 19016759
D020123 983 CDK1
CDC2
CDC28A
P34CDC2
cyclin-dependent kinase 1 (EC:2.7.11.23 2.7.11.22) [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of CDK1 mRNA affects cotreatment
/ decreases expression
mRNA 19223503
D020123 983 CDK1
CDC2
CDC28A
P34CDC2
cyclin-dependent kinase 1 (EC:2.7.11.23 2.7.11.22) [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of CDK1 protein affects cotreatment
/ decreases expression
protein 15767555
19223503
D020123 983 CDK1
CDC2
CDC28A
P34CDC2
cyclin-dependent kinase 1 (EC:2.7.11.23 2.7.11.22) [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of CDK1 protein affects cotreatment
/ decreases phosphorylation
protein 15767555
D020123 983 CDK1
CDC2
CDC28A
P34CDC2
cyclin-dependent kinase 1 (EC:2.7.11.23 2.7.11.22) [fulvestrant co-treated with Sirolimus] results in decreased expression of CDK1 mRNA affects cotreatment
/ decreases expression
mRNA 19016759
D020123 983 CDK1
CDC2
CDC28A
P34CDC2
cyclin-dependent kinase 1 (EC:2.7.11.23 2.7.11.22) Sirolimus results in decreased expression of CDK1 decreases expression
8419408
D020123 1017 CDK2
p33(CDK2)
cyclin-dependent kinase 2 (EC:2.7.11.22) [Sirolimus co-treated with TGFB1 protein] affects the localization of CDK2 protein affects cotreatment
/ affects localization
protein 14979923
D020123 1017 CDK2
p33(CDK2)
cyclin-dependent kinase 2 (EC:2.7.11.22) [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1A protein binds to CDK2 protein] affects binding
/ affects cotreatment
/ increases reaction
protein 14979923
D020123 1017 CDK2
p33(CDK2)
cyclin-dependent kinase 2 (EC:2.7.11.22) Sirolimus results in decreased activity of CDK2 protein decreases activity
protein 12393642
21528311
D020123 1017 CDK2
p33(CDK2)
cyclin-dependent kinase 2 (EC:2.7.11.22) [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL1 protein] which binds to CDK2 protein] affects binding
/ affects cotreatment
/ decreases reaction
protein 12417722
D020123 1017 CDK2
p33(CDK2)
cyclin-dependent kinase 2 (EC:2.7.11.22) [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL2 protein] which binds to CDK2 protein] affects binding
/ affects cotreatment
/ decreases reaction
protein 12417722
D020123 1017 CDK2
p33(CDK2)
cyclin-dependent kinase 2 (EC:2.7.11.22) [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1A protein] affects binding
/ affects cotreatment
/ increases reaction
protein 12417722
D020123 1017 CDK2
p33(CDK2)
cyclin-dependent kinase 2 (EC:2.7.11.22) [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein] affects binding
/ affects cotreatment
/ increases reaction
protein 12417722
D020123 1017 CDK2
p33(CDK2)
cyclin-dependent kinase 2 (EC:2.7.11.22) [TGFB1 protein co-treated with Sirolimus] results in decreased activity of CDK2 protein affects cotreatment
/ decreases activity
protein 12417722
D020123 1017 CDK2
p33(CDK2)
cyclin-dependent kinase 2 (EC:2.7.11.22) [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of CDK2 protein affects cotreatment
/ decreases phosphorylation
protein 12417722
D020123 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) Fluorouracil promotes the reaction [Sirolimus results in increased expression of CDKN1A mRNA] increases expression
/ increases reaction
mRNA 19764996
D020123 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) [S 1 (combination) co-treated with Sirolimus] results in increased expression of CDKN1A protein affects cotreatment
/ increases expression
protein 19764996
D020123 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1A protein binds to CDK2 protein] affects binding
/ affects cotreatment
/ increases reaction
protein 14979923
D020123 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) [Sirolimus co-treated with TGFB1 protein] results in increased expression of CDKN1A protein affects cotreatment
/ increases expression
protein 14979923
D020123 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) Sirolimus promotes the reaction [Fluorouracil results in increased expression of CDKN1A mRNA] increases expression
/ increases reaction
mRNA 19764996
D020123 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) Sirolimus results in increased expression of CDKN1A mRNA increases expression
mRNA 19764996
21528311
D020123 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) Sirolimus results in increased expression of CDKN1A protein increases expression
protein 21528311
D020123 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1A protein] affects binding
/ affects cotreatment
/ increases reaction
protein 12417722
D020123 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) [TGFB1 protein co-treated with Sirolimus] results in increased expression of CDKN1A protein affects cotreatment
/ increases expression
protein 17700525
D020123 1027 CDKN1B
CDKN4
KIP1
MEN1B
MEN4
P27KIP1
cyclin-dependent kinase inhibitor 1B (p27, Kip1) [Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3A protein]] which results in increased expression of CDKN1B protein decreases reaction
/ increases expression
/ increases phosphorylation
protein 21092744
D020123 1027 CDKN1B
CDKN4
KIP1
MEN1B
MEN4
P27KIP1
cyclin-dependent kinase inhibitor 1B (p27, Kip1) [decitabine co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Sirolimus] results in increased expression of CDKN1B mRNA affects cotreatment
/ increases expression
mRNA 18622747
D020123 1027 CDKN1B
CDKN4
KIP1
MEN1B
MEN4
P27KIP1
cyclin-dependent kinase inhibitor 1B (p27, Kip1) [Sirolimus co-treated with TGFB1 protein] affects the localization of CDKN1B protein affects cotreatment
/ affects localization
protein 14979923
D020123 1027 CDKN1B
CDKN4
KIP1
MEN1B
MEN4
P27KIP1
cyclin-dependent kinase inhibitor 1B (p27, Kip1) Sirolimus promotes the reaction [Cisplatin results in increased expression of CDKN1B mRNA] increases expression
/ increases reaction
mRNA 21092744
D020123 1027 CDKN1B
CDKN4
KIP1
MEN1B
MEN4
P27KIP1
cyclin-dependent kinase inhibitor 1B (p27, Kip1) Sirolimus results in decreased degradation of CDKN1B protein decreases degradation
protein 12565877
D020123 1027 CDKN1B
CDKN4
KIP1
MEN1B
MEN4
P27KIP1
cyclin-dependent kinase inhibitor 1B (p27, Kip1) Sirolimus results in increased expression of CDKN1B protein increases expression
protein 15070696
16455087
21092744
D020123 1027 CDKN1B
CDKN4
KIP1
MEN1B
MEN4
P27KIP1
cyclin-dependent kinase inhibitor 1B (p27, Kip1) [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein] affects binding
/ affects cotreatment
/ increases reaction
protein 12417722
D020123 1142 CHRNB3
cholinergic receptor, nicotinic, beta 3 (neuronal) Sirolimus inhibits the reaction [TP73 protein results in increased expression of CHRNB3 mRNA] decreases reaction
/ increases expression
mRNA 21245298
D020123 1278 COL1A2
OI4
collagen, type I, alpha 2 Sirolimus inhibits the reaction [Acetaldehyde results in increased expression of COL1A2 mRNA] decreases reaction
/ increases expression
mRNA 11343241
D020123 1593 CYP27A1
CP27
CTX
CYP27
cytochrome P450, family 27, subfamily A, polypeptide 1 (EC:1.14.13.15) [Cyclosporine co-treated with Sirolimus] results in decreased activity of CYP27A1 protein affects cotreatment
/ decreases activity
protein 17516993
D020123 1593 CYP27A1
CP27
CTX
CYP27
cytochrome P450, family 27, subfamily A, polypeptide 1 (EC:1.14.13.15) Sirolimus results in decreased activity of CYP27A1 protein decreases activity
protein 17516993
D020123 1574 CYP3A protein affects the metabolism of Sirolimus affects metabolic processing
protein 15760093
D020123 1576 CYP3A4
CP33
CP34
CYP3A
CYP3A3
CYPIIIA3
CYPIIIA4
HLP
NF-25
P450C3
P450PCN1
cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) CYP3A4 protein affects the metabolism of Sirolimus affects metabolic processing
protein 15707415
15964407
D020123 1576 CYP3A4
CP33
CP34
CYP3A
CYP3A3
CYPIIIA3
CYPIIIA4
HLP
NF-25
P450C3
P450PCN1
cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) CYP3A4 protein polymorphism affects the metabolism of Sirolimus affects metabolic processing
protein 15707415
D020123 1649 DDIT3
CEBPZ
CHOP
CHOP-10
CHOP10
GADD153
DNA-damage-inducible transcript 3 Sirolimus inhibits the reaction [arsenite results in increased expression of DDIT3 mRNA] decreases reaction
/ increases expression
mRNA 22215663
D020123 1649 DDIT3
CEBPZ
CHOP
CHOP-10
CHOP10
GADD153
DNA-damage-inducible transcript 3 Sirolimus inhibits the reaction [arsenite results in increased expression of DDIT3 protein] decreases reaction
/ increases expression
protein 22215663
D020123 1649 DDIT3
CEBPZ
CHOP
CHOP-10
CHOP10
GADD153
DNA-damage-inducible transcript 3 [Sirolimus results in decreased activity of MTOR protein] which results in decreased expression of DDIT3 protein decreases activity
/ decreases expression
protein 21321189
D020123 420357 Sirolimus inhibits the reaction [TP73 protein results in increased expression of DEPDC6 mRNA] decreases reaction
/ increases expression
mRNA 21245298
D020123 56616 DIABLO
DFNA64
SMAC
diablo, IAP-binding mitochondrial protein [7-hydroxystaurosporine co-treated with Sirolimus] affects the localization of DIABLO protein affects cotreatment
/ affects localization
protein 15767555
D020123 56616 DIABLO
DFNA64
SMAC
diablo, IAP-binding mitochondrial protein Boc-D-FMK inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] affects the localization of DIABLO protein] affects cotreatment
/ affects localization
/ decreases reaction
protein 15767555
D020123 1786 DNMT1
ADCADN
AIM
CXXC9
DNMT
HSN1E
MCMT
DNA (cytosine-5-)-methyltransferase 1 (EC:2.1.1.37) [fulvestrant co-treated with Sirolimus] results in decreased expression of DNMT1 mRNA affects cotreatment
/ decreases expression
mRNA 19016759
D020123 1806 DPYD
DHP
DHPDHASE
DPD
dihydropyrimidine dehydrogenase (EC:1.3.1.2) Sirolimus results in decreased expression of DPYD mRNA decreases expression
mRNA 19764996
D020123 1869 E2F1
E2F-1
RBAP1
RBBP3
RBP3
E2F transcription factor 1 [TGFB1 protein co-treated with Sirolimus] results in decreased expression of E2F1 mRNA affects cotreatment
/ decreases expression
mRNA 12417722
D020123 1869 E2F1
E2F-1
RBAP1
RBBP3
RBP3
E2F transcription factor 1 [TGFB1 protein co-treated with Sirolimus] results in decreased expression of E2F1 protein affects cotreatment
/ decreases expression
protein 12417722
D020123 1874 E2F4
E2F-4
E2F transcription factor 4, p107/p130-binding [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL1 protein] which binds to CDK2 protein] affects binding
/ affects cotreatment
/ decreases reaction
protein 12417722
D020123 1874 E2F4
E2F-4
E2F transcription factor 4, p107/p130-binding [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL2 protein] which binds to CDK2 protein] affects binding
/ affects cotreatment
/ decreases reaction
protein 12417722
D020123 1950 EGF
HOMG4
URG
epidermal growth factor Sirolimus inhibits the reaction [EGF protein results in increased phosphorylation of MTOR protein] decreases reaction
/ increases phosphorylation
protein 21187475
D020123 1956 EGFR
ERBB
ERBB1
HER1
PIG61
mENA
epidermal growth factor receptor (EC:2.7.10.1) AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of EGFR protein] decreases reaction
/ increases phosphorylation
protein 19151764
D020123 1977 EIF4E
AUTS19
CBP
EIF4E1
EIF4EL1
EIF4F
eukaryotic translation initiation factor 4E EIF4E protein inhibits the reaction [Sirolimus results in decreased expression of MDM2 protein] decreases expression
/ decreases reaction
protein 19560264
D020123 1977 EIF4E
AUTS19
CBP
EIF4E1
EIF4EL1
EIF4F
eukaryotic translation initiation factor 4E Sirolimus results in decreased activity of EIF4E protein decreases activity
protein 19560264
D020123 1978 EIF4EBP1
4E-BP1
4EBP1
BP-1
PHAS-I
eukaryotic translation initiation factor 4E binding protein 1 KIT protein mutant form promotes the reaction [Sirolimus results in decreased phosphorylation of EIF4EBP1 protein] decreases phosphorylation
/ increases reaction
protein 16597595
D020123 1978 EIF4EBP1
4E-BP1
4EBP1
BP-1
PHAS-I
eukaryotic translation initiation factor 4E binding protein 1 Sirolimus affects the reaction [Testosterone results in increased phosphorylation of EIF4EBP1 protein] affects reaction
/ increases phosphorylation
protein 21036700
D020123 1978 EIF4EBP1
4E-BP1
4EBP1
BP-1
PHAS-I
eukaryotic translation initiation factor 4E binding protein 1 [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of EIF4EBP1 protein affects cotreatment
/ decreases phosphorylation
protein 18622747
D020123 1978 EIF4EBP1
4E-BP1
4EBP1
BP-1
PHAS-I
eukaryotic translation initiation factor 4E binding protein 1 [Sirolimus co-treated with Cisplatin] results in decreased phosphorylation of EIF4EBP1 protein affects cotreatment
/ decreases phosphorylation
protein 19853261
D020123 1978 EIF4EBP1
4E-BP1
4EBP1
BP-1
PHAS-I
eukaryotic translation initiation factor 4E binding protein 1 Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EIF4EBP1 protein] decreases reaction
/ increases phosphorylation
protein 18021293
D020123 1978 EIF4EBP1
4E-BP1
4EBP1
BP-1
PHAS-I
eukaryotic translation initiation factor 4E binding protein 1 Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of EIF4EBP1 protein] decreases reaction
/ increases phosphorylation
protein 21898527
D020123 1978 EIF4EBP1
4E-BP1
4EBP1
BP-1
PHAS-I
eukaryotic translation initiation factor 4E binding protein 1 Sirolimus promotes the reaction [Acetaldehyde results in decreased phosphorylation of EIF4EBP1 protein] decreases phosphorylation
/ increases reaction
protein 16962100
D020123 1978 EIF4EBP1
4E-BP1
4EBP1
BP-1
PHAS-I
eukaryotic translation initiation factor 4E binding protein 1 Sirolimus promotes the reaction [Cisplatin results in decreased phosphorylation of EIF4EBP1 protein] decreases phosphorylation
/ increases reaction
protein 18058806
D020123 1978 EIF4EBP1
4E-BP1
4EBP1
BP-1
PHAS-I
eukaryotic translation initiation factor 4E binding protein 1 Sirolimus promotes the reaction [sodium arsenite results in decreased phosphorylation of EIF4EBP1 protein] decreases phosphorylation
/ increases reaction
protein 22869613
D020123 1978 EIF4EBP1
4E-BP1
4EBP1
BP-1
PHAS-I
eukaryotic translation initiation factor 4E binding protein 1 [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of EIF4EBP1 protein decreases activity
/ decreases phosphorylation
protein 14673156
20169165
D020123 1978 EIF4EBP1
4E-BP1
4EBP1
BP-1
PHAS-I
eukaryotic translation initiation factor 4E binding protein 1 Sirolimus results in decreased phosphorylation of EIF4EBP1 protein decreases phosphorylation
protein 11909977
12939469
15782132
16255777
16597595
19478560
19560264
20863555
22869613
D020123 1978 EIF4EBP1
4E-BP1
4EBP1
BP-1
PHAS-I
eukaryotic translation initiation factor 4E binding protein 1 sodium arsenite promotes the reaction [Sirolimus results in decreased phosphorylation of EIF4EBP1 protein] decreases phosphorylation
/ increases reaction
protein 22869613
D020123 1982 EIF4G2
AAG1
DAP5
NAT1
P97
eukaryotic translation initiation factor 4 gamma, 2 Sirolimus results in increased expression of EIF4G2 protein increases expression
protein 18491231
D020123 9700 ESPL1
ESP1
SEPA
extra spindle pole bodies homolog 1 (S. cerevisiae) (EC:3.4.22.49) [fulvestrant co-treated with Sirolimus] results in decreased expression of ESPL1 mRNA affects cotreatment
/ decreases expression
mRNA 19016759
D020123 2099 ESR1
ER
ESR
ESRA
ESTRR
Era
NR3A1
estrogen receptor 1 Sirolimus results in increased expression of ESR1 protein increases expression
protein 19016759
D020123 2099 ESR1
ER
ESR
ESRA
ESTRR
Era
NR3A1
estrogen receptor 1 Sirolimus results in increased phosphorylation of ESR1 protein increases phosphorylation
protein 19016759
D020123 2130 EWSR1
EWS
bK984G1.4
EWS RNA-binding protein 1 Sirolimus results in decreased expression of EWSR1 protein mutant form decreases expression
protein 15782132
D020123 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) Sirolimus promotes the reaction [TNF protein results in increased expression of F3 protein] increases expression
/ increases reaction
protein 19567381
D020123 356 FASLG
ALPS1B
APT1LG1
APTL
CD178
CD95-L
CD95L
FASL
TNFSF6
Fas ligand (TNF superfamily, member 6) Sirolimus results in decreased secretion of FASLG protein decreases secretion
protein 11692113
D020123 10826 FAXDC2
C5orf4
fatty acid hydroxylase domain containing 2 Sirolimus inhibits the reaction [TP73 protein results in increased expression of FAXDC2 mRNA] decreases reaction
/ increases expression
mRNA 21245298
D020123 114907 FBXO32
Fbx32
MAFbx
F-box protein 32 Sirolimus inhibits the reaction [TP73 protein results in increased expression of FBXO32 mRNA] decreases reaction
/ increases expression
mRNA 21245298
D020123 26271 FBXO5
EMI1
FBX5
Fbxo31
F-box protein 5 [fulvestrant co-treated with Sirolimus] results in decreased expression of FBXO5 mRNA affects cotreatment
/ decreases expression
mRNA 19016759
D020123 2252 FGF7
HBGF-7
KGF
fibroblast growth factor 7 Sirolimus inhibits the reaction [TP73 protein results in increased expression of FGF7 mRNA] decreases reaction
/ increases expression
mRNA 21245298
D020123 2280 FKBP1A
FKBP-12
FKBP-1A
FKBP1
FKBP12
PKC12
PKCI2
PPIASE
FK506 binding protein 1A, 12kDa (EC:5.2.1.8) Sirolimus binds to FKBP1A protein affects binding
protein 17438408
D020123 2280 FKBP1A
FKBP-12
FKBP-1A
FKBP1
FKBP12
PKC12
PKCI2
PPIASE
FK506 binding protein 1A, 12kDa (EC:5.2.1.8) [Sirolimus binds to FKBP1A protein] which results in increased activity of TGFB1 protein affects binding
/ increases activity
protein 12417722
D020123 2280 FKBP1A
FKBP-12
FKBP-1A
FKBP1
FKBP12
PKC12
PKCI2
PPIASE
FK506 binding protein 1A, 12kDa (EC:5.2.1.8) [Tacrolimus binds to FKBP1A protein] inhibits the reaction [Sirolimus binds to FKBP1A protein] affects binding
/ decreases reaction
protein 10361256
D020123 2348 FOLR1
FBP
FOLR
folate receptor 1 (adult) Sirolimus inhibits the reaction [TP73 protein results in increased expression of FOLR1 mRNA] decreases reaction
/ increases expression
mRNA 21245298
D020123 2305 FOXM1
FKHL16
FOXM1B
HFH-11
HFH11
HNF-3
INS-1
MPHOSPH2
MPP-2
MPP2
PIG29
TGT3
TRIDENT
forkhead box M1 [fulvestrant co-treated with Sirolimus] results in decreased expression of FOXM1 mRNA affects cotreatment
/ decreases expression
mRNA 19016759
D020123 2308 FOXO1
FKH1
FKHR
FOXO1A
forkhead box O1 Sirolimus results in increased phosphorylation of FOXO1 protein increases phosphorylation
protein 16227402
D020123 494532 Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3A protein] decreases reaction
/ increases phosphorylation
protein 21092744
D020123 494532 [Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3A protein]] which results in increased expression of BCL2L11 protein decreases reaction
/ increases expression
/ increases phosphorylation
protein 21092744
D020123 494532 [Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3A protein]] which results in increased expression of CDKN1B protein decreases reaction
/ increases expression
/ increases phosphorylation
protein 21092744
D020123 494532 FOXO3A protein results in increased susceptibility to [Cisplatin co-treated with Sirolimus] affects cotreatment
/ increases response to substance
protein 21092744
D020123 494532 Sirolimus promotes the reaction [Cisplatin results in increased expression of and results in increased localization of and results in increased activity of FOXO3A protein] increases activity
/ increases expression
/ increases localization
/ increases reaction
protein 21092744
D020123 494532 Sirolimus results in decreased degradation of and results in increased phosphorylation of FOXO3A protein decreases degradation
/ increases phosphorylation
protein 21092744
D020123 494532 [Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3A protein increases phosphorylation
protein 21092744
D020123 50943 FOXP3
AIID
DIETER
IPEX
PIDX
XPID
forkhead box P3 [TGFB1 protein modified form co-treated with Sirolimus] results in increased expression of FOXP3 mRNA affects cotreatment
/ increases expression
mRNA 20844194
D020123 50943 FOXP3
AIID
DIETER
IPEX
PIDX
XPID
forkhead box P3 [TGFB1 protein modified form co-treated with Sirolimus] results in increased expression of FOXP3 protein affects cotreatment
/ increases expression
protein 20844194
D020123 2512 FTL
NBIA3
ferritin, light polypeptide Sirolimus inhibits the reaction [TP73 protein results in increased expression of FTL mRNA] decreases reaction
/ increases expression
mRNA 21245298
D020123 9247 GCM2
GCMB
hGCMb
glial cells missing homolog 2 (Drosophila) Sirolimus promotes the reaction [TP73 protein affects the activity of GCM2 protein] affects activity
/ increases reaction
protein 21245298
D020123 2932 GSK3B
glycogen synthase kinase 3 beta (EC:2.7.11.1 2.7.11.26) [3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein] decreases activity
/ decreases expression
/ decreases reaction
protein 15753396
D020123 2932 GSK3B
glycogen synthase kinase 3 beta (EC:2.7.11.1 2.7.11.26) [Lithium Chloride results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein] decreases activity
/ decreases expression
/ decreases reaction
protein 15753396
D020123 2932 GSK3B
glycogen synthase kinase 3 beta (EC:2.7.11.1 2.7.11.26) [SB 216763 results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein] decreases activity
/ decreases expression
/ decreases reaction
protein 15753396
D020123 2932 GSK3B
glycogen synthase kinase 3 beta (EC:2.7.11.1 2.7.11.26) [Sirolimus results in decreased activity of MTOR protein] which results in increased phosphorylation of GSK3B protein decreases activity
/ increases phosphorylation
protein 17908691
D020123 2932 GSK3B
glycogen synthase kinase 3 beta (EC:2.7.11.1 2.7.11.26) Sirolimus results in increased activity of GSK3B protein increases activity
protein 15753396
D020123 2932 GSK3B
glycogen synthase kinase 3 beta (EC:2.7.11.1 2.7.11.26) [Sirolimus results in increased activity of GSK3B protein] which results in increased phosphorylation of and results in increased degradation of CCND1 protein increases activity
/ increases degradation
/ increases phosphorylation
protein 15753396
D020123 2952 GSTT1
glutathione S-transferase theta 1 (EC:2.5.1.18) GSTT1 gene mutant form results in increased susceptibility to Sirolimus increases response to substance
gene 12916871
D020123 3002 GZMB
CCPI
CGL-1
CGL1
CSP-B
CSPB
CTLA1
CTSGL1
HLP
SECT
granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1) (EC:3.4.21.79) Sirolimus results in decreased expression of GZMB protein decreases expression
protein 16477233
D020123 36301 Sirolimus inhibits the reaction [TP73 protein affects the activity of HEN1 protein] affects activity
/ decreases reaction
protein 21245298
D020123 3280 HES1
HES-1
HHL
HRY
bHLHb39
hes family bHLH transcription factor 1 Sirolimus results in decreased expression of HES1 protein decreases expression
protein 20038814
D020123 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) Sirolimus inhibits the reaction [4-hydroxyestradiol results in increased expression of HIF1A protein] decreases reaction
/ increases expression
protein 15050414
D020123 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of HIF1A protein] decreases reaction
/ increases expression
protein 21984483
D020123 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) Sirolimus inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein] affects binding
/ decreases reaction
/ increases activity
/ increases expression
protein 20335389
D020123 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) Sirolimus inhibits the reaction [IGF1 protein results in increased expression of HIF1A protein] decreases reaction
/ increases expression
protein 15297429
16682453
D020123 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) Sirolimus inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A mRNA] decreases reaction
/ increases expression
mRNA 19640849
D020123 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) Sirolimus inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein] decreases reaction
/ increases expression
protein 17968710
D020123 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) Sirolimus inhibits the reaction [sulprostone results in increased expression of HIF1A protein] decreases reaction
/ increases expression
protein 20335389
D020123 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) Sirolimus results in decreased expression of HIF1A protein decreases expression
protein 15634505
D020123 3156 HMGCR
LDLCQ3
3-hydroxy-3-methylglutaryl-CoA reductase (EC:1.1.1.34) Sirolimus results in increased expression of HMGCR mRNA increases expression
mRNA 17516993
D020123 3205 HOXA9
ABD-B
HOX1
HOX1.7
HOX1G
homeobox A9 Sirolimus inhibits the reaction [TP73 protein affects the activity of HOXA9 protein] affects activity
/ decreases reaction
protein 21245298
D020123 26353 HSPB8
CMT2L
DHMN2
E2IG1
H11
HMN2
HMN2A
HSP22
heat shock 22kDa protein 8 Sirolimus results in decreased expression of HSPB8 protein decreases expression
protein 21233418
D020123 3458 IFNG
IFG
IFI
interferon, gamma Sirolimus inhibits the reaction [IFNG protein results in decreased phosphorylation of STAT3 protein] decreases phosphorylation
/ decreases reaction
protein 16427044
D020123 3458 IFNG
IFG
IFI
interferon, gamma Sirolimus results in decreased secretion of IFNG protein decreases secretion
protein 11692113
D020123 3479 IGF1
IGF-I
IGF1A
IGFI
insulin-like growth factor 1 (somatomedin C) [Dexamethasone co-treated with Sirolimus] inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6KB1 protein] affects cotreatment
/ decreases reaction
/ increases phosphorylation
protein 15070696
D020123 3479 IGF1
IGF-I
IGF1A
IGFI
insulin-like growth factor 1 (somatomedin C) [Dexamethasone co-treated with Sirolimus] results in decreased activity of IGF1 protein affects cotreatment
/ decreases activity
protein 15070696
D020123 3479 IGF1
IGF-I
IGF1A
IGFI
insulin-like growth factor 1 (somatomedin C) [Sirolimus co-treated with IGF1 protein] results in increased expression of ACTA2 protein affects cotreatment
/ increases expression
protein 17908691
D020123 3479 IGF1
IGF-I
IGF1A
IGFI
insulin-like growth factor 1 (somatomedin C) [Sirolimus co-treated with IGF1 protein] results in increased expression of CALD1 protein affects cotreatment
/ increases expression
protein 17908691
D020123 3479 IGF1
IGF-I
IGF1A
IGFI
insulin-like growth factor 1 (somatomedin C) [Sirolimus co-treated with IGF1 protein] results in increased expression of MYH11 protein affects cotreatment
/ increases expression
protein 17908691
D020123 3479 IGF1
IGF-I
IGF1A
IGFI
insulin-like growth factor 1 (somatomedin C) Sirolimus inhibits the reaction [IGF1 protein results in increased expression of HIF1A protein] decreases reaction
/ increases expression
protein 15297429
16682453
D020123 3479 IGF1
IGF-I
IGF1A
IGFI
insulin-like growth factor 1 (somatomedin C) Sirolimus inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6KB1 protein] decreases reaction
/ increases phosphorylation
protein 15297429
D020123 3479 IGF1
IGF-I
IGF1A
IGFI
insulin-like growth factor 1 (somatomedin C) Sirolimus inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6 protein] decreases reaction
/ increases phosphorylation
protein 15297429
D020123 3479 IGF1
IGF-I
IGF1A
IGFI
insulin-like growth factor 1 (somatomedin C) Sirolimus inhibits the reaction [IGF1 protein results in increased secretion of IGFBP3 protein] decreases reaction
/ increases secretion
protein 16682453
D020123 3479 IGF1
IGF-I
IGF1A
IGFI
insulin-like growth factor 1 (somatomedin C) Sirolimus inhibits the reaction [IGF1 protein results in increased secretion of VEGFA protein] decreases reaction
/ increases secretion
protein 16682453
D020123 3479 IGF1
IGF-I
IGF1A
IGFI
insulin-like growth factor 1 (somatomedin C) Sirolimus results in increased susceptibility to IGF1 protein increases response to substance
protein 16227402
D020123 3480 IGF1R
CD221
IGFIR
IGFR
JTK13
insulin-like growth factor 1 receptor (EC:2.7.10.1) Sirolimus affects the activity of IGF1R protein affects activity
protein 16227402
D020123 3480 IGF1R
CD221
IGFIR
IGFR
JTK13
insulin-like growth factor 1 receptor (EC:2.7.10.1) Sirolimus promotes the reaction [IGF1R protein binds to and results in increased phosphorylation of IRS1 protein] affects binding
/ increases phosphorylation
/ increases reaction
protein 16227402
D020123 3486 IGFBP3
BP-53
IBP3
insulin-like growth factor binding protein 3 Sirolimus inhibits the reaction [IGF1 protein results in increased secretion of IGFBP3 protein] decreases reaction
/ increases secretion
protein 16682453
D020123 3586 IL10
CSIF
GVHDS
IL-10
IL10A
TGIF
interleukin 10 Sirolimus inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 protein] decreases reaction
/ increases expression
protein 11169223
D020123 3586 IL10
CSIF
GVHDS
IL-10
IL10A
TGIF
interleukin 10 Sirolimus inhibits the reaction [lipoteichoic acid results in increased expression of IL10 protein] decreases reaction
/ increases expression
protein 11169223
D020123 3586 IL10
CSIF
GVHDS
IL-10
IL10A
TGIF
interleukin 10 Sirolimus inhibits the reaction [Peptidoglycan results in increased expression of IL10 protein] decreases reaction
/ increases expression
protein 11169223
D020123 3586 IL10
CSIF
GVHDS
IL-10
IL10A
TGIF
interleukin 10 Sirolimus results in decreased expression of IL10 mRNA decreases expression
mRNA 11169223
D020123 55540 IL17RB
CRL4
EVI27
IL17BR
IL17RH1
interleukin 17 receptor B [fulvestrant co-treated with Sirolimus] results in decreased expression of IL17RB mRNA affects cotreatment
/ decreases expression
mRNA 19016759
D020123 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased expression of CCND2 protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 15778701
D020123 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased expression of CCND3 protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 15778701
D020123 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased phosphorylation of RB1 protein] affects cotreatment
/ decreases reaction
/ increases phosphorylation
protein 15778701
D020123 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 Sirolimus inhibits the reaction [IL2 protein results in increased expression of CCND2 mRNA] decreases reaction
/ increases expression
protein 15778701
D020123 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 Sirolimus inhibits the reaction [IL2 protein results in increased expression of CCND3 mRNA] decreases reaction
/ increases expression
protein 15778701
D020123 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RB1 protein] decreases reaction
/ increases phosphorylation
protein 10373522
D020123 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RBL2 protein] decreases reaction
/ increases phosphorylation
protein 10373522
D020123 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein] decreases reaction
/ increases phosphorylation
protein 15778701
D020123 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 Sirolimus results in decreased susceptibility to IL2 protein decreases response to substance
protein 10373522
D020123 3559 IL2RA
CD25
IDDM10
IL2R
TCGFR
interleukin 2 receptor, alpha Sirolimus inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2RA protein] affects cotreatment
/ decreases reaction
/ increases secretion
protein 8586487
D020123 3559 IL2RA
CD25
IDDM10
IL2R
TCGFR
interleukin 2 receptor, alpha Sirolimus inhibits the reaction [Ionomycin results in increased secretion of IL2RA protein] decreases reaction
/ increases secretion
protein 8586487
D020123 3559 IL2RA
CD25
IDDM10
IL2R
TCGFR
interleukin 2 receptor, alpha Sirolimus inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of IL2RA protein] decreases reaction
/ increases secretion
protein 8586487
D020123 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) [Dexamethasone co-treated with Sirolimus] inhibits the reaction [IL6 protein results in increased phosphorylation of RPS6KB1 protein] affects cotreatment
/ decreases reaction
/ increases phosphorylation
protein 15070696
D020123 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) [Dexamethasone co-treated with Sirolimus] results in decreased activity of IL6 protein affects cotreatment
/ decreases activity
protein 15070696
D020123 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) Sirolimus results in increased expression of IL6 increases expression
16314788
D020123 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) [TGFB1 protein modified form co-treated with Sirolimus] results in decreased expression of IL6 mRNA affects cotreatment
/ decreases expression
mRNA 20844194
D020123 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) [TGFB1 protein modified form co-treated with Sirolimus] results in decreased expression of IL6 protein affects cotreatment
/ decreases expression
protein 20844194
D020123 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 Sirolimus inhibits the reaction [IL8 protein results in increased phosphorylation of RPS6 protein] decreases reaction
/ increases phosphorylation
protein 17606477
D020123 51147 ING4
my036
p29ING4
inhibitor of growth family, member 4 Sirolimus inhibits the reaction [TP73 protein results in increased expression of ING4 mRNA] decreases reaction
/ increases expression
mRNA 21245298
D020123 3667 IRS1
HIRS-1
insulin receptor substrate 1 Sirolimus affects the phosphorylation of IRS1 protein affects phosphorylation
protein 17908691
D020123 3667 IRS1
HIRS-1
insulin receptor substrate 1 Sirolimus promotes the reaction [IGF1R protein binds to and results in increased phosphorylation of IRS1 protein] affects binding
/ increases phosphorylation
/ increases reaction
protein 16227402
D020123 3667 IRS1
HIRS-1
insulin receptor substrate 1 Sirolimus promotes the reaction [IRS1 protein binds to PIK3R1 protein] affects binding
/ increases reaction
protein 17908691
D020123 3667 IRS1
HIRS-1
insulin receptor substrate 1 [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased activity of IRS1 protein decreases activity
/ increases activity
protein 17908691
D020123 3667 IRS1
HIRS-1
insulin receptor substrate 1 Sirolimus results in decreased degradation of IRS1 protein decreases degradation
protein 16227402
17908691
D020123 3667 IRS1
HIRS-1
insulin receptor substrate 1 Sirolimus results in decreased phosphorylation of IRS1 protein decreases phosphorylation
protein 16227402
D020123 3684 ITGAM
CD11B
CR3A
MAC-1
MAC1A
MO1A
SLEB6
integrin, alpha M (complement component 3 receptor 3 subunit) Sirolimus promotes the reaction [Tretinoin results in increased localization of and results in increased expression of ITGAM protein] increases expression
/ increases localization
/ increases reaction
protein 20574048
D020123 3684 ITGAM
CD11B
CR3A
MAC-1
MAC1A
MO1A
SLEB6
integrin, alpha M (complement component 3 receptor 3 subunit) Sirolimus results in increased expression of ITGAM protein increases expression
protein 20574048
D020123 182 JAG1
AGS
AHD
AWS
CD339
HJ1
JAGL1
jagged 1 Sirolimus results in decreased expression of JAG1 protein decreases expression
protein 20038814
D020123 133746 JMY
WHDC1L3
junction mediating and regulatory protein, p53 cofactor Sirolimus inhibits the reaction [TP73 protein results in decreased expression of JMY mRNA] decreases expression
/ decreases reaction
mRNA 21245298
D020123 3815 KIT
C-Kit
CD117
PBT
SCFR
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (EC:2.7.10.1) KIT protein mutant form promotes the reaction [Sirolimus results in decreased phosphorylation of EIF4EBP1 protein] decreases phosphorylation
/ increases reaction
protein 16597595
D020123 3817 KLK2
KLK2A2
hGK-1
hK2
kallikrein-related peptidase 2 (EC:3.4.21.35) Sirolimus promotes the reaction [Testosterone results in increased expression of KLK2 protein] increases expression
/ increases reaction
protein 21036700
D020123 354 KLK3
APS
KLK2A1
PSA
hK3
kallikrein-related peptidase 3 (EC:3.4.21.77) bicalutamide inhibits the reaction [Sirolimus results in increased expression of KLK3 protein] decreases reaction
/ increases expression
protein 18776922
D020123 354 KLK3
APS
KLK2A1
PSA
hK3
kallikrein-related peptidase 3 (EC:3.4.21.77) Sirolimus results in increased expression of KLK3 protein increases expression
protein 18776922
D020123 3897 L1CAM
CAML1
CD171
HSAS
HSAS1
MASA
MIC5
N-CAM-L1
N-CAML1
NCAM-L1
S10
SPG1
L1 cell adhesion molecule L1CAM affects the susceptibility to Sirolimus affects response to substance
21097529
D020123 4085 MAD2L1
HSMAD2
MAD2
MAD2 mitotic arrest deficient-like 1 (yeast) [fulvestrant co-treated with Sirolimus] results in decreased expression of MAD2L1 mRNA affects cotreatment
/ decreases expression
mRNA 19016759
D020123 84557 MAP1LC3A
ATG8E
LC3
LC3A
MAP1ALC3
MAP1BLC3
microtubule-associated protein 1 light chain 3 alpha [Sirolimus inhibits the reaction [MTOR protein binds to RPTOR protein]] which results in increased expression of MAP1LC3A protein alternative form affects binding
/ decreases reaction
/ increases expression
protein 21742779
D020123 81631 MAP1LC3B
ATG8F
LC3B
MAP1A/1BLC3
MAP1LC3B-a
microtubule-associated protein 1 light chain 3 beta Sirolimus results in increased expression of MAP1LC3B mRNA increases expression
mRNA 19815708
D020123 81631 MAP1LC3B
ATG8F
LC3B
MAP1A/1BLC3
MAP1LC3B-a
microtubule-associated protein 1 light chain 3 beta Sirolimus results in increased expression of MAP1LC3B protein increases expression
protein 19815708
D020123 81631 MAP1LC3B
ATG8F
LC3B
MAP1A/1BLC3
MAP1LC3B-a
microtubule-associated protein 1 light chain 3 beta Sirolimus results in increased expression of MAP1LC3B protein modified form increases expression
protein 21212465
D020123 5604 MAP2K1
CFC3
MAPKK1
MEK1
MKK1
PRKMK1
mitogen-activated protein kinase kinase 1 (EC:2.7.12.2) [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of MAP2K1 protein affects cotreatment
/ decreases expression
protein 15767555
D020123 5604 MAP2K1
CFC3
MAPKK1
MEK1
MKK1
PRKMK1
mitogen-activated protein kinase kinase 1 (EC:2.7.12.2) [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of MAP2K1 protein affects cotreatment
/ decreases phosphorylation
protein 15767555
D020123 5605 MAP2K2
CFC4
MAPKK2
MEK2
MKK2
PRKMK2
mitogen-activated protein kinase kinase 2 (EC:2.7.12.2) [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of MAP2K2 protein affects cotreatment
/ decreases phosphorylation
protein 15767555
D020123 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of MAPK1 protein affects cotreatment
/ decreases phosphorylation
protein 15767555
D020123 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK1 protein] decreases reaction
/ increases phosphorylation
protein 19151764
D020123 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK1 protein] decreases reaction
/ increases activity
/ increases phosphorylation
protein 21984483
D020123 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) Sirolimus results in decreased phosphorylation of MAPK1 protein decreases phosphorylation
protein 16255777
D020123 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) Sirolimus results in increased phosphorylation of MAPK1 protein increases phosphorylation
protein 19151764
D020123 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of MAPK3 protein affects cotreatment
/ decreases phosphorylation
protein 15767555
D020123 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK3 protein] decreases reaction
/ increases phosphorylation
protein 19151764
D020123 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK3 protein] decreases reaction
/ increases activity
/ increases phosphorylation
protein 21984483
D020123 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) Sirolimus results in decreased phosphorylation of MAPK3 protein decreases phosphorylation
protein 16255777
D020123 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) Sirolimus results in increased phosphorylation of MAPK3 protein increases phosphorylation
protein 19151764
D020123 5599 MAPK8
JNK
JNK-46
JNK1
JNK1A2
JNK21B1/2
PRKM8
SAPK1
SAPK1c
mitogen-activated protein kinase 8 (EC:2.7.11.24) [7-hydroxystaurosporine co-treated with Sirolimus] results in increased phosphorylation of MAPK8 protein affects cotreatment
/ increases phosphorylation
protein 15767555
D020123 5599 MAPK8
JNK
JNK-46
JNK1
JNK1A2
JNK21B1/2
PRKM8
SAPK1
SAPK1c
mitogen-activated protein kinase 8 (EC:2.7.11.24) anthra(1,9-cd)pyrazol-6(2H)-one inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased phosphorylation of MAPK8 protein] affects cotreatment
/ decreases reaction
/ increases phosphorylation
protein 15767555
D020123 10150 MBNL2
MBLL
MBLL39
PRO2032
muscleblind-like splicing regulator 2 Sirolimus inhibits the reaction [TP73 protein results in increased expression of MBNL2 mRNA] decreases reaction
/ increases expression
mRNA 21245298
D020123 4170 MCL1
BCL2L3
EAT
MCL1-ES
MCL1L
MCL1S
Mcl-1
TM
bcl2-L-3
mcl1/EAT
myeloid cell leukemia sequence 1 (BCL2-related) [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of MCL1 protein affects cotreatment
/ decreases expression
protein 15767555
D020123 4193 MDM2
ACTFS
HDMX
hdm2
MDM2 oncogene, E3 ubiquitin protein ligase EIF4E protein inhibits the reaction [Sirolimus results in decreased expression of MDM2 protein] decreases expression
/ decreases reaction
protein 19560264
D020123 4193 MDM2
ACTFS
HDMX
hdm2
MDM2 oncogene, E3 ubiquitin protein ligase Sirolimus inhibits the reaction [Pravastatin results in increased phosphorylation of MDM2 protein] decreases reaction
/ increases phosphorylation
protein 15625077
D020123 4193 MDM2
ACTFS
HDMX
hdm2
MDM2 oncogene, E3 ubiquitin protein ligase Sirolimus promotes the reaction [TP73 protein binds to MDM2 promoter] affects binding
/ increases reaction
promoter 21245298
D020123 4193 MDM2
ACTFS
HDMX
hdm2
MDM2 oncogene, E3 ubiquitin protein ligase Sirolimus results in decreased expression of MDM2 protein decreases expression
protein 19560264
D020123 387169 TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR151 mRNA] increases expression
/ increases reaction
mRNA 21245298
D020123 406954 MIR181A2
MIRN181A
MIRN181A2
hsa-mir-181a-2
microRNA 181a-2 Sirolimus inhibits the reaction [TP73 protein results in decreased expression of MIR181A2 mRNA] decreases expression
/ decreases reaction
mRNA 21245298
D020123 406965 MIR190A
MIR190
MIRN190
hsa-mir-190a
miR-190
microRNA 190a TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR190A mRNA] increases expression
/ increases reaction
mRNA 21245298
D020123 407026 MIR29C
MIRN29C
miRNA29C
microRNA 29c TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR29C mRNA] increases expression
/ increases reaction
mRNA 21245298
D020123 442898 MIR324
MIRN324
hsa-mir-324
microRNA 324 TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR324 mRNA] increases expression
/ increases reaction
mRNA 21245298
D020123 494328 MIR379
MIRN379
hsa-mir-379
microRNA 379 TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR379 mRNA] increases expression
/ increases reaction
mRNA 21245298
D020123 574034 MIR433
MIRN433
hsa-mir-433
miRNA433
microRNA 433 TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR433 mRNA] increases expression
/ increases reaction
mRNA 21245298
D020123 574506 MIR503
MIRN503
hsa-mir-503
microRNA 503 TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR503 mRNA] increases expression
/ increases reaction
mRNA 21245298
D020123 574513 MIR508
MIRN508
hsa-mir-508
microRNA 508 TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR508 mRNA] increases expression
/ increases reaction
mRNA 21245298
D020123 723778 MIR650
MIRN650
hsa-mir-650
microRNA 650 TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR650 mRNA] increases expression
/ increases reaction
mRNA 21245298
D020123 724024 MIR654
MIRN654
hsa-mir-654
microRNA 654 TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR654 mRNA] increases expression
/ increases reaction
mRNA 21245298
D020123 768212 MIR758
MIRN758
hsa-mir-758
microRNA 758 TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR758 mRNA] increases expression
/ increases reaction
mRNA 21245298
D020123 100126348 MIR760
MIRN760
hsa-mir-760
microRNA 760 TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR760 mRNA] increases expression
/ increases reaction
mRNA 21245298
D020123 4288 MKI67
KIA
MIB-1
marker of proliferation Ki-67 [ABT-737 co-treated with Sirolimus] results in decreased expression of MKI67 protein affects cotreatment
/ decreases expression
protein 19773376
D020123 4288 MKI67
KIA
MIB-1
marker of proliferation Ki-67 Sirolimus results in decreased expression of MKI67 protein decreases expression
protein 19773376
D020123 64223 MLST8
GBL
GbetaL
LST8
POP3
WAT1
MTOR associated protein, LST8 homolog (S. cerevisiae) Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein binds to MLST8 protein] affects binding
/ decreases activity
protein 19505958
D020123 4312 MMP1
CLG
CLGN
matrix metallopeptidase 1 (interstitial collagenase) (EC:3.4.24.7) Sirolimus results in increased expression of MMP1 mRNA increases expression
mRNA 21742783
D020123 4312 MMP1
CLG
CLGN
matrix metallopeptidase 1 (interstitial collagenase) (EC:3.4.24.7) Sirolimus results in increased secretion of MMP1 protein increases secretion
protein 21742783
D020123 4481 MSR1
CD204
SCARA1
SR-A
SRA
phSR1
phSR2
macrophage scavenger receptor 1 Sirolimus results in decreased expression of MSR1 mRNA decreases expression
mRNA 17016853
D020123 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) MTOR protein inhibits the reaction [Sirolimus results in decreased activity of RPS6KB2 protein] decreases activity
/ decreases reaction
protein 12087098
D020123 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) [Oxygen deficiency co-treated with Sirolimus] results in decreased expression of MTOR protein affects cotreatment
/ decreases expression
protein 17968710
D020123 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) [Sirolimus co-treated with Photosensitizing Agents] affects the phosphorylation of MTOR protein affects cotreatment
/ affects phosphorylation
protein 19125612
D020123 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of MTOR protein] decreases reaction
/ increases phosphorylation
protein 21898527
D020123 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) Sirolimus inhibits the reaction [EGF protein results in increased phosphorylation of MTOR protein] decreases reaction
/ increases phosphorylation
protein 21187475
D020123 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) [Sirolimus inhibits the reaction [MTOR protein binds to RPTOR protein]] which results in increased expression of MAP1LC3A protein alternative form affects binding
/ decreases reaction
/ increases expression
protein 21742779
D020123 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) Sirolimus inhibits the reaction [Oxygen deficiency results in increased expression of MTOR mRNA] decreases reaction
/ increases expression
mRNA 17968710
D020123 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) Sirolimus promotes the reaction [Cisplatin results in decreased phosphorylation of MTOR protein] decreases phosphorylation
/ increases reaction
protein 18058806
D020123 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) Sirolimus results in decreased activity of MTOR protein decreases activity
protein 11602639
15050414
15782132
17996122
18381446
20169165
21321189
22574221
D020123 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein] affects binding
/ decreases activity
protein 18776922
D020123 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein binds to MLST8 protein] affects binding
/ decreases activity
protein 19505958
D020123 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) [Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein]] which results in increased activity of AR protein affects binding
/ decreases activity
/ increases activity
protein 18776922
D020123 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein] decreases activity
/ decreases reaction
/ increases activity
/ increases phosphorylation
protein 15919668
D020123 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) [Sirolimus results in decreased activity of MTOR protein] which results in decreased activity of RPS6KB1 protein decreases activity
protein 14673156
D020123 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) [Sirolimus results in decreased activity of MTOR protein] which results in decreased expression of DDIT3 protein decreases activity
/ decreases expression
protein 21321189
D020123 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) [Sirolimus results in decreased activity of MTOR protein] which results in decreased expression of PKM protein decreases activity
/ decreases expression
protein 22574221
D020123 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of EIF4EBP1 protein decreases activity
/ decreases phosphorylation
protein 14673156
20169165
D020123 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of RPS6KB1 protein decreases activity
/ decreases phosphorylation
protein 20169165
22574221
D020123 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of RPS6 protein decreases activity
/ decreases phosphorylation
protein 17908691
20169165
D020123 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of TP53 protein decreases activity
/ decreases phosphorylation
protein 11602639
D020123 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) [Sirolimus results in decreased activity of MTOR protein] which results in increased phosphorylation of GSK3B protein decreases activity
/ increases phosphorylation
protein 17908691
D020123 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) [Sirolimus results in decreased activity of MTOR protein] which results in increased susceptibility to afimoxifene decreases activity
/ increases response to substance
protein 19016759
D020123 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) [Sirolimus results in decreased activity of MTOR protein] which results in increased susceptibility to fulvestrant decreases activity
/ increases response to substance
protein 19016759
D020123 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) Sirolimus results in decreased expression of MTOR mRNA decreases expression
mRNA 19698219
D020123 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) Sirolimus results in decreased phosphorylation of MTOR protein decreases phosphorylation
protein 19125612
19815708
20682991
21168265
21450334
D020123 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) [Sirolimus results in decreased phosphorylation of MTOR protein] which results in decreased chemical synthesis of Reactive Oxygen Species decreases chemical synthesis
/ decreases phosphorylation
protein 20680277
D020123 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) Sirolimus results in increased activity of MTOR protein increases activity
protein 19151764
D020123 222166 MTURN
C7orf41
Ells1
maturin, neural progenitor differentiation regulator homolog (Xenopus) Sirolimus inhibits the reaction [TP73 protein results in increased expression of MTURN mRNA] decreases reaction
/ increases expression
mRNA 21245298
D020123 4609 MYC
MRTL
MYCC
bHLHe39
c-Myc
v-myc avian myelocytomatosis viral oncogene homolog [Sirolimus co-treated with letrozole] results in decreased expression of MYC protein affects cotreatment
/ decreases expression
protein 20054642
D020123 4629 MYH11
AAT4
FAA4
SMHC
SMMHC
myosin, heavy chain 11, smooth muscle [Sirolimus co-treated with IGF1 protein] results in increased expression of MYH11 protein affects cotreatment
/ increases expression
protein 17908691
D020123 4629 MYH11
AAT4
FAA4
SMHC
SMMHC
myosin, heavy chain 11, smooth muscle [Sirolimus results in increased activity of AKT2 protein] which results in increased expression of MYH11 protein increases activity
/ increases expression
protein 17908691
D020123 4629 MYH11
AAT4
FAA4
SMHC
SMMHC
myosin, heavy chain 11, smooth muscle Sirolimus results in increased expression of MYH11 protein increases expression
protein 17908691
D020123 4638 MYLK
AAT7
KRP
MLCK
MLCK1
MLCK108
MLCK210
MSTP083
MYLK1
smMLCK
myosin light chain kinase (EC:2.7.11.18) Sirolimus inhibits the reaction [TP73 protein results in increased expression of MYLK mRNA] decreases reaction
/ increases expression
mRNA 21245298
D020123 26509 MYOF
FER1L3
myoferlin Sirolimus inhibits the reaction [TP73 protein results in increased expression of MYOF mRNA] decreases reaction
/ increases expression
mRNA 21245298
D020123 10403 NDC80
HEC
HEC1
HsHec1
KNTC2
TID3
hsNDC80
NDC80 kinetochore complex component [fulvestrant co-treated with Sirolimus] results in decreased expression of NDC80 mRNA affects cotreatment
/ decreases expression
mRNA 19016759
D020123 4751 NEK2
HsPK21
NEK2A
NLK1
NIMA-related kinase 2 (EC:2.7.11.1) [fulvestrant co-treated with Sirolimus] results in decreased expression of NEK2 mRNA affects cotreatment
/ decreases expression
mRNA 19016759
D020123 4790 NFKB1
EBP-1
KBF1
NF-kB1
NF-kappa-B
NF-kappaB
NFKB-p105
NFKB-p50
NFkappaB
p105
p50
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 Sirolimus inhibits the reaction [Doxorubicin results in increased activity of NFKB1 protein] decreases reaction
/ increases activity
protein 15571967
D020123 4792 NFKBIA
IKBA
MAD-3
NFKBI
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha Sirolimus inhibits the reaction [Doxorubicin results in increased degradation of and results in decreased expression of NFKBIA protein] decreases expression
/ decreases reaction
/ increases degradation
protein 15571967
D020123 4792 NFKBIA
IKBA
MAD-3
NFKBI
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha Sirolimus inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] decreases reaction
/ increases phosphorylation
protein 18789402
D020123 4830 NME1
AWD
GAAD
NB
NBS
NDKA
NDPK-A
NDPKA
NM23
NM23-H1
NME/NM23 nucleoside diphosphate kinase 1 (EC:2.7.4.6) [fulvestrant co-treated with Sirolimus] results in decreased expression of NME1 mRNA affects cotreatment
/ decreases expression
mRNA 19016759
D020123 10874 NMU
neuromedin U Sirolimus inhibits the reaction [TP73 protein results in increased expression of NMU mRNA] decreases reaction
/ increases expression
mRNA 21245298
D020123 4846 NOS3
ECNOS
eNOS
nitric oxide synthase 3 (endothelial cell) (EC:1.14.13.39) Aspirin inhibits the reaction [Sirolimus results in decreased expression of NOS3 protein] decreases expression
/ decreases reaction
protein 19520256
D020123 4846 NOS3
ECNOS
eNOS
nitric oxide synthase 3 (endothelial cell) (EC:1.14.13.39) cilostazol inhibits the reaction [Sirolimus results in decreased expression of NOS3 protein] decreases expression
/ decreases reaction
protein 19520256
D020123 4846 NOS3
ECNOS
eNOS
nitric oxide synthase 3 (endothelial cell) (EC:1.14.13.39) Sirolimus results in decreased expression of NOS3 mRNA decreases expression
mRNA 19815708
D020123 4846 NOS3
ECNOS
eNOS
nitric oxide synthase 3 (endothelial cell) (EC:1.14.13.39) Sirolimus results in decreased expression of NOS3 protein decreases expression
protein 19520256
D020123 10062 NR1H3
LXR-a
LXRA
RLD-1
nuclear receptor subfamily 1, group H, member 3 Sirolimus affects the expression of NR1H3 protein affects expression
protein 17016853
D020123 9971 NR1H4
BAR
FXR
HRR-1
HRR1
RIP14
nuclear receptor subfamily 1, group H, member 4 Sirolimus inhibits the reaction [TP73 protein results in decreased expression of NR1H4 mRNA] decreases expression
/ decreases reaction
mRNA 21245298
D020123 4973 OLR1
CLEC8A
LOX1
LOXIN
SCARE1
SLOX1
oxidized low density lipoprotein (lectin-like) receptor 1 Sirolimus affects the expression of OLR1 protein affects expression
protein 17016853
D020123 5018 OXA1L
OXA1
oxidase (cytochrome c) assembly 1-like Sirolimus inhibits the reaction [TP73 protein results in increased expression of OXA1L mRNA] decreases reaction
/ increases expression
mRNA 21245298
D020123 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) ATG5 protein affects the reaction [Sirolimus inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein]] affects reaction
/ decreases reaction
/ increases cleavage
protein 19682553
D020123 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) Sirolimus inhibits the reaction [Ethanol results in increased cleavage of PARP1 protein] decreases reaction
/ increases cleavage
protein 21410490
D020123 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) Sirolimus inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein] decreases reaction
/ increases cleavage
protein 19682553
D020123 7849 PAX8
paired box 8 Sirolimus promotes the reaction [TP73 protein affects the activity of PAX8 protein] affects activity
/ increases reaction
protein 21245298
D020123 5111 PCNA
proliferating cell nuclear antigen [fulvestrant co-treated with Sirolimus] results in decreased expression of PCNA mRNA affects cotreatment
/ decreases expression
mRNA 19016759
D020123 5111 PCNA
proliferating cell nuclear antigen Sirolimus results in decreased expression of PCNA protein decreases expression
protein 9151781
D020123 27250 PDCD4
H731
programmed cell death 4 (neoplastic transformation inhibitor) Sirolimus promotes the reaction [Tretinoin results in increased expression of PDCD4 protein] increases expression
/ increases reaction
protein 17259349
D020123 27250 PDCD4
H731
programmed cell death 4 (neoplastic transformation inhibitor) Sirolimus results in increased expression of PDCD4 mRNA increases expression
mRNA 17259349
D020123 27250 PDCD4
H731
programmed cell death 4 (neoplastic transformation inhibitor) Sirolimus results in increased expression of PDCD4 protein increases expression
protein 17259349
D020123 5155 PDGFB
IBGC5
PDGF-2
PDGF2
SIS
SSV
c-sis
platelet-derived growth factor beta polypeptide Sirolimus inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein] decreases reaction
/ increases activity
/ increases phosphorylation
protein 15919668
D020123 5155 PDGFB
IBGC5
PDGF-2
PDGF2
SIS
SSV
c-sis
platelet-derived growth factor beta polypeptide [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein] decreases activity
/ decreases reaction
/ increases activity
/ increases phosphorylation
protein 15919668
D020123 5290 PIK3CA
CLOVE
CWS5
MCAP
MCM
MCMTC
PI3K
p110-alpha
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (EC:2.7.11.1 2.7.1.153) Sirolimus results in decreased susceptibility to PIK3CA protein decreases response to substance
protein 10373522
D020123 5290 PIK3CA
CLOVE
CWS5
MCAP
MCM
MCMTC
PI3K
p110-alpha
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (EC:2.7.11.1 2.7.1.153) Sirolimus results in increased activity of PIK3CA protein increases activity
protein 16227402
D020123 5290 PIK3CA
CLOVE
CWS5
MCAP
MCM
MCMTC
PI3K
p110-alpha
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (EC:2.7.11.1 2.7.1.153) wortmannin inhibits the reaction [Sirolimus results in increased activity of PIK3CA protein] decreases reaction
/ increases activity
protein 16227402
D020123 5295 PIK3R1
AGM7
GRB1
p85
p85-ALPHA
phosphoinositide-3-kinase, regulatory subunit 1 (alpha) Sirolimus promotes the reaction [IRS1 protein binds to PIK3R1 protein] affects binding
/ increases reaction
protein 17908691
D020123 5315 PKM
CTHBP
OIP3
PK3
PKM2
TCB
THBP1
pyruvate kinase, muscle (EC:2.7.1.40) [Sirolimus results in decreased activity of MTOR protein] which results in decreased expression of PKM protein decreases activity
/ decreases expression
protein 22574221
D020123 5366 PMAIP1
APR
NOXA
phorbol-12-myristate-13-acetate-induced protein 1 [[Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein] which results in increased expression of PMAIP1 protein affects cotreatment
/ increases expression
protein 20686837
D020123 5468 PPARG
CIMT1
GLM1
NR1C3
PPARG1
PPARG2
PPARgamma
peroxisome proliferator-activated receptor gamma Sirolimus affects the expression of PPARG protein affects expression
protein 17016853
D020123 5468 PPARG
CIMT1
GLM1
NR1C3
PPARG1
PPARG2
PPARgamma
peroxisome proliferator-activated receptor gamma [Sirolimus co-treated with Cyclosporine] results in decreased expression of PPARG protein affects cotreatment
/ decreases expression
protein 17016853
D020123 5468 PPARG
CIMT1
GLM1
NR1C3
PPARG1
PPARG2
PPARgamma
peroxisome proliferator-activated receptor gamma [Sirolimus co-treated with Tacrolimus] results in increased expression of PPARG protein affects cotreatment
/ increases expression
protein 17016853
D020123 5551 PRF1
FLH2
HPLH2
P1
PFN1
PFP
perforin 1 (pore forming protein) Sirolimus results in decreased expression of PRF1 protein decreases expression
protein 16477233
D020123 5580 PRKCD
MAY1
PKCD
nPKC-delta
protein kinase C, delta (EC:2.7.10.2 2.7.11.13) Sirolimus affects the localization of PRKCD protein affects localization
protein 20082316
D020123 5580 PRKCD
MAY1
PKCD
nPKC-delta
protein kinase C, delta (EC:2.7.10.2 2.7.11.13) Sirolimus results in decreased phosphorylation of PRKCD protein decreases phosphorylation
protein 20082316
D020123 5580 PRKCD
MAY1
PKCD
nPKC-delta
protein kinase C, delta (EC:2.7.10.2 2.7.11.13) sodium arsenite promotes the reaction [Sirolimus results in decreased phosphorylation of PRKCD protein] decreases phosphorylation
/ increases reaction
protein 20082316
D020123 5582 PRKCG
PKC-gamma
PKCC
PKCG
SCA14
protein kinase C, gamma (EC:2.7.11.13) Sirolimus inhibits the reaction [PRKCG protein mutant form binds to PRKCG protein mutant form] affects binding
/ decreases reaction
protein 20398063
D020123 5582 PRKCG
PKC-gamma
PKCC
PKCG
SCA14
protein kinase C, gamma (EC:2.7.11.13) Sirolimus results in increased degradation of PRKCG protein mutant form increases degradation
protein 20398063
D020123 5583 PRKCH
PKC-L
PKCL
PRKCL
nPKC-eta
protein kinase C, eta (EC:2.7.11.13) PRKCH results in decreased susceptibility to Sirolimus decreases response to substance
16832347
D020123 5583 PRKCH
PKC-L
PKCL
PRKCL
nPKC-eta
protein kinase C, eta (EC:2.7.11.13) [Tetradecanoylphorbol Acetate results in increased activity of PRKCH protein] inhibits the reaction [Sirolimus results in decreased phosphorylation of RPS6 protein] decreases phosphorylation
/ decreases reaction
/ increases activity
protein 16832347
D020123 5717 PSMD11
Rpn6
S9
p44.5
proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 Sirolimus results in decreased expression of PSMD11 mRNA decreases expression
mRNA 15782132
D020123 5717 PSMD11
Rpn6
S9
p44.5
proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 Sirolimus results in decreased expression of PSMD11 protein decreases expression
protein 15782132
D020123 5728 PTEN
10q23del
BZS
CWS1
DEC
GLM2
MHAM
MMAC1
PTEN1
TEP1
phosphatase and tensin homolog (EC:3.1.3.67 3.1.3.16 3.1.3.48) [decitabine co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Sirolimus] results in increased expression of PTEN mRNA affects cotreatment
/ increases expression
mRNA 18622747
D020123 5728 PTEN
10q23del
BZS
CWS1
DEC
GLM2
MHAM
MMAC1
PTEN1
TEP1
phosphatase and tensin homolog (EC:3.1.3.67 3.1.3.16 3.1.3.48) PTEN protein results in decreased susceptibility to Sirolimus decreases response to substance
protein 19625624
D020123 5731 PTGER1
EP1
prostaglandin E receptor 1 (subtype EP1), 42kDa Sirolimus inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein] affects binding
/ decreases reaction
/ increases activity
/ increases expression
protein 20335389
D020123 9232 PTTG1
EAP1
HPTTG
PTTG
TUTR1
pituitary tumor-transforming 1 [fulvestrant co-treated with Sirolimus] results in decreased expression of PTTG1 mRNA affects cotreatment
/ decreases expression
mRNA 19016759
D020123 5888 RAD51
BRCC5
HRAD51
HsRad51
HsT16930
MRMV2
RAD51A
RECA
RAD51 recombinase [fulvestrant co-treated with Sirolimus] results in decreased expression of RAD51 mRNA affects cotreatment
/ decreases expression
mRNA 19016759
D020123 5894 RAF1
CRAF
NS5
Raf-1
c-Raf
v-raf-1 murine leukemia viral oncogene homolog 1 (EC:2.7.11.1) [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of RAF1 protein affects cotreatment
/ decreases expression
protein 15767555
D020123 5925 RB1
OSRC
RB
p105-Rb
pRb
pp110
retinoblastoma 1 [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased phosphorylation of RB1 protein] affects cotreatment
/ decreases reaction
/ increases phosphorylation
protein 15778701
D020123 5925 RB1
OSRC
RB
p105-Rb
pRb
pp110
retinoblastoma 1 [Sirolimus co-treated with letrozole] results in decreased expression of RB1 protein affects cotreatment
/ decreases expression
protein 20054642
D020123 5925 RB1
OSRC
RB
p105-Rb
pRb
pp110
retinoblastoma 1 [Sirolimus co-treated with TGFB1 protein] results in decreased phosphorylation of RB1 protein affects cotreatment
/ decreases phosphorylation
protein 14979923
D020123 5925 RB1
OSRC
RB
p105-Rb
pRb
pp110
retinoblastoma 1 Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RB1 protein] decreases reaction
/ increases phosphorylation
protein 10373522
D020123 5925 RB1
OSRC
RB
p105-Rb
pRb
pp110
retinoblastoma 1 Sirolimus results in decreased phosphorylation of RB1 protein decreases phosphorylation
protein 8419408
12393642
12565877
15753396
17121904
21528311
D020123 5925 RB1
OSRC
RB
p105-Rb
pRb
pp110
retinoblastoma 1 [tanespimycin co-treated with Sirolimus] results in decreased phosphorylation of RB1 protein affects cotreatment
/ decreases phosphorylation
protein 17121904
D020123 5925 RB1
OSRC
RB
p105-Rb
pRb
pp110
retinoblastoma 1 [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of RB1 protein affects cotreatment
/ decreases phosphorylation
protein 17700525
D020123 5933 RBL1
CP107
PRB1
p107
retinoblastoma-like 1 (p107) [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL1 protein] which binds to CDK2 protein] affects binding
/ affects cotreatment
/ decreases reaction
protein 12417722
D020123 5934 RBL2
P130
Rb2
retinoblastoma-like 2 (p130) Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RBL2 protein] decreases reaction
/ increases phosphorylation
protein 10373522
D020123 5934 RBL2
P130
Rb2
retinoblastoma-like 2 (p130) [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL2 protein] which binds to CDK2 protein] affects binding
/ affects cotreatment
/ decreases reaction
protein 12417722
D020123 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A Sirolimus inhibits the reaction [Doxorubicin results in increased activity of RELA protein] decreases reaction
/ increases activity
protein 15571967
D020123 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A Sirolimus inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein] affects localization
/ decreases reaction
protein 18789402
D020123 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A Sirolimus inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein] decreases reaction
/ increases localization
protein 22003094
D020123 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A Sirolimus inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein] decreases reaction
/ increases phosphorylation
protein 22003094
D020123 5978 REST
NRSF
XBR
RE1-silencing transcription factor Sirolimus promotes the reaction [TP73 protein affects the activity of REST protein] affects activity
/ increases reaction
protein 21245298
D020123 253260 RICTOR
AVO3
PIA
hAVO3
RPTOR independent companion of MTOR, complex 2 Sirolimus results in decreased expression of RICTOR protein decreases expression
protein 18776922
D020123 728380 Sirolimus inhibits the reaction [TP73 protein results in decreased expression of RPL7P26 mRNA] decreases expression
/ decreases reaction
mRNA 21245298
D020123 51065 RPS27L
ribosomal protein S27-like Sirolimus promotes the reaction [TP73 protein binds to RPS27L promoter] affects binding
/ increases reaction
promoter 21245298
D020123 6194 RPS6
S6
ribosomal protein S6 Sirolimus inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6 protein] decreases reaction
/ increases phosphorylation
protein 15297429
D020123 6194 RPS6
S6
ribosomal protein S6 Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein] decreases reaction
/ increases phosphorylation
protein 15778701
D020123 6194 RPS6
S6
ribosomal protein S6 Sirolimus inhibits the reaction [IL8 protein results in increased phosphorylation of RPS6 protein] decreases reaction
/ increases phosphorylation
protein 17606477
D020123 6194 RPS6
S6
ribosomal protein S6 Sirolimus inhibits the reaction [Testosterone results in increased phosphorylation of RPS6 protein] decreases reaction
/ increases phosphorylation
protein 21036700
D020123 6194 RPS6
S6
ribosomal protein S6 [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of RPS6 protein decreases activity
/ decreases phosphorylation
protein 17908691
20169165
D020123 6194 RPS6
S6
ribosomal protein S6 Sirolimus results in decreased phosphorylation of RPS6 protein decreases phosphorylation
protein 10373522
12939469
16832347
17121904
19478560
19625624
20038814
20863555
21212465
21245298
21450334
D020123 6194 RPS6
S6
ribosomal protein S6 [Tetradecanoylphorbol Acetate results in increased activity of PRKCH protein] inhibits the reaction [Sirolimus results in decreased phosphorylation of RPS6 protein] decreases phosphorylation
/ decreases reaction
/ increases activity
protein 16832347
D020123 6195 RPS6KA1
HU-1
MAPKAPK1A
RSK
RSK1
ribosomal protein S6 kinase, 90kDa, polypeptide 1 (EC:2.7.11.1) Sirolimus results in increased phosphorylation of RPS6KA1 protein increases phosphorylation
protein 19151764
D020123 6198 RPS6KB1
PS6K
S6K
S6K-beta-1
S6K1
STK14A
p70_S6KA
p70(S6K)-alpha
p70-S6K
p70-alpha
ribosomal protein S6 kinase, 70kDa, polypeptide 1 (EC:2.7.11.1) [Dexamethasone co-treated with Sirolimus] inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6KB1 protein] affects cotreatment
/ decreases reaction
/ increases phosphorylation
protein 15070696
D020123 6198 RPS6KB1
PS6K
S6K
S6K-beta-1
S6K1
STK14A
p70_S6KA
p70(S6K)-alpha
p70-S6K
p70-alpha
ribosomal protein S6 kinase, 70kDa, polypeptide 1 (EC:2.7.11.1) [Dexamethasone co-treated with Sirolimus] inhibits the reaction [IL6 protein results in increased phosphorylation of RPS6KB1 protein] affects cotreatment
/ decreases reaction
/ increases phosphorylation
protein 15070696
D020123 6198 RPS6KB1
PS6K
S6K
S6K-beta-1
S6K1
STK14A
p70_S6KA
p70(S6K)-alpha
p70-S6K
p70-alpha
ribosomal protein S6 kinase, 70kDa, polypeptide 1 (EC:2.7.11.1) [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of RPS6KB1 protein affects cotreatment
/ decreases phosphorylation
protein 18622747
D020123 6198 RPS6KB1
PS6K
S6K
S6K-beta-1
S6K1
STK14A
p70_S6KA
p70(S6K)-alpha
p70-S6K
p70-alpha
ribosomal protein S6 kinase, 70kDa, polypeptide 1 (EC:2.7.11.1) Sirolimus inhibits the reaction [Acetaldehyde results in increased activity of RPS6KB1 protein] decreases reaction
/ increases activity
protein 16962100
D020123 6198 RPS6KB1
PS6K
S6K
S6K-beta-1
S6K1
STK14A
p70_S6KA
p70(S6K)-alpha
p70-S6K
p70-alpha
ribosomal protein S6 kinase, 70kDa, polypeptide 1 (EC:2.7.11.1) Sirolimus inhibits the reaction [arsenite results in increased phosphorylation of RPS6KB1 protein] decreases reaction
/ increases phosphorylation
protein 22215663
D020123 6198 RPS6KB1
PS6K
S6K
S6K-beta-1
S6K1
STK14A
p70_S6KA
p70(S6K)-alpha
p70-S6K
p70-alpha
ribosomal protein S6 kinase, 70kDa, polypeptide 1 (EC:2.7.11.1) Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of RPS6KB1 protein] decreases reaction
/ increases activity
/ increases phosphorylation
protein 21984483
D020123 6198 RPS6KB1
PS6K
S6K
S6K-beta-1
S6K1
STK14A
p70_S6KA
p70(S6K)-alpha
p70-S6K
p70-alpha
ribosomal protein S6 kinase, 70kDa, polypeptide 1 (EC:2.7.11.1) Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of RPS6KB1 protein] decreases reaction
/ increases phosphorylation
protein 21898527
D020123 6198 RPS6KB1
PS6K
S6K
S6K-beta-1
S6K1
STK14A
p70_S6KA
p70(S6K)-alpha
p70-S6K
p70-alpha
ribosomal protein S6 kinase, 70kDa, polypeptide 1 (EC:2.7.11.1) Sirolimus inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6KB1 protein] decreases reaction
/ increases phosphorylation
protein 15297429
D020123 6198 RPS6KB1
PS6K
S6K
S6K-beta-1
S6K1
STK14A
p70_S6KA
p70(S6K)-alpha
p70-S6K
p70-alpha
ribosomal protein S6 kinase, 70kDa, polypeptide 1 (EC:2.7.11.1) Sirolimus inhibits the reaction [Orotic Acid results in increased phosphorylation of RPS6KB1 protein] decreases reaction
/ increases phosphorylation
protein 22863860
D020123 6198 RPS6KB1
PS6K
S6K
S6K-beta-1
S6K1
STK14A
p70_S6KA
p70(S6K)-alpha
p70-S6K
p70-alpha
ribosomal protein S6 kinase, 70kDa, polypeptide 1 (EC:2.7.11.1) Sirolimus inhibits the reaction [oxophenylarsine results in increased phosphorylation of RPS6KB1 protein] decreases reaction
/ increases phosphorylation
protein 16183647
D020123 6198 RPS6KB1
PS6K
S6K
S6K-beta-1
S6K1
STK14A
p70_S6KA
p70(S6K)-alpha
p70-S6K
p70-alpha
ribosomal protein S6 kinase, 70kDa, polypeptide 1 (EC:2.7.11.1) Sirolimus inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein] decreases reaction
/ increases activity
/ increases phosphorylation
protein 15919668
D020123 6198 RPS6KB1
PS6K
S6K
S6K-beta-1
S6K1
STK14A
p70_S6KA
p70(S6K)-alpha
p70-S6K
p70-alpha
ribosomal protein S6 kinase, 70kDa, polypeptide 1 (EC:2.7.11.1) Sirolimus inhibits the reaction [Testosterone results in increased phosphorylation of RPS6KB1 protein] decreases reaction
/ increases phosphorylation
protein 21036700
D020123 6198 RPS6KB1
PS6K
S6K
S6K-beta-1
S6K1
STK14A
p70_S6KA
p70(S6K)-alpha
p70-S6K
p70-alpha
ribosomal protein S6 kinase, 70kDa, polypeptide 1 (EC:2.7.11.1) Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein] decreases reaction
/ increases phosphorylation
protein 19567381
D020123 6198 RPS6KB1
PS6K
S6K
S6K-beta-1
S6K1
STK14A
p70_S6KA
p70(S6K)-alpha
p70-S6K
p70-alpha
ribosomal protein S6 kinase, 70kDa, polypeptide 1 (EC:2.7.11.1) Sirolimus promotes the reaction [sodium arsenite results in decreased phosphorylation of RPS6KB1 protein] decreases phosphorylation
/ increases reaction
protein 22869613
D020123 6198 RPS6KB1
PS6K
S6K
S6K-beta-1
S6K1
STK14A
p70_S6KA
p70(S6K)-alpha
p70-S6K
p70-alpha
ribosomal protein S6 kinase, 70kDa, polypeptide 1 (EC:2.7.11.1) [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein] decreases activity
/ decreases reaction
/ increases activity
/ increases phosphorylation
protein 15919668
D020123 6198 RPS6KB1
PS6K
S6K
S6K-beta-1
S6K1
STK14A
p70_S6KA
p70(S6K)-alpha
p70-S6K
p70-alpha
ribosomal protein S6 kinase, 70kDa, polypeptide 1 (EC:2.7.11.1) [Sirolimus results in decreased activity of MTOR protein] which results in decreased activity of RPS6KB1 protein decreases activity
protein 14673156
D020123 6198 RPS6KB1
PS6K
S6K
S6K-beta-1
S6K1
STK14A
p70_S6KA
p70(S6K)-alpha
p70-S6K
p70-alpha
ribosomal protein S6 kinase, 70kDa, polypeptide 1 (EC:2.7.11.1) [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of RPS6KB1 protein decreases activity
/ decreases phosphorylation
protein 20169165
22574221
D020123 6198 RPS6KB1
PS6K
S6K
S6K-beta-1
S6K1
STK14A
p70_S6KA
p70(S6K)-alpha
p70-S6K
p70-alpha
ribosomal protein S6 kinase, 70kDa, polypeptide 1 (EC:2.7.11.1) Sirolimus results in decreased activity of RPS6KB1 protein decreases activity
protein 17908691
21544240
D020123 6198 RPS6KB1
PS6K
S6K
S6K-beta-1
S6K1
STK14A
p70_S6KA
p70(S6K)-alpha
p70-S6K
p70-alpha
ribosomal protein S6 kinase, 70kDa, polypeptide 1 (EC:2.7.11.1) [Sirolimus results in decreased activity of RPS6KB1 protein] which results in decreased abundance of Superoxides decreases abundance
/ decreases activity
protein 21544240
D020123 6198 RPS6KB1
PS6K
S6K
S6K-beta-1
S6K1
STK14A
p70_S6KA
p70(S6K)-alpha
p70-S6K
p70-alpha
ribosomal protein S6 kinase, 70kDa, polypeptide 1 (EC:2.7.11.1) [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased abundance of Nitric Oxide decreases activity
/ increases abundance
protein 21544240
D020123 6198 RPS6KB1
PS6K
S6K
S6K-beta-1
S6K1
STK14A
p70_S6KA
p70(S6K)-alpha
p70-S6K
p70-alpha
ribosomal protein S6 kinase, 70kDa, polypeptide 1 (EC:2.7.11.1) [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased activity of IRS1 protein decreases activity
/ increases activity
protein 17908691
D020123 6198 RPS6KB1
PS6K
S6K
S6K-beta-1
S6K1
STK14A
p70_S6KA
p70(S6K)-alpha
p70-S6K
p70-alpha
ribosomal protein S6 kinase, 70kDa, polypeptide 1 (EC:2.7.11.1) Sirolimus results in decreased phosphorylation of and results in decreased activity of RPS6KB1 protein decreases activity
/ decreases phosphorylation
protein 15914125
17616671
D020123 6198 RPS6KB1
PS6K
S6K
S6K-beta-1
S6K1
STK14A
p70_S6KA
p70(S6K)-alpha
p70-S6K
p70-alpha
ribosomal protein S6 kinase, 70kDa, polypeptide 1 (EC:2.7.11.1) Sirolimus results in decreased phosphorylation of RPS6KB1 protein decreases phosphorylation
protein 15070696
15782132
19625624
20574048
20682991
21168265
22869613
D020123 6198 RPS6KB1
PS6K
S6K
S6K-beta-1
S6K1
STK14A
p70_S6KA
p70(S6K)-alpha
p70-S6K
p70-alpha
ribosomal protein S6 kinase, 70kDa, polypeptide 1 (EC:2.7.11.1) sodium arsenite promotes the reaction [Sirolimus results in decreased phosphorylation of RPS6KB1 protein] decreases phosphorylation
/ increases reaction
protein 22869613
D020123 6199 RPS6KB2
KLS
P70-beta
P70-beta-1
P70-beta-2
S6K-beta2
S6K2
SRK
STK14B
p70(S6K)-beta
p70S6Kb
ribosomal protein S6 kinase, 70kDa, polypeptide 2 (EC:2.7.11.1) MTOR protein inhibits the reaction [Sirolimus results in decreased activity of RPS6KB2 protein] decreases activity
/ decreases reaction
protein 12087098
D020123 6199 RPS6KB2
KLS
P70-beta
P70-beta-1
P70-beta-2
S6K-beta2
S6K2
SRK
STK14B
p70(S6K)-beta
p70S6Kb
ribosomal protein S6 kinase, 70kDa, polypeptide 2 (EC:2.7.11.1) Sirolimus inhibits the reaction [Phosphatidic Acids results in increased activity of RPS6KB2 protein] decreases reaction
/ increases activity
protein 12087098
D020123 6199 RPS6KB2
KLS
P70-beta
P70-beta-1
P70-beta-2
S6K-beta2
S6K2
SRK
STK14B
p70(S6K)-beta
p70S6Kb
ribosomal protein S6 kinase, 70kDa, polypeptide 2 (EC:2.7.11.1) Sirolimus results in decreased activity of RPS6KB2 protein decreases activity
protein 12087098
D020123 57521 RPTOR
KOG1
Mip1
regulatory associated protein of MTOR, complex 1 RPTOR protein inhibits the reaction [Sirolimus results in increased activity of AR protein] decreases reaction
/ increases activity
protein 18776922
D020123 57521 RPTOR
KOG1
Mip1
regulatory associated protein of MTOR, complex 1 [Sirolimus inhibits the reaction [MTOR protein binds to RPTOR protein]] which results in increased expression of MAP1LC3A protein alternative form affects binding
/ decreases reaction
/ increases expression
protein 21742779
D020123 57521 RPTOR
KOG1
Mip1
regulatory associated protein of MTOR, complex 1 Sirolimus inhibits the reaction [Orotic Acid results in decreased phosphorylation of RPTOR protein] decreases phosphorylation
/ decreases reaction
protein 22863860
D020123 57521 RPTOR
KOG1
Mip1
regulatory associated protein of MTOR, complex 1 Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein] affects binding
/ decreases activity
protein 18776922
D020123 57521 RPTOR
KOG1
Mip1
regulatory associated protein of MTOR, complex 1 Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein binds to MLST8 protein] affects binding
/ decreases activity
protein 19505958
D020123 57521 RPTOR
KOG1
Mip1
regulatory associated protein of MTOR, complex 1 [Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein]] which results in increased activity of AR protein affects binding
/ decreases activity
/ increases activity
protein 18776922
D020123 6236 RRAD
RAD
RAD1
REM3
Ras-related associated with diabetes Sirolimus promotes the reaction [TP73 protein binds to RRAD promoter] affects binding
/ increases reaction
promoter 21245298
D020123 950 SCARB2
AMRF
CD36L2
EPM4
HLGP85
LGP85
LIMP-2
LIMPII
SR-BII
scavenger receptor class B, member 2 Sirolimus results in decreased expression of SCARB2 mRNA decreases expression
mRNA 17016853
D020123 6319 SCD
FADS5
MSTP008
SCD1
SCDOS
stearoyl-CoA desaturase (delta-9-desaturase) (EC:1.14.19.1) Sirolimus inhibits the reaction [TP73 protein results in decreased expression of SCD mRNA] decreases expression
/ decreases reaction
mRNA 21245298
D020123 10512 SEMA3C
SEMAE
SemE
sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C Sirolimus inhibits the reaction [TP73 protein results in increased expression of SEMA3C mRNA] decreases reaction
/ increases expression
mRNA 21245298
D020123 5265 SERPINA1
A1A
A1AT
AAT
PI
PI1
PRO2275
alpha1AT
serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 Sirolimus affects the localization of SERPINA1 protein affects localization
protein 20511674
D020123 5054 SERPINE1
PAI
PAI-1
PAI1
PLANH1
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 Sirolimus inhibits the reaction [TP73 protein results in decreased expression of SERPINE1 mRNA] decreases expression
/ decreases reaction
mRNA 21245298
D020123 23411 SIRT1
SIR2L1
sirtuin 1 Aspirin inhibits the reaction [Sirolimus results in decreased expression of SIRT1 protein] decreases expression
/ decreases reaction
protein 19520256
D020123 23411 SIRT1
SIR2L1
sirtuin 1 cilostazol inhibits the reaction [Sirolimus results in decreased expression of SIRT1 protein] decreases expression
/ decreases reaction
protein 19520256
D020123 23411 SIRT1
SIR2L1
sirtuin 1 Sirolimus results in decreased expression of SIRT1 protein decreases expression
protein 19520256
D020123 22933 SIRT2
SIR2
SIR2L
SIR2L2
sirtuin 2 (EC:3.5.1.-) Sirolimus inhibits the reaction [TP73 protein results in increased expression of SIRT2 mRNA] decreases reaction
/ increases expression
mRNA 21245298
D020123 6502 SKP2
FBL1
FBXL1
FLB1
p45
S-phase kinase-associated protein 2, E3 ubiquitin protein ligase Sirolimus results in decreased expression of SKP2 protein decreases expression
protein 21092744
D020123 6564 SLC15A1
HPECT1
HPEPT1
PEPT1
solute carrier family 15 (oligopeptide transporter), member 1 Sirolimus inhibits the reaction [rosiglitazone results in increased expression of and results in increased activity of SLC15A1 protein] decreases reaction
/ increases activity
/ increases expression
protein 22108913
D020123 201895 SMIM14
C4orf34
small integral membrane protein 14 Sirolimus inhibits the reaction [TP73 protein results in increased expression of SMIM14 mRNA] decreases reaction
/ increases expression
mRNA 21245298
D020123 8878 SQSTM1
A170
OSIL
PDB3
ZIP3
p60
p62
p62B
sequestosome 1 Sirolimus results in decreased expression of SQSTM1 protein decreases expression
protein 19773376
D020123 10809 STARD10
NY-CO-28
PCTP2
SDCCAG28
StAR-related lipid transfer (START) domain containing 10 Sirolimus inhibits the reaction [TP73 protein results in increased expression of STARD10 mRNA] decreases reaction
/ increases expression
mRNA 21245298
D020123 6774 STAT3
APRF
HIES
signal transducer and activator of transcription 3 (acute-phase response factor) Sirolimus inhibits the reaction [IFNG protein results in decreased phosphorylation of STAT3 protein] decreases phosphorylation
/ decreases reaction
protein 16427044
D020123 6774 STAT3
APRF
HIES
signal transducer and activator of transcription 3 (acute-phase response factor) Sirolimus results in decreased phosphorylation of STAT3 protein decreases phosphorylation
protein 20038814
D020123 412 STS
ARSC
ARSC1
ASC
ES
SSDD
XLI
steroid sulfatase (microsomal), isozyme S (EC:3.1.6.2) Sirolimus inhibits the reaction [Tretinoin results in increased activity of STS protein] decreases reaction
/ increases activity
protein 16178010
D020123 6857 SYT1
P65
SVP65
SYT
synaptotagmin I Sirolimus inhibits the reaction [TP73 protein results in increased expression of SYT1 mRNA] decreases reaction
/ increases expression
mRNA 21245298
D020123 6886 TAL1
SCL
TCL5
bHLHa17
tal-1
T-cell acute lymphocytic leukemia 1 Sirolimus inhibits the reaction [TP73 protein affects the activity of TAL1 protein] affects activity
/ decreases reaction
protein 21245298
D020123 6941 TCF19
SC1
TCF-19
transcription factor 19 [fulvestrant co-treated with Sirolimus] results in decreased expression of TCF19 mRNA affects cotreatment
/ decreases expression
mRNA 19016759
D020123 7003 TEAD1
AA
NTEF-1
REF1
TCF-13
TCF13
TEAD-1
TEF-1
TEA domain family member 1 (SV40 transcriptional enhancer factor) Sirolimus promotes the reaction [TP73 protein affects the activity of TEAD1 protein] affects activity
/ increases reaction
protein 21245298
D020123 7015 TERT
CMM9
DKCA2
DKCB4
EST2
PFBMFT1
TCS1
TP2
TRT
hEST2
hTRT
telomerase reverse transcriptase (EC:2.7.7.49) Sirolimus results in decreased expression of TERT mRNA decreases expression
mRNA 12939469
16455087
20863555
D020123 7015 TERT
CMM9
DKCA2
DKCB4
EST2
PFBMFT1
TCS1
TP2
TRT
hEST2
hTRT
telomerase reverse transcriptase (EC:2.7.7.49) Sirolimus results in decreased expression of TERT protein decreases expression
protein 17996122
D020123 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [Sirolimus binds to FKBP1A protein] which results in increased activity of TGFB1 protein affects binding
/ increases activity
protein 12417722
D020123 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [Sirolimus co-treated with TGFB1 protein] affects the localization of CDK2 protein affects cotreatment
/ affects localization
protein 14979923
D020123 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [Sirolimus co-treated with TGFB1 protein] affects the localization of CDKN1B protein affects cotreatment
/ affects localization
protein 14979923
D020123 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1A protein binds to CDK2 protein] affects binding
/ affects cotreatment
/ increases reaction
protein 14979923
D020123 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [Sirolimus co-treated with TGFB1 protein] results in decreased phosphorylation of RB1 protein affects cotreatment
/ decreases phosphorylation
protein 14979923
D020123 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [Sirolimus co-treated with TGFB1 protein] results in increased expression of CDKN1A protein affects cotreatment
/ increases expression
protein 14979923
D020123 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL1 protein] which binds to CDK2 protein] affects binding
/ affects cotreatment
/ decreases reaction
protein 12417722
D020123 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL2 protein] which binds to CDK2 protein] affects binding
/ affects cotreatment
/ decreases reaction
protein 12417722
D020123 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1A protein] affects binding
/ affects cotreatment
/ increases reaction
protein 12417722
D020123 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein] affects binding
/ affects cotreatment
/ increases reaction
protein 12417722
D020123 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [TGFB1 protein co-treated with Sirolimus] results in decreased activity of CDK2 protein affects cotreatment
/ decreases activity
protein 12417722
D020123 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [TGFB1 protein co-treated with Sirolimus] results in decreased expression of E2F1 mRNA affects cotreatment
/ decreases expression
protein 12417722
D020123 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [TGFB1 protein co-treated with Sirolimus] results in decreased expression of E2F1 protein affects cotreatment
/ decreases expression
protein 12417722
D020123 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of CDK2 protein affects cotreatment
/ decreases phosphorylation
protein 12417722
D020123 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of RB1 protein affects cotreatment
/ decreases phosphorylation
protein 17700525
D020123 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [TGFB1 protein co-treated with Sirolimus] results in increased expression of CDKN1A protein affects cotreatment
/ increases expression
protein 17700525
D020123 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [TGFB1 protein modified form co-treated with Sirolimus] results in decreased expression of IL6 mRNA affects cotreatment
/ decreases expression
protein 20844194
D020123 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [TGFB1 protein modified form co-treated with Sirolimus] results in decreased expression of IL6 protein affects cotreatment
/ decreases expression
protein 20844194
D020123 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [TGFB1 protein modified form co-treated with Sirolimus] results in increased expression of FOXP3 mRNA affects cotreatment
/ increases expression
protein 20844194
D020123 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [TGFB1 protein modified form co-treated with Sirolimus] results in increased expression of FOXP3 protein affects cotreatment
/ increases expression
protein 20844194
D020123 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 TGFB1 protein results in increased susceptibility to Sirolimus increases response to substance
protein 17700525
D020123 8914 TIMELESS
TIM
TIM1
hTIM
timeless circadian clock [fulvestrant co-treated with Sirolimus] results in decreased expression of TIMELESS mRNA affects cotreatment
/ decreases expression
mRNA 19016759
D020123 7078 TIMP3
HSMRK222
K222
K222TA2
SFD
TIMP metallopeptidase inhibitor 3 Sirolimus results in decreased expression of TIMP3 mRNA decreases expression
mRNA 21742783
D020123 7078 TIMP3
HSMRK222
K222
K222TA2
SFD
TIMP metallopeptidase inhibitor 3 Sirolimus results in decreased expression of TIMP3 protein decreases expression
protein 21742783
D020123 51522 TMEM14C
C6orf53
MSTP073
NET26
bA421M1.6
transmembrane protein 14C Sirolimus inhibits the reaction [TP73 protein results in increased expression of TMEM14C mRNA] decreases reaction
/ increases expression
mRNA 21245298
D020123 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein] decreases reaction
/ increases phosphorylation
protein 19567381
D020123 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Sirolimus promotes the reaction [TNF protein results in increased expression of F3 protein] increases expression
/ increases reaction
protein 19567381
D020123 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Sirolimus results in increased expression of TNF increases expression
16314788
D020123 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Sirolimus promotes the reaction [TP53 protein results in increased expression of BBC3 protein] increases expression
/ increases reaction
protein 19560264
D020123 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of TP53 protein decreases activity
/ decreases phosphorylation
protein 11602639
D020123 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Sirolimus results in decreased phosphorylation of TP53 protein decreases phosphorylation
protein 11602639
D020123 8626 TP63
AIS
B(p51A)
B(p51B)
EEC3
KET
LMS
NBP
OFC8
RHS
SHFM4
TP53CP
TP53L
TP73L
p40
p51
p53CP
p63
p73H
p73L
tumor protein p63 Sirolimus results in decreased expression of TP63 protein decreases expression
protein 20038814
D020123 7161 TP73
P73
tumor protein p73 [Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein affects cotreatment
/ increases expression
protein 20686837
D020123 7161 TP73
P73
tumor protein p73 [[Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein] which results in increased expression of BBC3 protein affects cotreatment
/ increases expression
protein 20686837
D020123 7161 TP73
P73
tumor protein p73 [[Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein] which results in increased expression of PMAIP1 protein affects cotreatment
/ increases expression
protein 20686837
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein affects the activity of HEN1 protein] affects activity
/ decreases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein affects the activity of HOXA9 protein] affects activity
/ decreases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein affects the activity of TAL1 protein] affects activity
/ decreases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein affects the activity of ZIC2 protein] affects activity
/ decreases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in decreased expression of ACER2 mRNA] decreases expression
/ decreases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in decreased expression of JMY mRNA] decreases expression
/ decreases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in decreased expression of MIR181A2 mRNA] decreases expression
/ decreases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in decreased expression of NR1H4 mRNA] decreases expression
/ decreases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in decreased expression of RPL7P26 mRNA] decreases expression
/ decreases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in decreased expression of SCD mRNA] decreases expression
/ decreases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in decreased expression of SERPINE1 mRNA] decreases expression
/ decreases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in decreased expression of YPEL1 mRNA] decreases expression
/ decreases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in increased expression of BTBD11 mRNA] decreases reaction
/ increases expression
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in increased expression of C9ORF3 mRNA] decreases reaction
/ increases expression
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in increased expression of CAV3 mRNA] decreases reaction
/ increases expression
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in increased expression of CCNG2 mRNA] decreases reaction
/ increases expression
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in increased expression of CHRNB3 mRNA] decreases reaction
/ increases expression
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in increased expression of DEPDC6 mRNA] decreases reaction
/ increases expression
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in increased expression of FAXDC2 mRNA] decreases reaction
/ increases expression
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in increased expression of FBXO32 mRNA] decreases reaction
/ increases expression
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in increased expression of FGF7 mRNA] decreases reaction
/ increases expression
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in increased expression of FOLR1 mRNA] decreases reaction
/ increases expression
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in increased expression of FTL mRNA] decreases reaction
/ increases expression
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in increased expression of ING4 mRNA] decreases reaction
/ increases expression
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in increased expression of MBNL2 mRNA] decreases reaction
/ increases expression
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in increased expression of MTURN mRNA] decreases reaction
/ increases expression
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in increased expression of MYLK mRNA] decreases reaction
/ increases expression
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in increased expression of MYOF mRNA] decreases reaction
/ increases expression
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in increased expression of NMU mRNA] decreases reaction
/ increases expression
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in increased expression of OXA1L mRNA] decreases reaction
/ increases expression
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in increased expression of SEMA3C mRNA] decreases reaction
/ increases expression
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in increased expression of SIRT2 mRNA] decreases reaction
/ increases expression
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in increased expression of SMIM14 mRNA] decreases reaction
/ increases expression
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in increased expression of STARD10 mRNA] decreases reaction
/ increases expression
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in increased expression of SYT1 mRNA] decreases reaction
/ increases expression
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in increased expression of TMEM14C mRNA] decreases reaction
/ increases expression
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus inhibits the reaction [TP73 protein results in increased expression of ZNRD1 mRNA] decreases reaction
/ increases expression
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus promotes the reaction [TP73 protein affects the activity of GCM2 protein] affects activity
/ increases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus promotes the reaction [TP73 protein affects the activity of PAX8 protein] affects activity
/ increases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus promotes the reaction [TP73 protein affects the activity of REST protein] affects activity
/ increases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus promotes the reaction [TP73 protein affects the activity of TEAD1 protein] affects activity
/ increases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus promotes the reaction [TP73 protein binds to MDM2 promoter] affects binding
/ increases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus promotes the reaction [TP73 protein binds to RPS27L promoter] affects binding
/ increases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus promotes the reaction [TP73 protein binds to RRAD promoter] affects binding
/ increases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 Sirolimus results in increased expression of TP73 protein increases expression
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR151 mRNA] increases expression
/ increases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR190A mRNA] increases expression
/ increases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR29C mRNA] increases expression
/ increases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR324 mRNA] increases expression
/ increases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR379 mRNA] increases expression
/ increases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR433 mRNA] increases expression
/ increases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR503 mRNA] increases expression
/ increases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR508 mRNA] increases expression
/ increases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR650 mRNA] increases expression
/ increases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR654 mRNA] increases expression
/ increases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR758 mRNA] increases expression
/ increases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR760 mRNA] increases expression
/ increases reaction
protein 21245298
D020123 7161 TP73
P73
tumor protein p73 TP73 protein results in increased susceptibility to [Sirolimus co-treated with Cisplatin] affects cotreatment
/ increases response to substance
protein 20686837
D020123 7272 TTK
CT96
ESK
MPH1
MPS1
MPS1L1
PYT
TTK protein kinase (EC:2.7.12.1) [fulvestrant co-treated with Sirolimus] results in decreased expression of TTK mRNA affects cotreatment
/ decreases expression
mRNA 19016759
D020123 7298 TYMS
HST422
TMS
TS
thymidylate synthetase (EC:2.1.1.45) Sirolimus results in decreased expression of TYMS decreases expression
20682991
D020123 7298 TYMS
HST422
TMS
TS
thymidylate synthetase (EC:2.1.1.45) Sirolimus results in decreased expression of TYMS mRNA decreases expression
mRNA 19764996
D020123 8725 URI1
C19orf2
NNX3
PPP1R19
RMP
URI
URI1, prefoldin-like chaperone URI1 results in decreased susceptibility to Sirolimus decreases response to substance
21397856
D020123 7422 VEGFA
MVCD1
VEGF
VPF
vascular endothelial growth factor A Sirolimus inhibits the reaction [4-hydroxyestradiol results in increased expression of VEGFA protein] decreases reaction
/ increases expression
protein 15050414
D020123 7422 VEGFA
MVCD1
VEGF
VPF
vascular endothelial growth factor A Sirolimus inhibits the reaction [IGF1 protein results in increased secretion of VEGFA protein] decreases reaction
/ increases secretion
protein 16682453
D020123 7422 VEGFA
MVCD1
VEGF
VPF
vascular endothelial growth factor A Sirolimus inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA mRNA] decreases reaction
/ increases expression
mRNA 17968710
D020123 7422 VEGFA
MVCD1
VEGF
VPF
vascular endothelial growth factor A Sirolimus results in decreased expression of VEGFA mRNA decreases expression
mRNA 15930297
D020123 7490 WT1
AWT1
EWS-WT1
GUD
NPHS4
WAGR
WIT-2
WT33
Wilms tumor 1 Sirolimus results in decreased expression of WT1 mRNA decreases expression
mRNA 18927120
D020123 7490 WT1
AWT1
EWS-WT1
GUD
NPHS4
WAGR
WIT-2
WT33
Wilms tumor 1 Sirolimus results in decreased expression of WT1 protein decreases expression
protein 18927120
D020123 7490 WT1
AWT1
EWS-WT1
GUD
NPHS4
WAGR
WIT-2
WT33
Wilms tumor 1 Sirolimus results in decreased expression of WT1 protein mutant form decreases expression
protein 15782132
D020123 7494 XBP1
TREB5
XBP-1
XBP2
X-box binding protein 1 Sirolimus inhibits the reaction [arsenite results in increased splicing of XBP1 mRNA] decreases reaction
/ increases splicing
mRNA 22215663
D020123 331 XIAP
API3
BIRC4
IAP-3
ILP1
MIHA
XLP2
hIAP-3
hIAP3
X-linked inhibitor of apoptosis Sirolimus promotes the reaction [Cisplatin results in decreased expression of XIAP protein] decreases expression
/ increases reaction
protein 18058806
D020123 29799 YPEL1
yippee-like 1 (Drosophila) Sirolimus inhibits the reaction [TP73 protein results in decreased expression of YPEL1 mRNA] decreases expression
/ decreases reaction
mRNA 21245298
D020123 7546 ZIC2
HPE5
Zic family member 2 Sirolimus inhibits the reaction [TP73 protein affects the activity of ZIC2 protein] affects activity
/ decreases reaction
protein 21245298
D020123 30834 ZNRD1
HTEX-6
Rpa12
TEX6
ZR14
hZR14
tctex-6
zinc ribbon domain containing 1 (EC:2.7.7.6) Sirolimus inhibits the reaction [TP73 protein results in increased expression of ZNRD1 mRNA] decreases reaction
/ increases expression
mRNA 21245298
D020123 11130 ZWINT
HZwint-1
KNTC2AP
ZWINT1
ZW10 interacting kinetochore protein [fulvestrant co-treated with Sirolimus] results in decreased expression of ZWINT mRNA affects cotreatment
/ decreases expression
mRNA 19016759

Related Disease

Diseases related to proteins in ChEMBL interactions

OMIM (161)

OMIM preferred title UniProt
#100100 Abdominal muscles, absence of, with urinary tract abnormality and cryptorchidism P20309
#100800 Achondroplasia; ach P22607
#615224 Advanced sleep phase syndrome, familial, 2; fasps2 P48730
#300755 Agammaglobulinemia, x-linked; xla Q06187
#103780 Alcohol dependence P08172
P14416
P31645
#614373 Amyotrophic lateral sclerosis 16, juvenile; als16 Q99720
#207410 Antley-bixler syndrome without genital anomalies or disordered steroidogenesis; abs2 P21802
#613780 Aortic aneurysm, familial thoracic 7; aat7 Q15746
#101200 Apert syndrome P21802
#615091 Autism, susceptibility to, 19; auts19 P06730
#615007 Basal ganglia calcification, idiopathic, 4; ibgc4 P09619
#123790 Beare-stevenson cutis gyrata syndrome; bstvs P21802
#614592 Bent bone dysplasia syndrome; bbds P21802
#109800 Bladder cancer P22607
#602025 Body mass index quantitative trait locus 9; bmiq9 P41968
#114480 Breast cancer O96017
P31749
#300615 Brunner syndrome P21397
#600880 Budd-chiari syndrome; bdchs O60674
#610474 Camptodactyly, tall stature, and hearing loss syndrome P22607
#615279 Cardiofaciocutaneous syndrome 3; cfc3 Q02750
#600858 Cardiomyopathy, familial hypertrophic, 6; cmh6 Q9UGJ0
#116600 Cataract 6, multiple types; ctrct6 P29317
#209880 Central hypoventilation syndrome, congenital; cchs P07949
#603956 Cervical cancer P22607
#613630 Cocoon syndrome O15111
#303600 Coffin-lowry syndrome; cls P51812
#114500 Colorectal cancer; crc P07949
P29320
P31749
P84022
#615109 Cowden syndrome 6; cws6 P31749
#123500 Crouzon syndrome P21802
#612247 Crouzon syndrome with acanthosis nigricans; can P22607
#162800 Cyclic neutropenia P08246
#127750 Dementia, lewy body; dlb P37840
#612522 Diabetes mellitus, insulin-dependent, 22; iddm22 P51681
#610549 Diabetes mellitus, insulin-resistant, with acanthosis nigricans P06213
#125853 Diabetes mellitus, noninsulin-dependent; niddm P06213
P31751
#246200 Donohue syndrome P06213
#609535 Drug metabolism, poor, cyp2c19-related P33261
#608902 Drug metabolism, poor, cyp2d6-related P10635
#615363 Estrogen resistance; estrr P03372
#600274 Frontotemporal dementia; ftd P10636
#613659 Gastric cancer P04626
#137215 Gastric cancer, hereditary diffuse; hdgc P04626
#606764 Gastrointestinal stromal tumor; gist P10721
P16234
#231095 Ghosal hematodiaphyseal dysplasia; ghdd P24557
#177700 Glaucoma 1, open angle, p; glc1p Q9UHD2
#137800 Glioma susceptibility 1; glm1 P04626
#613027 Glycogen storage disease ixc; gsd9c P15735
#261740 Glycogen storage disease of heart, lethal congenital Q9UGJ0
#602089 Hemangioma, capillary infantile P35916
P35968
#114550 Hepatocellular carcinoma P08581
#142623 Hirschsprung disease, susceptibility to, 1; hscr1 P07949
#609423 Human immunodeficiency virus type 1, susceptibility to P41597
P51681
#237450 Hyperbilirubinemia, rotor type; hblrr Q9Y6L6
#607685 Hypereosinophilic syndrome, idiopathic; hes P16234
#602485 Hyperinsulinemic hypoglycemia, familial, 3; hhf3 P35557
#609968 Hyperinsulinemic hypoglycemia, familial, 5; hhf5 P06213
#146000 Hypochondroplasia; hch P22607
#147950 Hypogonadotropic hypogonadism 2 with or without anosmia; hh2 P11362
#240900 Hypoinsulinemic hypoglycemia with hemihypertrophy; hihghh P31751
#612244 Inflammatory bowel disease 13; ibd13 P08183
#256800 Insensitivity to pain, congenital, with anhidrosis; cipa P04629
#270450 Insulin-like growth factor i, resistance to P08069
#603932 Intervertebral disc disease; idd P14780
#610799 Invasive pneumococcal disease, recurrent isolated, 1; ipd1 Q9NWZ3
#607676 Irak4 deficiency Q9NWZ3
#307200 Isolated growth hormone deficiency, type iii; ighd3 Q06187
#123150 Jackson-weiss syndrome; jws P21802
#607785 Juvenile myelomonocytic leukemia; jmml P09619
#182000 Keratosis, seborrheic P22607
#149730 Lacrimoauriculodentodigital syndrome; ladd P21802
P22607
#611554 Leopard syndrome 2 P04049
#601626 Leukemia, acute myeloid; aml O60674
P09619
P10721
P36888
#608232 Leukemia, chronic myeloid; cml P00519
#221820 Leukoencephalopathy, diffuse hereditary, with spheroids; hdls P07333
#609265 Li-fraumeni syndrome 2; lfs2 O96017
#609192 Loeys-dietz syndrome, type 1a; lds1a P36897
#608967 Loeys-dietz syndrome, type 2a; lds2a P36897
#613795 Loeys-dietz syndrome, type 3; lds3 P84022
#613688 Long qt syndrome 2; lqt2 Q12809
#211980 Lung cancer P00533
P04626
#153100 Lymphedema, hereditary, ia P35916
#613011 Lymphoproliferative syndrome 1; lpfs1 Q08881
#608516 Major depressive disorder; mdd P08172
#613375 Maturity-onset diabetes of the young, type 11; mody11 P51451
#125851 Maturity-onset diabetes of the young, type 2; mody2 P35557
#606391 Maturity-onset diabetes of the young; mody P35557
#603387 Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome; mpph Q9Y243
#614104 Mental retardation, autosomal dominant 7; mrd7 Q13627
#300844 Mental retardation, x-linked 19; mrx19 P51812
#300558 Mental retardation, x-linked 30; mrx30 O75914
%300852 Mental retardation, x-linked 88; mrx88 P50052
#613073 Metaphyseal anadysplasia 2; mandp2 P14780
#602849 Muenke syndrome; mnkes P22607
#171400 Multiple endocrine neoplasia, type iia; men2a P07949
#162300 Multiple endocrine neoplasia, type iib; men2b P07949
#126200 Multiple sclerosis, susceptibility to; ms P08575
#132800 Multiple self-healing squamous epithelioma, susceptibility to; msse P36897
#608931 Myasthenic syndrome, congenital, associated with acetylcholine receptor deficiency O15146
#607948 Mycobacterium tuberculosis, susceptibility to P11473
#254450 Myelofibrosis O60674
#254500 Myeloma, multiple P22607
#131440 Myeloproliferative disorder, chronic, with eosinophilia P09619
#159900 Myoclonic dystonia P14416
#228550 Myofibromatosis, infantile, 1; imf1 P09619
#160900 Myotonic dystrophy 1; dm1 Q09013
#613014 Neuroblastoma, susceptibility to, 3; nblst3 Q9UM73
#202700 Neutropenia, severe congenital, 1, autosomal dominant; scn1 P08246
#162900 Nevus, epidermal P22607
#611553 Noonan syndrome 5; ns5 P04049
#601665 Obesity P32245
#613886 Obesity, hyperphagia, and developmental delay Q16620
#164230 Obsessive-compulsive disorder; ocd P31645
#604715 Orthostatic intolerance P23975
#259500 Osteogenic sarcoma O96017
#166250 Osteoglophonic dysplasia; ogd P11362
#259730 Osteopetrosis, autosomal recessive 3; optb3 P00918
#167000 Ovarian cancer P04626
#168601 Parkinson disease 1, autosomal dominant; park1 P37840
#605543 Parkinson disease 4, autosomal dominant; park4 P37840
#168600 Parkinson disease, late-onset; pd P37840
#260540 Parkinson-dementia syndrome P10636
#613135 Parkinsonism-dystonia, infantile; pkdys Q01959
#175200 Peutz-jeghers syndrome; pjs Q15831
#101600 Pfeiffer syndrome P11362
P21802
#171300 Pheochromocytoma P07949
#172700 Pick disease of brain P10636
#172800 Piebald trait; pbt P10721
#262190 Pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities P06213
#263300 Polycythemia vera; pv O60674
#176807 Prostate cancer O96017
P29323
#603688 Prostate cancer/brain cancer susceptibility P29323
#176920 Proteus syndrome P31749
#191830 Renal adysplasia P07949
#605074 Renal cell carcinoma, papillary, 1; rccp1 P08581
#607276 Resting heart rate, variation in P08588
#613862 Retinitis pigmentosa 38; rp38 Q12866
#609579 Scaphocephaly, maxillary retrusion, and mental retardation P21802
#269840 Selective t-cell defect; stcd P43403
#600802 Severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-negative P52333
#608971 Severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-positive P08575
#609620 Short qt syndrome 1; sqt1 Q12809
#243060 Spermatogenic failure 5; spgf5 Q9UQB9
#605361 Spinocerebellar ataxia 14; sca14 P05129
#271665 Spondylometaepiphyseal dysplasia, short limb-hand type Q16832
%612223 Stature quantitative trait locus 11; stqtl11 Q00534
#601367 Stroke, ischemic P24723
#601104 Supranuclear palsy, progressive, 1; psnp1 P10636
#614868 T-cell immunodeficiency, recurrent infections, and autoimmunity with or without cardiac malformations; tiiac Q13043
#273300 Testicular germ cell tumor; tgct O94804
P10721
P22607
Q15831
#187600 Thanatophoric dysplasia, type i; td1 P22607
#187601 Thanatophoric dysplasia, type ii; td2 P22607
#614521 Thrombocythemia 3; thcyt3 O60674
#155240 Thyroid carcinoma, familial medullary; mtc P07949
#188550 Thyroid carcinoma, papillary P04629
P07949
#190300 Tremor, hereditary essential, 1; etm1 P35462
#190440 Trigonocephaly 1; trigno1 P11362
#600195 Venous malformations, multiple cutaneous and mucosal; vmcm Q02763
#277440 Vitamin d-dependent rickets, type 2a; vddr2a P11473
#610379 West nile virus, susceptibility to P51681
#194200 Wolff-parkinson-white syndrome Q9UGJ0
#112100 Yt blood group antigen P22303

KEGG DISEASE (99)

KEGG disease name UniProt
H00882 Cocoon syndrome O15111 (related)
H00770 Congenital myasthenic syndrome O15146 (related)
H00012 Polycythemia vera O60674 (related)
O60674 (marker)
H00480 Non-syndromic X-linked mental retardation O75914 (related)
P50052 (related)
P51812 (related)
H00881 Li-Fraumeni syndrome O96017 (related)
H00018 Gastric cancer O96020 (related)
P00533 (related)
P04626 (related)
P08581 (related)
P21802 (related)
P24864 (related)
H00055 Laryngeal cancer O96020 (related)
P00533 (related)
P00533 (marker)
P24864 (related)
H00001 Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia) P00519 (related)
P00519 (marker)
H00004 Chronic myeloid leukemia (CML) P00519 (related)
P00519 (marker)
H00016 Oral cancer P00533 (related)
P00533 (marker)
H00017 Esophageal cancer P00533 (related)
P35354 (related)
H00022 Bladder cancer P00533 (related)
P04626 (related)
P22607 (related)
P53355 (related)
H00028 Choriocarcinoma P00533 (related)
P03956 (related)
P04626 (related)
P07333 (related)
H00030 Cervical cancer P00533 (related)
P04626 (related)
H00042 Glioma P00533 (related)
P00533 (marker)
P09619 (related)
P16234 (related)
H00241 Combined proximal and distal renal tubular acidosis (RTA type 3) P00918 (related)
H00436 Osteopetrosis P00918 (related)
H00026 Endometrial Cancer P03372 (marker)
P04626 (related)
Q92731 (marker)
H00599 46,XX disorders of sex development (Disorders related to androgen excess) P04150 (related)
H00019 Pancreatic cancer P04626 (related)
Q15831 (related)
H00027 Ovarian cancer P04626 (related)
P31751 (related)
H00031 Breast cancer P04626 (related)
P04626 (marker)
H00046 Cholangiocarcinoma P04626 (related)
P08581 (related)
P35354 (related)
H00032 Thyroid cancer P04629 (related)
P07949 (related)
P07949 (marker)
H00043 Neuroblastoma P04629 (related)
P04629 (marker)
Q16620 (related)
H00265 Hereditary sensory and autonomic neuropathy (HSAN) P04629 (related)
H00063 Spinocerebellar ataxia (SCA) P05129 (related)
H00719 Leprechaunism P06213 (related)
H00942 Rabson-Mendenhall syndrome P06213 (related)
H01228 Insulin-resistant diabetes mellitus with acanthosis nigricans (IRAN) P06213 (related)
H01267 Familial hyperinsulinemic hypoglycemia (HHF) P06213 (related)
P35557 (related)
H00093 Combined immunodeficiencies (CIDs) P06239 (related)
P43403 (related)
H00079 Asthma P07550 (related)
H00822 Renal agenesis and Renal adysplasia P07949 (related)
H00910 Hirschsprung disease (HD) P07949 (related)
H00916 Congenital central hypoventilation syndrome (CCHS) P07949 (related)
H00015 Malignant pleural mesothelioma P08069 (related)
H00050 Synovial sarcoma P08069 (related)
H01274 Growth delay due to insulin-like growth factor I resistance P08069 (related)
H00100 Neutropenic disorders P08246 (related)
H00091 T-B+Severe combined immunodeficiencies (SCIDs) P08575 (related)
P52333 (related)
H00021 Renal cell carcinoma P08581 (related)
H00036 Osteosarcoma P08684 (marker)
H00014 Non-small cell lung cancer P08922 (related)
Q9UM73 (related)
H00058 Amyotrophic lateral sclerosis (ALS) P10636 (related)
H00077 Progressive supranuclear palsy (PSP) P10636 (related)
H00078 Frontotemporal lobar degeneration (FTLD) P10636 (related)
H00003 Acute myeloid leukemia (AML) P10721 (related)
P10721 (marker)
P36888 (related)
H00170 Piebaldism P10721 (related)
H00023 Testicular cancer P10721 (marker)
H00255 Hypogonadotropic hypogonadism P11362 (related)
H00443 Osteoglophonic dysplasia (OD) P11362 (related)
H00458 Craniosynostosis P11362 (related)
P21802 (related)
P22607 (related)
H00516 Isolated orofacial clefts P11362 (related)
H01207 Trigonocephaly P11362 (related)
H00342 Tuberculosis P11473 (related)
H00784 Localized autosomal recessive hypotrichosis P11473 (related)
H01143 Vitamin D-dependent rickets P11473 (related)
H01205 Coumarin resistance P11712 (related)
H00025 Penile cancer P14780 (related)
P35354 (related)
H00479 Metaphyseal dysplasias P14780 (related)
H00069 Glycogen storage diseases (GSD) P15735 (related)
Q9UGJ0 (related)
H00548 Brunner syndrome P21397 (related)
H00642 Lacrimo-auriculo-dento-digital syndrome (LADD) P21802 (related)
P22607 (related)
H00010 Multiple myeloma P22607 (related)
P30281 (related)
H00505 FGFR3-related short limb skeletal dysplasias P22607 (related)
H00997 CATSHL syndrome P22607 (related)
H01031 Orthostatic intolerance (OI) P23975 (related)
H00490 Diaphyseal dysplasia with anemia (Ghosal) P24557 (related)
H01202 Cataract P29317 (related)
H00539 PTEN hamartoma tumor syndrome (PHTS) P31749 (related)
H00420 Familial partial lipodystrophy (FPL) P31751 (related)
H01171 Poor drug metabolism (PM) P33261 (related)
H00410 Maturity onset diabetes of the young (MODY) P35557 (related)
P51451 (related)
H00512 Permanent neonatal diabetes mellitus (PNDM) P35557 (related)
H00535 Lymphedemas P35916 (related)
H00800 Loeys-Dietz syndrome (LDS) P36897 (related)
H00801 Familial thoracic aortic aneurysm and dissection (TAAD) P36897 (related)
Q15746 (related)
H00057 Parkinson's disease (PD) P37840 (related)
H00066 Lewy body dementia (LBD) P37840 (related)
H00005 Chronic lymphocytic leukemia (CLL) P43403 (marker)
H00574 Coffin-Lowry syndrome (CLS) P51812 (related)
H00606 Early infantile epileptic encephalopathy P53779 (related)
H00523 Noonan syndrome and related disorders Q02750 (related)
H00531 Venous malformations Q02763 (related)
H00408 Type I diabetes mellitus Q04759 (related)
H00085 Agammaglobulinemias Q06187 (related)
H00254 Pituitary Dwarfism (PD) Q06187 (related)
H00107 Other well-defined immunodeficiency syndromes Q08881 (related)
H00568 Myotonic dystrophy (DM) Q09013 (related)
H00720 Long QT syndrome Q12809 (related)
H00725 Short QT syndrome Q12809 (related)
H00527 Retinitis pigmentosa (RP) Q12866 (related)
H00666 Peutz-Jeghers syndrome Q15831 (related)
H00777 Spondylometaepiphyseal dysplasia, short limb-hand type Q16832 (related)
H00096 Defects of toll-like receptor signaling Q9NWZ3 (related)
H00292 Hypertrophic cardiomyopathy (HCM) Q9UGJ0 (related)
H01154 Wolff-Parkinson-White (WPW) syndrome Q9UGJ0 (related)
H01282 Spermatogenic failure Q9UQB9 (related)

Diseases related to CTD interactions

108 disease from interactions of metabolites

MeSH disease OMIM compound disease name evidence type reference
pmid
D058186 D020123 Acute Kidney Injury marker/mechanism
16316336
16889550
19376416
D000419 D020123 Albuminuria marker/mechanism
16095517
D000740 D020123 Anemia marker/mechanism
16314788
17038905
17565578
18339148
18724224
19100499
19553912
20054028
D000799 D020123 Angioedema marker/mechanism
15147436
17377381
D050197 D020123 Atherosclerosis therapeutic
17449502
19893993
D001321 D020123 Autistic Disorder therapeutic
21115397
D001927 D020123 Brain Diseases marker/mechanism
17543796
D020520 D020123 Brain Infarction marker/mechanism
17548556
D019559 D020123 Capillary Leak Syndrome marker/mechanism
10328196
D002277 D020123 Carcinoma therapeutic
12417722
D006528 D020123 Carcinoma, Hepatocellular therapeutic
19335982
D002294 D020123 Carcinoma, Squamous Cell therapeutic
19435901
D002305 D020123 Cardiac Tamponade marker/mechanism
16048611
D006332 D020123 Cardiomegaly therapeutic
19321761
19397913
21357504
D020212 D020123 Carotid Artery Injuries therapeutic
20031680
D002779 D020123 Cholestasis therapeutic
20417810
D003251 D020123 Constriction, Pathologic therapeutic
19815708
D023903 D020123 Coronary Restenosis therapeutic
15057437
D003329 D020123 Coronary Vasospasm marker/mechanism
16682323
D016757 D020123 Death, Sudden, Cardiac marker/mechanism
17920355
D051799 D020123 Delayed Graft Function marker/mechanism
20017105
D003711 D020123 Demyelinating Diseases marker/mechanism
therapeutic
18589148
20739560
D003873 D020123 Dermatitis, Exfoliative marker/mechanism
15589473
D003928 D020123 Diabetic Nephropathies therapeutic
19424027
D003967 D020123 Diarrhea marker/mechanism
15102967
D003875 D020123 Drug Eruptions marker/mechanism
15589473
D004487 D020123 Edema marker/mechanism
17362756
18589147
D005076 D020123 Exanthema marker/mechanism
15102967
18044728
20815021
D005334 D020123 Fever marker/mechanism
18023106
D005549 D020123 Foreign-Body Reaction marker/mechanism
19564562
D015432 D020123 Glomerulonephritis, Membranoproliferative marker/mechanism
15112032
D015433 D020123 Glomerulonephritis, Membranous marker/mechanism
15112032
D005923 D020123 Glomerulosclerosis, Focal Segmental marker/mechanism
therapeutic
17362756
17550925
18927120
D018149 D020123 Glucose Intolerance marker/mechanism
20622751
D006086 D020123 Graft vs Host Disease therapeutic
15625544
16635790
17531780
18097008
18776081
D006258 D020123 Head and Neck Neoplasms therapeutic
19435901
D006463 D020123 Hemolytic-Uremic Syndrome marker/mechanism
15625544
17288963
D006504 D020123 Hepatic Veno-Occlusive Disease marker/mechanism
18776081
D006816 D020123 Huntington Disease therapeutic
17921520
D006937 D020123 Hypercholesterolemia marker/mechanism
10221490
12742468
16316336
18589147
19057397
D006943 D020123 Hyperglycemia marker/mechanism
20358864
D006947 D020123 Hyperkalemia marker/mechanism
15102967
D006949 D020123 Hyperlipidemias marker/mechanism
12394605
16856996
17690032
D006965 D020123 Hyperplasia therapeutic
15919358
20031680
D006973 D020123 Hypertension marker/mechanism
17261647
17478757
D015228 D020123 Hypertriglyceridemia marker/mechanism
10221490
12742468
15102967
19057397
D006984 D020123 Hypertrophy therapeutic
19211884
D033461 D020123 Hyperuricemia marker/mechanism
12394605
D007008 D020123 Hypokalemia marker/mechanism
10221490
12742468
12742489
17347279
19656910
D007239 D020123 Infection marker/mechanism
20815021
D007249 D020123 Inflammation marker/mechanism
20358864
D007674 D020123 Kidney Diseases marker/mechanism
therapeutic
12394605
12584269
12660339
15102967
17003813
17147461
17261434
17347279
17504225
18339148
19671594
19926370
20832541
21865292
D007683 D020123 Kidney Tubular Necrosis, Acute marker/mechanism
12544890
D015451 D020123 Leukemia, Lymphocytic, Chronic, B-Cell therapeutic
12393642
D007970 D020123 Leukopenia marker/mechanism
10221490
12742468
17690032
D008103 D020123 Liver Cirrhosis therapeutic
20511674
D008106 D020123 Liver Cirrhosis, Experimental therapeutic
10535884
17050028
D017563 D020123 Lung Diseases, Interstitial marker/mechanism
12795665
15219060
D008209 D020123 Lymphedema marker/mechanism
18339149
D008210 D020123 Lymphocele marker/mechanism
12364859
12795665
17656338
D016403 D020123 Lymphoma, Large B-Cell, Diffuse therapeutic
16856892
D008275 D020123 Magnesium Deficiency marker/mechanism
19656910
D008545 D020123 Melanoma therapeutic
19282848
D008546 D020123 Melanoma, Experimental therapeutic
19922502
D008654 D020123 Mesothelioma therapeutic
19853261
D017566 D020123 Microvascular Angina marker/mechanism
19218771
D009062 D020123 Mouth Neoplasms therapeutic
19435901
D009101 D020123 Multiple Myeloma therapeutic
15070696
D009135 D020123 Muscular Diseases marker/mechanism
14688534
D009203 D020123 Myocardial Infarction marker/mechanism
17920355
D058426 D020123 Neointima therapeutic
18838155
D009361 D020123 Neoplasm Invasiveness therapeutic
21996746
D009362 D020123 Neoplasm Metastasis therapeutic
19922502
D009369 D020123 Neoplasms therapeutic
19384183
D009374 D020123 Neoplasms, Experimental therapeutic
19773376
D009389 D020123 Neovascularization, Pathologic therapeutic
19773376
D009397 D020123 Nephrocalcinosis marker/mechanism
8887267
D009404 D020123 Nephrotic Syndrome marker/mechanism
16504675
18927120
D009845 D020123 Oligospermia marker/mechanism
17845575
D019226 D020123 Oral Ulcer marker/mechanism
18044728
D010300 D020123 Parkinson Disease therapeutic
19682553
D010850 D020123 Picornaviridae Infections marker/mechanism
8971030
D011014 D020123 Pneumonia marker/mechanism
15219060
D016891 D020123 Polycystic Kidney, Autosomal Dominant therapeutic
19651290
D007690 D020123 Polycystic Kidney Diseases therapeutic
19321761
D011115 D020123 Polyneuropathies marker/mechanism
18589148
D011183 D020123 Postoperative Complications marker/mechanism
therapeutic
11605780
17645704
D054198 D020123 Precursor Cell Lymphoblastic Leukemia-Lymphoma therapeutic
21898527
D054218 D020123 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma therapeutic
19246562
D017096 D020123 Prion Diseases therapeutic
19183256
D011507 D020123 Proteinuria marker/mechanism
15112032
16314786
16426332
16912706
16954170
17147461
17175308
17175309
17362756
17452413
17889121
18261172
18442299
18567692
18622299
18631865
18690929
19054382
19100416
19356053
19671594
19925471
19926370
20055793
D011565 D020123 Psoriasis therapeutic
10328196
D012019 D020123 Reflex Sympathetic Dystrophy marker/mechanism
17575313
18212635
D015427 D020123 Reperfusion Injury marker/mechanism
11553517
17362745
D012206 D020123 Rhabdomyolysis marker/mechanism
19376416
D012878 D020123 Skin Neoplasms therapeutic
15233824
D013281 D020123 Stomatitis, Aphthous marker/mechanism
18339148
D013529 D020123 Surgical Wound Dehiscence marker/mechanism
12196058
D013921 D020123 Thrombocytopenia marker/mechanism
10221490
12742468
12795665
D013927 D020123 Thrombosis marker/mechanism
15032417
15364828
15919358
17097164
17145250
17711654
19567381
D057049 D020123 Thrombotic Microangiopathies marker/mechanism
12603218
12830473
14724447
15147429
16310579
16421477
17531780
19120084
D014402 D020123 Tuberous Sclerosis therapeutic
18495876
21115397
D014456 D020123 Ulcer marker/mechanism
20815021
D014605 D020123 Uveitis therapeutic
1336536
D018366 D020123 Vasculitis, Leukocytoclastic, Cutaneous marker/mechanism
12352895
15307846
15589473
15667620
16623879
D018754 D020123 Ventricular Dysfunction therapeutic
21357504
D015430 D020123 Weight Gain therapeutic
19397913
D015431 D020123 Weight Loss marker/mechanism
20358864